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OUTLINE OF THE THESIS 
Radioimmunodetection and radioimmunotherapy studies have shown that monoclonal 
antibodies can be used to target radionuclides selectively to tumors. However, due to 
the slow clearance of monoclonal antibodies from the circulation, high background 
levels persists over a long time. The persisting high blood levels hamper timely 
radioimmunodetection. In addition, in radioimmunotherapy the maximum dose that 
can be administered safely is limited, due to the relatively high radiation doses 
delivered to nontarget organs (especially the bone marrow). These drawbacks can be 
addressed in t w o ways: either by enhancing the uptake of radiolabeled monoclonal 
antibody in the tumor, or by reducing the exposure to nontarget organs. Several 
approaches have been used to reduce the exposure of nontarget organs. Among these 
are pretargeting protocols that make use of antitumor χ antichelate bispecific 
antibodies. In these pretargeting protocols, the antitumor χ antichelate antibody is 
administered first. After some time the radionuclide is administered as a rapidly 
clearing low-molecular-weight ligand. This separated administration leads to kinetics 
of tumor accretion and whole-body clearance of the radiolabel that are fundamentally 
different from those after a single injection with radiolabeled antibodies. 
Ten years ago, the first experiments were performed with antitumor χ antichelate 
bispecific monoclonal antibodies. In animal as well as in patient studies, rapid 
targeting of the tumors was achieved following injection of the radiolabeled chelate. In 
addition, low amounts of radioactivity were observed in nontarget organs. Thus, 
bispecific antibody-based pretargeting methods seemed a promising approach to 
enhance the efficacy of radioimmunotherapy. 
The aim of the studies described in this thesis was the development and 
optimization of two-phase radioimmunotargeting with bispecific monoclonal 
antibodies. Firstly, monoclonal antibodies against the radiolabeled chelates DTPA and 
DOTA were produced. Secondly, bispecific antibodies, using the anti-DTPA or anti-
DOTA antibodies and the high-affinity anti-renal cell carcinoma antibody G250, were 
developed. Thirdly, the bispecific antibodies were characterized in vitro with respect 
to affinity constant, metal selectivity and chelate selectivity. Thereafter, a multistep 
targeting protocol using these bsMAbs was developed in experimental animal models. 
Chapter 1 reviews approaches to enhance the tumor-to-background ratios 
obtained with directly labeled antibodies. Strategies to increase the tumor localization 
of radiolabeled antibodies are discussed as well as methods to decrease the exposure 
of nontarget organs. Special emphasis is given to pretargeting approaches and 
particularly to bispecific antibody based pretargeting strategies. 
In Chapter 2 the development and characterization of three anti-renal cell 
carcinoma χ anti-DTPA bispecific monoclonal antibodies is described. Bispecific 
antibodies were prepared by somatic fusion of the anti-renal cell carcinoma antibody 
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producing hybridoma G250 and the anti-DTPA MAb producing hybridomas DTY4, 
DTIn2 and D T I n l . Individual purification protocols were developed to obtain the 
bispecific antibody in pure form. 
The biodistribution of the parental antibody G250 was determined in t w o animal 
models for renal cell carcinoma that might allow study of the in vivo behavior of the 
newly developed bispecific antibodies (Chapter ЗА). The NU-12 nude mouse model 
appeared to provide the best representation of the biodistribution of G250 in patients 
and was the model of choise for further two-phase approach studies. 
In Chapter 3B the SK-RC-52 animal model (used in Chapter ЗА) was used to 
study the retention of 186Re-MAG3-G250, l 1 1ln-DTPA-G250 and 1 2 5I-G250 in the 
tumor. In this model G250 was extensively metabolized. 1 1 1 ln was well retained in the 
tumor, whereas 1B6Re and 1 2 5 l were not, indicating that not all radiometals are retained 
in the tumor after metabolization. 
In Chapter 4 factors influencing two-phase targeting were studied in rats with 
focal Staphylococcus aureus infection as a model system. In the first phase the anti-
DTPA monoclonal antibody DTInl was injected. As targeting radiopharmaceutical 
99mTc-DTPA was used. The two-phase approach was optimized with respect to the 
interval between both injections, the clearance of circulating DTInl by background 
reduction agents (three-step targeting) and the antibody-to-chelate ratio. With the 
three-step protocol infections were very rapidly targeted (within 3.5 h) with extremely 
low background activity compared to directly labeled nonspecific IgG. 
In Chapter 5 two-phase targeting of NU-12 renal cell carcinoma xenografts is 
described using the bispecific monoclonal antibody G250 χ DTInl and 111ln-DTPA. 
The pretargeting protocol was optimized with respect to the interval between both 
injections, the antibody dose as well as the DTPA dose. Finally, the biodistribution of 
111ln-DTPA was studied over time. Using the carefully tuned optimal protocol, high 
111ln-DTPA tumor uptake and very high tumor-to-blood ratios could be obtained. 
In Chapter 6 studies were performed to further enhance the efficacy of 
pretargeting of NU-12 tumors. The clearance of circulating G250 χ DTInl was 
enhanced via background-reducing agents (three-phase protocol). No improvement 
with time regarding tumor-to-blood ratios was observed compared with the two-step 
protocol. However, the repeated administration of l 1 1ln-DTPA did improve the efficacy 
of radioimmunotargeting. With this approach significantly higher amounts of i n l n -
DTPA were taken up in the tumor. In addition, the uptake and retention of 111ln-DTPA 
in the tumor could be enhanced using the bivalent chelate 11,ln-diDTPA-FKYK instead 
of n i ln-DTPA. 
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Chapter 1 
EXPERIMENTAL APPROACHES TO IMPROVE TUMOR-TO-
NONTUMOR RATIOS OF RADIOLABELED MONOCLONAL 
ANTIBODIES 
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Experimental approaches to improve tumor to-nontumor ratios of radiolabeled monoclonal antibodies 
Monoclonal antibodies (MAbs) against tumor-associated antigens have been shown to 
localize preferentially in tumors. These antibodies can be used as vehicles to direct 
toxic compounds, such as cytotoxic agents or radionuclides, to the tumor. The 
advantage of radiolabeled antibodies as compared to antibodies conjugated with toxic 
agents, is that the radiation emitted by the radionuclide can damage targets at a point 
distant from the point of antibody localization. However, with radiolabeled antibodies 
high background in nontarget organs is observed due to the relatively slow clearance 
of antibodies from the blood. This high background activity results in low tumor-to-
background ratios, which are unfavorable for radioimmunoscintigraphy (long time 
needed for visualization) and radioimmunotherapy (high radiation absorbed doses (rad 
doses) to nontarget organs). These low tumor-to-background ratios can be improved 
either by increasing the accumulation of antibodies in the tumor or by reducing the 
amount of antibodies in the nontarget organs. Several approaches to achieve higher 
tumor-to-background ratios will be discussed below, with special emphasis on 
pretargeting approaches, in particular those using bispecific antibodies. 
APPROACHES TO INCREASE THE TUMOR LOCALIZATION OF 
RADIOLABELED ANTIBODIES 
In Table 1 approaches to improve the tumor uptake of radiolabeled MAbs are 
summarized. The various strategies to enhance the tumor uptake of radiolabeled MAb 
will be discussed in detail in the following paragraphs. 
TABLE 1 
Strategies to enhance radiolabeled MAb tumor uptake 
Second generation MAbs 
Regional administration of MAbs 
Antibody protein dose 
Antibody cocktails 
Biological response modifiers 
External irradiation and hyperthermia 
Improved radiolabeling methods 
Second generation monoclonal antibodies 
Monoclonal antibodies against a series of tumor-associated antigens have been 
developed via immunization protocols using tumor cells. The affinity constant (Ka) of 
these so-called "first generation anti-tumor antibodies" is relatively low. Antibodies 
with a higher Ka might show increased tumor uptake. Fujimorij et al. (1) have shown 
in a mathematical model that the average total MAb concentration in the tumor 
increased with increasing Ka, provided that the initial MAb concentration is high 
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enough. However, increasing the Ka might result in more heterogeneous distribution of 
the M Ab in the tumor (1). Second generation M Abs, with a higher Ka, have been 
developed by immunization with the tumor-associated antigen that is recognized by 
the first generation MAb. Muraro et al. (2) developed a series of second generation 
MAbs (e.g., CC 49) against the TAG-72 antigen present on colon carcinoma cells. The 
Ka of the second generation MAbs were 1.4 to 10.9-fold higher compared with the 
first generation MAb B72.3. Indeed, in biodistribution studies in mice the second 
generation antibodies showed higher uptake expressed as percentage of the injected 
dose per gram tumor (%ID/g) and higher tumor-to-normal tissue ratios in comparison 
to B72.3 (3). In patients with colorectal cancer however, no improvement in uptake in 
the tumor and in normal tissues was observed (4). Hansen et al. (5) developed second 
generation MAbs against carcinoembryonic antigen (CEA) (e.g., MN-14). The MN-14 
antibody had a 10-fold higher Ka than its progenitor NP-4. Again, the uptake of MN-14 
in tumors in nude mice 7 to 14 days postinjection (p.i.) improved 1.4 to 2.8-fold 
compared to the first generation MAb NP-4 (5). In this case it also could be shown 
that in patients with medullary thyroid cancer higher doses (cGy/MBq) to the tumor 
were delivered using 1 3 1I-MN-14 compared with 131l-NP-4 (6). 
In conclusion, for each MAb/tumor system the influence of antibody Ka on the 
biodistribution should be determined in patients by comparing the biodistribution of 
first and second generation MAbs. 
Regional administration of MAbs 
Intracavitary administration of radiolabeled MAb theoreticaly could lead to increased 
tumor uptake, provided that there is enough retention of the antibody at the site of 
the tumor. Several routes of intracavitary MAb administration have been investigated, 
i.e., intratumoral, peritumoral, intrapleural, intrapericardial, subcutane, lymphatic, 
intravesical, submucosal, and intraperitoneal. 
In several animal models radiolabeled antibody was injected directly into the 
tumor. A 7- to 10-fold higher tumor uptake was found compared with intravenous 
(i.V.) injection (7,8). The antibody was retained well in the tumor following 
intratumoral injection, since 18 days p.i. tumor uptake was still as high as 44 %ID/g 
(8). In addition, uptake in normal organs was low, due to the good retention of MAb 
in the tumor (7,8). Peritumoral injection of MAb also led to higher tumor uptake (3-
fold increase compared with i.v. injection), although tumor uptake was lower than 
after intratumoral injection (7). Radiolabeled MAbs have also been administered 
intratumorally in patients with glioma or melanoma. Responses were seen in these 
patients with 1 3 1 l and 90Y labeled MAbs (9,10). Pectasides et al. (11) injected 1 3 Ί -
MAbs HMFG1, HMFG2 and AUA1 intrapleurally and intrapericardially in patients with 
malignant effusions, and achieved complete responses in 10 out of 13 patients. No 
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significant toxicity was observed. 
Subcutaneous (s.c.) administration of antibody has been used to deliver MAbs to 
metastasized local and regional lymph nodes. In patients with melanoma uptake of 
radiolabeled MAb was enhanced in tumor-positive lymph nodes but not in tumor-
negative lymph nodes after s.c. administration of the radiolabeled MAb (12). Mulshine 
et al. (13) showed that lymph nodes can be targeted equally well after intralymphatic 
administration of radiolabeled MAb compared to s.c. injection. Patients with rectal 
carcinoma were injected submucosally near the tumor wi th radiolabeled F(ab')2 
fragments in an attempt to detect local lymph node metastases (14). However, 
diffusion of the antibody in the interstitium hampered the visual detection of lymph 
node involvement. 
Radiolabeled antibody has been injected ¡ntravesically in patients with superficial 
bladder cancer (15). Preferential tumor uptake as compared to the normal urethelium 
was achieved. However, cytotoxic amounts of radiolabel could not be delivered to the 
tumor, due to insufficient penetration of tumor papillae by the radiolabeled antibody. 
Radioimmunotherapy along the intraperitoneal (i.p.) route of administration could 
be an attractive strategy for malignancies whose spread is confined to the peritoneum 
(e.g., ovarian carcinoma, peritoneal mesothelioma) or for malignancies with spread in 
this compartment in addition to regional and hepatic metastases {e.g., colorectal 
carcinoma, gastric carcinoma). In several preclinical studies a direct comparison 
between i.v. and i.p. injection has been performed (16-19). In mice with i.p. located 
solid tumor deposits as well as tumor cell containing ascites, relative good targeting of 
radioiodinated Mab to ascitic cells was observed, especially after i.p. injection 
(16,18,19). In contrast, uptake in solid tumors was low in these mice (18,19). 
Removal of ascitic fluid prior to administration of radioiodinated MAb led to a higher 
uptake in solid tumors (19). Uptake in solid tumors was similar or higher after i.p. 
injection compared with i.v. injection (17-19). Tibben et al. (19) estimated the rad 
dose that could be guided to solid tumors. In these estimations based on 
biodistribution measurements at frequent time points, higher areas under the curve for 
the tumor were obtained after i.p. administration than after i.v. administration. In s.c. 
tumors (representative of nonperitoneal metastases) tumor uptake was either similar 
after i.v. and i.p. injection (19) or higher uptake after i.v. injection compared to i.p. 
injection (16). In several clinical studies a comparison of both i.v. and i.p. injected 
radiolabeled antibody has been performed in the same patient. In patients with ovarian 
cancer tumor uptake was not different in solid tumor masses, however, in ascites 
higher uptake was observed after ¡.p. injection of radiolabeled antibody (20). In 
patients with metastatic colorectal cancer peritoneal metastases were targeted to a 
greater extent after i.p. injection, whereas hematogenously spread, regional lymph 




In conclusion, regional administration of radiolabeled antibody can lead to higher 
tumor uptake (beneficial for radioimmunodetection) and prolonged retention (beneficial 
for radioimmunotherapy) compared to i.v. injection. The main disadvantage of regional 
administration is however, that particular tumor sites will not be targeted. 
Protein dose of the antibody 
In a modeling analysis Fujimori et al. (1) have shown that a higher initial MAb plasma 
concentration leads to a higher concentration in the tumor (nM) and to a more 
homogeneous distribution of MAb in the tumor. 
In animal experiments the tumor uptake of radiolabeled MAb (%ID/g) did not 
increase when increasing amounts of radiolabeled MAb were injected, while the 
absolute amount (цд MAb/g tumor) of radiolabeled MAb in the tumor did increase 
(22,23). At doses above the tumor saturating dose tumor uptake decreased. In some 
animal models circulating antigen or antigen in nontarget organs could be blocked by 
administration of cold antibody prior to the administration of the radiolabeled antibody. 
After predosing with the same antibody as given later, tumor uptake was elevated in 
nude mice with tumors (24). This was an antigen specific effect, because after 
predosing with a nonspecific antibody no elevated tumor uptake was achieved (25). 
Boerman et al. (22) compared the effect of antibody protein dose of 2 different 
anti-colon carcinoma MAbs on the efficacy of radioimmunotherapy in mice with GW-
39 tumors. In small tumors the growth rate was more effectively reduced with the 
low protein dose compared with the high protein dose. However, in large tumors no 
differences were observed between low and high protein dose (22). 
Carrasquillo er al. (26) studied the influence of antibody protein dose on the 
imaging performance in patients with metastatic melanoma using 1 1 1 ln-9.2.27 MAb. 
Higher protein doses (50 or 100 mg) resulted in prolonged blood-pool retention, less 
uptake in spleen and bone marrow, and appeared to have a positive effect on tumor 
imaging. The beneficial effect of higher antibody dose could not be obtained using a 
nonspecific human gamma globulin, thus suggesting the presence of an antigenic sink 
that was saturated at higher doses of specific antibody (26). In patients with renal cell 
carcinoma Oosterwijk et al. (27) and Steffens étal. (28), studying respectively murine 
MAb G250 and chimeric MAb G250, tumor uptake was high at low antibody dose 
levels and decreased at doses higher than 10 mg, indicating saturation of tumor 
antigen at higher protein doses. 
In conclusion, for each MAb/tumor system the optimal protein dose should be 
determined, in order to achieve high tumor uptake. In some cases, predosing will 
saturate antigen expressed in normal tissues resulting in improved tumor targeting. In 
other cases, tumor antigens can be saturated at higher protein doses. No protein dose 
should be administered above the protein dose leading to saturation. 
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Antibody cocktails 
Injection of a mixture of antibodies directed against different tumor-associated 
antigens has been proposed to enhance tumor uptake of radiolabeled MAbs. In this 
way, different sites of the same cell or different cancer cells within a heterogeneous 
tumor might be targeted. Furthermore, mixtures of antibodies against the same tumor-
associated antigen, having different Kas, might enhance tumor uptake. 
In a preclinical study Sharkey et al. (29) have compared the capacities of four 
different anti-CEA monoclonal antibodies to target colon carcinoma xenografts as a 
single antibody or in various combinations of antibodies. Combining individual MAbs 
did not improve tumor localization. In contrast, in the same colon carcinoma model 
system, a mixture of anti-CEA and anti-colon-specific antigen-p antibodies resulted in 
potentiation of anti-CEA antibody uptake (increased tumor-to-nontumor ratios) without 
affecting anti-colon-specific antigen-p antibody uptake (30). Such data indicate that 
the use of cocktails of MAbs directed against different tumor-associated antigens may 
in some cases increase the tumor uptake of radiolabeled MAbs. 
Concomittant use of biological response modifiers 
The biodistribution of radiolabeled antibodies could be influenced by biological 
response modifiers (e.g., interferon (IFN), tumor necrosis factor (TNF) and ¡nterleukin-
2 (IL-2)). Preclinical studies showed that injection of IFN-a upregulated the expression 
of a 90 kD glycoprotein found on breast and colon carcinomas (31,32). More cells 
expressed the antigen and the number of antigenic sites per cell increased (31). In 
these studies, the increased antigen expression led to a higher tumor uptake of 
radiolabeled MAb B6.2. The increased tumor uptake was shown to be dependent on 
the dose of IFN-a (31), the duration of IFN-a administration (32) and the route of 
administration (32). A linear relationship was found between the amount of circulating 
IFN-a and the increased tumor uptake of radiolabeled MAb (31,32). 
IFN-γ enhanced the expression of CEA in WiDr and HT-29 colon carcinoma 
xenografts in nude mice (33,34). After combined administration of radiolabeled MAb 
and IFN-γ but not after administration of the MAb alone, specific tumor uptake of 
radiolabeled MAb was observed. Combined administration in a 
radioimmunotherapeutic setting led to an increase of tumor doubling time (33). IFN-γ 
also caused enhanced expression of TAG-72 antigen on HT-29 tumor cells (34). 
Combined therapy with radiolabeled anti-TAG-72 MAb CC49 and IFN-γ resulted in an 
increased therapeutic efficacy compared to radiolabeled MAb alone (34). 
In patients with metastatic malignant melanoma the effect of administration of 
IFN-a on the biodistribution of MAb 96.5 was studied (35). More lung lesions were 
visualized in the IFN-a pretreated group, whereas no differences were observed in the 
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sensitivity to detect other lesions. The plasma XVt and the volume of distribution of 
MAb 96.5 were longer and greater in patients that had been treated with IFN-ct. 
Higher tumor-to-blood ratios were obtained in the IFN-ct group as determined by 
region-of-interest analysis. MAb 96.5 biodistribution in normal organs was not 
different in both groups (35). In contrast, in patients with metastatic breast cancer 
administration of IFN-a did not alter pharmacokinetics of MAb CC49 (36). Although 
administration of IFN-a resulted in enhanced antigen expression, only slightly 
enhanced tumor uptake was observed in IFN-a treated patients. Similar sensitivity 
was observed in IFN-a treated and nontreated groups (36). In patients with intra­
abdominal adenocarcinoma and ascites the effect of IFN-γ on TAG-72 or CEA 
expression was studied (37). Expression of antigen, albeit at a low level, was a 
prerequisite for IFN-γ to be able to induce enhancement of antigen expression. 
Repeated escalating dose injections of IFN-γ induced longlasting changes in antigen 
expression (37). 
In an animal model intratumoral or i.v. injection of TNF-a resulted in higher 
vascular permeability, whereas blood flow and vascular volume remained unchanged. 
The higher vascular permeability caused a 2 7 % higher uptake in LoVo tumors of 1 2 5 l -
anti-CEA MAb 35 (38). 
Tumor uptake of radiolabeled M Abs could be enhanced by administration of IL-2 
shortly before the administration of the radiolabeled MAb (39,40). The enhanced 
tumor uptake appeared to be IL-2 dose dependent (40). However, enhanced uptake 
was not only observed in tumors but also in normal organs and was the result of 
increased vascular permeability and not of altered blood f low (39,40). DeNardo era/. 
(41) showed that using polyethylene glycol conjugated-IL-2 at a low dose the uptake 
of radiolabeled MAb Lym-1 in Raji tumors was significantly increased, whereas no 
increase was observed in the amount of MAb in normal organs. This tumor specific 
increased MAb uptake could also be achieved by injection of a MAb-IL-2 conjugate 
prior to the administration of radiolabeled MAb (39). 
External irradiation and local hyperthermia 
It has been proposed that the uptake of MAbs in tumors can be enhanced by 
administration of external irradiation to the tumor. The uptake of U l ln-AUA1 MAb in 
LOVO colon carcinoma tumors increased 9 0 % (3 days p.i.) after administration of 
> 4 0 0 cGy X-rays 24 h before MAb injection (42). Increased tumor uptake was X-ray 
dose dependent. Uptake of control antibody was slightly enhanced. Uptake in normal 
organs did not increase. The vascular volume of the tumor was significantly lower 
after X-ray administration, whereas the vascular permeability was increased. 
Enhanced uptake of 111ln-ZCE025 anti-CEA MAb in the tumor was achieved by 
proton irradiation in mice with NCI-H441 tumors (43). A 3-fold increase was obtained 
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3 days p.i. when 10 Gy were given 2 h before MAb administration. Proton irradiation 
could be fractionated in 5 doses of 2 Gy (leading to a 182% increase in MAb uptake). 
However, administration of 5 doses of 7.2 Gy did not result in increased uptake of 
radiolabeled MAb, probably due to disturbance of the tumor vasculature. The 
increased uptake as a result of irradiation might be antibody/antigen system specific, 
since with the anti-TAG-72 Mab B72.3 uptake was not enhanced in mice with colon 
carcinoma xenografts (44). 
Enhanced tumor uptake (40-100% higher uptake) also has been achieved after 
hyperthermia of the tumor for 1-4 h at 41-43°C, by immersing the tumor bearing leg 
completely in a water bath, either shortly before or after injection of radiolabeled MAb 
(45-47). Uptake of control MAb was also increased (45-47). Increased uptake was 
caused by increased blood flow/vascular permeability (45-47). However, hyperthermia 
may also have induced increased antigen expression in the tumor, which may have led 
to enhanced uptake of radiolabeled MAb (46). Distribution of MAb was not altered in 
the tumor: i.e., IgG was still heterogeneously distributed throughout the tumor (46). 
In therapy experiments combined treatment with hyperthermia and radiolabeled 
Mab resulted in enhanced growth retardation as compared with both therapeutic 
approaches alone (46,48). 
Improved radiolabeling methods 
The most widely used radionuclides to label antibodies are isotopes of iodine. 
With the standard radioiodination techniques (iodogen or chloramine-T) radioiodine is 
rapidly excreted from the cell after metabolization of the radiolabeled antibody. 
Radioimmunotargeting approaches might be improved if the radionuclide is better 
retained in the cell. Therefore, methods have been developed to enhance the retention 
of the radiolabel. The uptake of radioiodinated MAb 81C6 in D-54 MG glioma tumors 
could be increased by a factor 4.5 using the N-succinimidyl-3-(tri-n-
butylstannyl)benzoate (ATE) radioiodination method compared with the iodogen 
method (49). Tumor localization with the ATE method was higher than 20 %ID/g from 
8 to 48 h p.i., whereas tumor localization with the iodogen method was maximal at 8 
h p.i. (12 %ID/g). Due to this increased uptake and retention the cumulative activity in 
these tumors was 3-fold greater using the ATE method. 
Hnatowich et al. (50) developed a simple and efficient method to radiolabel IgG 
with 1,1 ln via the cyclic anhydride diethylene triamine pentaacetic acid (DTPA) 
chelator. However, in stability tests in serum 11 l ln was released from DTPA (51). For 
radiolabeling of MAbs with radiometals like n i l n or 90Y stability of the chelate used to 
incorporate the radiolabel is very important, since release of indium or yttrium in vivo 
will lead to the deposition of the radionuclides in liver and bone. Therefore, several 
other chelates were tested for labeling proteins with metallic radionuclides. The mixed 
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anhydride DTPA gave rise to more stable conjugates as indicated by the high tumor 
uptake and low normal organ uptake (52,53). Introduction of an isothiocyanato-benzyl 
(SCN-Bz) group between the MAb and the DTPA also led to a more stable , n l n -
chelate-MAb (52,53). Introduction of methyl groups to the backbone of SCN-Bz-DTPA 
further increased the stability (53,54). High uptake in the tumor, slow clearance from 
the blood and low uptake in liver and bone were obtained (53,54). In addition to 
noncyclic DTPA-like chelates, macrocyclic chelates have been tested to radiolabel 
proteins with metallic nuclides (e.g., 1,4,7,10-tetraazacyclododecane tetraacetic acid 
(DOTA)). SCN-Bz-DOTA proved to be even better than methyl substituded SCN-Bz-
DTPA, as indicated by the very low bone uptake of yttrium (55). 
In conclusion, the uptake and retention of radiolabeled MAb in tumors depended 
largely on the method of radiolabeling. Increased uptake or retention in the tumor is 
especially important in radioimmunotherapeutic protocols, where optimal tumor uptake 
and retention is of utmost importance. 
STRATEGIES TO INCREASE CLEARANCE OF CIRCULATING 
RADIOLABELED ANTIBODIES 
In addition to approaches to enhance the tumor uptake of radiolabeled MAbs, various 
approaches have been proposed to reduce the amount of radiolabeled MAb in 
nontarget tissues (mainly rapid removal of radiolabeled Mab from the circulation) as 
listed in Table 2. 
TABLE 2 
Strategies to reduce the amount of circulating 
Antibody fragments 
Metabohzable linkers 




Fragments of antibodies like F(ab')2, Fab and scFv, clear more rapidly from the blood 
and the intratumoral penetration of antibody fragments is increased. In a series of 
comparative studies in mice with tumor xenografts the F(ab')2 fragment cleared more 
rapidly from the circulation and normal organs than whole IgG (56-61). However, 
concomitantly, the uptake of the F(ab')2 fragment in the tumor in most studies was 
lower than that of whole IgG (56-59,61). Overall, the tumor-to-blood ratios obtained 
with F(ab')2 fragments were higher than those observed with IgG (56-61). The 
clearance of the Fab fragment from the blood was even faster than the clearance of 
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the F(ab')2 fragment (59-61) The tumor-to-blood ratios, however, were similar for 
F(ab')2 and Fab, due to the lower uptake of Fab in the tumor compared with F(ab')2. 
With Fab fragments the maximum tumor-to-blood ratio was achieved earlier after 
injection of the fragment than of the F(ab')2 fragment (59,60) The even smaller single 
chain Fv fragments have also been studied in animal models Uptake of scFv in the 
tumor was lower than that of Fab and blood clearance was faster. The tumor-to-blood 
ratios however, were lower compared with Fab (60). In summary, for 
radioimmunoscintigraphic studies F(ab')2 might be the antibody form of choise, since 
with F(ab')2 both high uptake in the tumor and high tumor-to-blood ratios are 
obtained. 
In a detailed study, Buist et al (62) reported about the biodistribution of 
simultaneously administered radioiodinated MOv18 whole IgG and F(ab')2 in patients 
with ovarian cancer The uptake of whole IgG in the tumor was significantly higher 
than the uptake of F(ab')2, both at 2 and at 6 days ρ ι. (3 6-fold and 6 9-fold higher, 
respectively). Since the amount of radiolabel in nontarget organs was also similarly 
higher for whole IgG, tumor-to-nontumor ratios were not different The retention time 
in the tumor and in nontarget tissues was longer for whole IgG than for F(ab')2. A 
similar study was performed in patients with colorectal cancer using the anti-CEA 
antibody IMMU-4 (63). The uptake in the tumor and in nontarget organs was similar 
for whole IgG and F(ab')2 In addition, other pharmacokinetics of IgG and F(ab')2 were 
similar In a radioimmunoscintigraphy study of patients with head and neck cancer IgG 
and F(ab')2 were equally well suited for radioimmunoscintigraphy (64) In contrast, in 
patients with colorectal carcinoma the percentage of positive radioimmunoscintigrams 
was higher for 17-1A F(ab')2 than for IgG (65) These data indicate that in patients 
the choice of antibody form is less clear cut than in radioimmunotargeting experiments 
in animals. For each individual antibody a comparison between IgG and F(ab')2 seems 
necessary to select the antibody form of choice 
The therapeutic efficacy of radiolabeled IgG and F(ab')2 has been compared in 
several preclinical studies (66-70) Blumenthal et al (66) injected similar amounts of 
radioactivity (74 MBq) of 131l-NP-4 whole IgG and F(ab')2 in hamsters with GW-39 
tumors in their cheek pouch. IgG appeared more effective than F(ab')2 In other 
studies the dose of radioantibodies were selected in such way that the radiation doses 
to the tumor were identical (67,68). In these experiments therapeutic efficacy of 
whole IgG and F(ab')2 was similar. However, with the F(ab')2 fragments lower rad 
doses were delivered to the blood compared with IgG (lower toxicity). Therefore, 
higher amounts of radiolabeled F(ab')2 can be administered in these experiments and 
this might result in an increase in therapeutic efficacy of the F(ab')2 fragment (68). 
Finally, in some studies IgG and F(ab')2 were compared at their maximum tolerated 
dose (MTD) (69,70). In mice with s.c. tumors 131l-lgG and 131l-F(ab')2 appeared equally 
effective In contrast, 90Y-lgG was more effective than 90Y-F(ab')2. With both antibody 
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forms 131l-labeled MAb were more effective than 90Y-labeled Mab (69). In an animal 
model of micrometastases in the lung, Blumenthal et al. (70) studied the whole IgG 
and the F(ab')2 fragment of two different antibodies at MTD. With both antibodies 
different effects were observed. The whole IgG form of the anti-CEA antibody NP-4 
was more effective than F(ab')2 ¡n small tumor nodules, whereas in larger nodules IgG 
and F(ab')2 were equally effective. The anti-colon-specific antigen-p antibody Mu-9 
IgG and its F(ab')2 were equally effective in small nodules. In larger nodules IgG was 
more effective than F(ab')2. The total rad doses delivered to the blood were lower 
with F(ab')2 fragments compared to IgG, however, the rate of the rad dose was 
similar in the first 24-48 h p.i. (69,70). In conclusion, the animal studies described 
above, although carefully designed, do not provide a clear cut answer about the most 
effective antibody form for radioimmunotherapy. Which antibody form should be used 
may depend on the MAb itself, the location of the tumor, the size of the tumor and 
the radionuclide attached to it. 
The therapeutic efficacy of whole IgG and F(ab')2 has also been compared in 
several clinical studies. Lane et al. (71) gave higher radioactivity doses of F(ab')2 
compared with IgG. In other studies similar doses of IgG and F(ab')2were administered 
(72,73). Clearance of F(ab')2 from the blood and whole body was either faster (72) or 
similar to that of IgG (71, 73). The rad dose to the tumor was either higher for the 
IgG (72) or quite similar for IgG and F(ab')2 (71 , 73). With F(ab')2 a higher initial dose 
rate to the tumor was achieved due to the more rapid penetration of F(ab')2 in the 
tumor (71). In conclusion, in clinical studies no significant differences were observed 
in the therapeutic window between IgG and F(ab')2. 
Metabolizable linkers 
The tumor-to-nontumor ratios might be increased in case the labeled antibody is 
bound tightly to the tumor, while the labeled antibody in normal organs and blood is 
metabolized and removed rapidly. With 111ln-labeled MAbs e.g., in most studies high 
uptake of 111ln in the liver is observed, leading to relatively low tumor-to-liver ratios 
(58,61). Several linkers have been introduced between MAb and 11lln-chelate, to test 
whether this approach could improve target-to-nontarget ratios. The i n ln-chelate 
conjugated to the MAb via the standard nonmetabolizable peptide bond {e.g., DTPA) 
or thiourea bond (e.g., SCN-Bz-DTPA) was compared with the 111ln-chelate conjugated 
via enzyme metabolizable diester, disulfide or tartaramide linkers or non-enzyme 
metabolizable alifatic or thioether linkers (74-77). With a diester linker higher target-
to-blood ratios were found, mainly caused by more rapid clearance of the MAb-
diester-chelate from the blood (74-77). The uptake in the target varied from increased 
(74,75), similar (77) or decreased (76) using the diester chelate. In all studies 
decreased uptake in the liver was observed (74-77). With the enzyme-cleavable 
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disulfide linker, tumor uptake of the MAb increased and the amount of activity in 
blood and liver decreased, resulting in increased tumor-to-blood and tumor-to-liver 
ratios (75). With the enzyme-cleavable tartaramide linker improved tumor-to-blood and 
tumor-to-liver ratios were obtained, although the improvement was not as good as 
observed with the diester linker (77). The use of an non-cleavable alifatic linkage or 
thioether linkage did not result in improved tumor-to-blood ratios (75,77). 
With 99mTc-labeled Fab' fragments, frequently high kidney uptake was observed 
(78). This high uptake might be overcome by using the bifunctional chelate RP-1 
(containing an ester linkage) (79). The uptake in the tumor did not decrease compared 
to directly labeled Fab', whereas the rad dose to the kidney was reduced with 50-
75%. 
In conclusion, tumor-to-nontumor ratios could be improved using enzyme-
cleavable linkers interpositioned between the MAb and the radiolabeled chelate. Best 
results were obtained using the diester and disulfide linkers. With the non-enzyme-
cleavable linkers tumor-to-nontumor ratios did not improve. 
Background reducing agents 
A method of clearing antibody present in the circulation and in extravascular spaces 
without removing antibody from the tumor would improve tumor-to-nontumor ratios. 
Second antibody 
In the early 1980s studies were performed in which radiolabeled goat anti-CEA 
antibody was cleared from the circulation by liposomally entrapped horse antigoat 
IgG. Both in animal (80) as well as clinical studies (81) clearance of radiolabeled 
antibody from the blood was enhanced after injection of a second antibody. The 
enhanced clearance of the radiolabeled antibody from the blood was dependent on the 
dose of the second antibody (80). In animal studies the tumor uptake of a primary 
antibody was slightly decreased 24 h p.i. of a second antibody (80). The primary 
antibody was cleared as immune complex via the liver and the spleen. Tumor-to-blood 
ratios were significantly higher after injection of the second antibody (80,81). 
Several preclinical (82-84) and clinical (85,86) studies demonstrated that 
entrapment of the second antibody in liposomes was not necessary to achieve rapid 
clearance of the radiolabeled antibody from the blood. Not only the dose of the 
second antibody, but also the interval between primary and secondary antibody 
injection affected the outcome of the experiments (83,84). 
Injection of the second antibody did not influence the therapeutic efficacy of the 
radiolabeled antibody. The toxicity, however, was reduced due to the enhanced 
clearance of the radiolabeled MAb from the circulation (87). Therefore, higher 
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amounts of radiolabeled MAb can be administered in a therapeutic setting (88). 
Sharkey et al. (88) also pointed out that the second antibody method would not be 
useful for radiometal-labeled MAbs. Higher total rad doses would be delivered to the 
liver compared with the tumor, due to the retention of the radiolabel after 
metabolization of primary antibody-secondary antibody complexes in the liver. For 
non-residualizing radionuclides, such as iodine, however, this approach could offer an 
elegant and rapid way to increase tumor-to-nontumor ratios. 
Biotin-avidin 
The avid interaction between (strept)avidin and biotin can be used to enhance the 
removal of radiolabeled antibodies from the circulation. Biotinylated MAb was 
removed from the circulation after administration of streptavidin (89). This approach 
has been further investigated in a series of studies (90,91). Rapid clearance of MAb-
biotin from the blood was observed after streptavidin injection, at the expense of a 
reduction in the amount of MAb-biotin in the tumor. The complexes formed by 
radiolabeled MAb-biotin and streptavidin cleared via the liver and the spleen (90,91). 
The number of biotin molecules per MAb affected the rate of the clearance (90). At 4 
biotins per MAb tumor-to-blood ratios did not improve, whereas at 9 or 22 biotins per 
MAb rapid clearance from the blood was observed, resulting in increased tumor-to-
blood ratios (90). In addition, the avidin dose appeared also of importance (91). At 
higher avidin doses tumor-to-blood ratios increased more rapidly. Also the interval 
between both injections influenced the biodistribution of the radiolabeled MAb (91). 
Tumor-to-blood ratios were higher at a 24-h interval between the two injections than 
at a 6-h interval. Clearance of complexes between MAb-biotin and streptavidin could 
be directed to the liver using galactosylated streptavidin as clearing agent (92). 
Administration of a second avidin dose, to catch MAb-biotin that reentered the 
circulation, resulted in a further decrease in the amount of MAb-biotin in the blood. 
The uptake of MAb-biotin in the tumor was not reduced after the second injection 
(93). 
PRETARGETING APPROACHES 
Pretargeting approaches can be used to increase tumor-to-nontumor ratios. The 
difference between the above mentioned ways to enhance the tumor-to-nontumor 
ratios en pretargeting approaches is, that in pretargeting approaches the antitumor 
MAb and the radionuclide are administered sequentially. The unlabeled antitumor 
antibody is administered first and is allowed to clear from the circulation. Thereafter 
the radionuclide is given as a low-molecular-weight ligand. The main advantage of 
these approaches is the very rapid excretion of non tumor-bound small ligand through 
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the kidneys. Several pretargeting procedures are being used, depending on different 
interactions between the first and second injectâtes. Figure 1 provides a schematic 
representatation of the various systems described in the literature. These pretargeting 
approaches have been tested in preclinical as well as clinical studies. 
Monoclonal antibody-enzyme prodrug systems 
Hawkins et al. (94) developed a two-phase system based on dihydrofolate reductase 
conjugated to an antitransferrin MAb (first phase) and 1l1ln-DTPA-methotrexate 
(second phase). In vitro, MAb-dihydrofolate reductase bound to tumor cells could be 
targeted with 111ln-DTPA-methotrexate. No in vivo studies have been performed. 
DNA-DNA hybridization systems 
Bos et al. (95) developed a two-phase system based on DNA-DNA hybridization. In in 
vitro studies an antitumor MAb-oligonucleotide conjugate was bound specifically to 
tumor cells and could be targeted with radioiodinated complementary oligonucleotide. 
Mardirossian et al. (96) showed that the structure of the oligonucleotide influenced 
their in vivo use. Radiolabeled phosphodiester DNA and radiolabeled phosphorothioate 
DNA could not be used for in vivo two-step targeting of beads derivatized with 
complementary DNA, because of their rapid breakdown by nucleases on one hand and 
their high affinity for serum proteins on the other. In contrast, peptide nucleic acids 
(PNA, in which the charged phosphate-ribose backbone has been replaced by an 
uncharged polyamide backbone) could be used succesfully for in vivo two-step 
targeting. Nonbound PNA was rapidly cleared via the kidneys (96). In preliminary 
experiments, 99nTc labeled complementary single stranded PNA was specifically bound 
in the tumor to the previously administered single stranded PNA-streptavidin (97). 
The avidin-biotin system 
The avid interaction between avidin and biotin has also been exploited in pretargeting 
approaches. In contrast with the background reduction approach mentioned above, in 
pretargeting approaches the radionuclide is administered in the second step instead of 
the first step. 
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FIGURE 1. Pretargeting approaches. In the first step the targeting molecule is injected. This targeting 
molecule can be cleared from the circulation using a chase molecule. In the next step the radiolabeled 
chelate is administered. This radiolabeled molecule forms a complex with the pretargeted molecule at 
the site of the tumor. 
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In preclinical experiments three different multistep approaches have been tested: 
(a) avidin-conjugated IgG followed by radiolabeled biotin (98), (b) biotinylated IgG 
followed by radiolabeled streptavidin (89,99,100) and (c) biotinylated IgG followed by 
avidin and radiolabeled biotin (89). In all three pretargeting approaches specific 
localization of the radiolabeled pharmaceutical in the target was achieved. Tumor-to-
nontumor ratios improved more rapidly in the pretargeting protocol compared with 
directly labeled MAb (99). However, wi th the radiolabeled streptavidin uptake in the 
liver was high, probably caused by immunecomplex formation between circulating 
IgG-biotin and labeled streptavidin (89,99). Additionally, uptake of radiolabeled 
streptavidin in the kidney was high (99,100). Paganelli et al. (89) developed a three-
step protocol to overcome the high background activity of radiolabeled streptavidin. In 
the three-step protocol cold avidin was injected prior to injection of radiolabeled biotin. 
The main advantage of this cold avidin injection appeared to be the clearance of 
circulating MAb-biotin. But also signal amplification in the tumor was obtained (89). 
Significant higher tumor-to-nontumor ratios were obtained using this three-step 
protocol (89). These data indicate that protocols based on radiolabeled biotin are more 
succesfull than protocols based on radiolabeled (strept)avidin. 
In mice with breast cancer and with small cell lung cancer xenografts, durable, 
complete regressions of tumor have been obtained with no apparent signs of toxicity 
using a three-step protocol (101). Two-subsequent injections of 90Y-DOTA-biotin 
resulted in two-fold higher amounts of radiolabel in the tumor (102). 
The three pretargeting strategies mentioned above have also been evaluated in 
patients. In 10 patients with squamous cell carcinoma of the lung a two-step protocol 
based on MAb-streptavidin followed by i n ln-biot in was compared with i n ln-biot in 
alone. Eight patients had a positive radioimmunoscintigram. In 5 of these 8 patients 
no difference in image quality was found between 111ln-biotin alone and 1 l l ln-biotin 
plus pretargeting with MAb-streptavidin. In the other 3 patients better images were 
obtained after pretargeting (103). In patients with ovarian cancer n i ln-streptavidin 
was injected ¡.p. after priming with MOv18-biotin Mab. Positive 
radioimmunoscintigrams were observed. However, 11lln-streptavidin was cleared 
slowly from the blood (T,AP 45 h). In contrast to findings in animal experiments 
(99,100), no high kidney uptake was observed in humans, due to the i.p. injection of 
radiolabeled streptavidin (104). Paganelli et al. (105) used the three-step protocol to 
image patients wi th CEA-positive tumors. 111ln-biotin cleared rapidly from the blood. 
Due to this rapid clearance, tumor-to-blood ratios increased rapidly. Significantly lower 
rad doses were delivered to for instance the liver compared with l l1ln-F(ab')2 MAb. 
When , n ln-biot in was administered without pretargeting with biotinylated MAb and 
streptavidin, no positive scintigrams were obtained. The uptake of l11ln-biotin in the 
tumor was approximately 0.012 %ID/g. A similar three-step protocol was used to 
image patients with choroidal melanoma. In this study an intrapatient comparison was 
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made with the 99mTc-labeled F(ab')2 fragment of the antimelanoma MAb 225.28S. 
Tumor uptake was similar using the pretargeting approach or the directly labeled 
F(ab')2 fragment. However, significantly higher tumor-to-nontumor ratios were 
observed in the three-step protocol, due to the rapid clearance of unbound 9 9 mTc-
biotin-dioxine derivate (99mTc-PnAO-biotin) (106). 
Objective tumor responses have been observed in patients using a three-step 
protocol with 90Y-DOTA-biotin (102). No toxicity was observed. 
Several problems are inherent to the avidin-biotin pretargeting strategies. First, 
the immunogenicity of avidin and streptavidin (103-105). This major disadvantage can 
not easily be circumvented since there is no human counterpart of avidin/streptavidin. 
Second, endogenous biotin may interfere with these protocols as shown in animal 
models (107,108), although this interference may be less severe in humans (108). 
Still, a major advantage is that the avidin/biotin approach can be used, without any 
difficulty, for each MAb. 
PRETARGETING WITH BISPECIFIC ANTITUMOR X ANTICHELATE 
MONOCLONAL ANTIBODIES 
In contrast to monoclonal antibodies, bispecific monoclonal antibodies (bsMAbs) 
recognize two different antigens monovalently. Bispecific antibodies have been used 
to target drugs, like ricin-Α, vinca alkaloids or anthracyclines, to tumor cells (109). 
Bifunctional antibodies can also be used to redirect cytotoxic cells, such as T-cells and 
NK-cells, by binding both a tumor-associated antigen and a receptor on the cytotoxic 
cell membrane (109). Furthermore, bispecific antibodies can be used to target 
radiolabeled chelates to the tumor. 
In antitumor χ antichelate bispecific antibody based pretargeting protocols, the 
unlabeled bispecific antibody is injected first and thereafter the rapidly clearing 
radiolabeled low-molecular-weight chelate is administered. Most of the bsMAbs have 
been produced either in chemical or in biological systems (109,110). In addition, 
bispecific antibody fragments have also been produced in prokaryotic systems (111). 
Chemical production of bispecific monoclonal antibodies 
Bispecific monoclonal antibodies can be prepared by conjugation of two monoclonal 
antibodies of different specificities. Heteroconjugates of Fab' and Fab' (112), Fab' and 
F(ab')2 (113) and of IgG and IgG (114) have been described. Chemically conjugated 
bsMAbs can be produced faster and can be purified more easily compared to 
biologically produced bsMAbs. However, chemical manipulations may harm the 
¡mmunoreactivity of the antibody. In addition, chemically produced bispecific MAbs 
may suffer from batch-to-batch variation (110). 
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Biological production of bispecific monoclonal antibodies 
Two different methods have been used for the biological production of bispecific 
antibodies. First, fusion of t w o hybridoma cell lines secreting different MAbs to 
quadroma cells producing bispecific antibody (115). Second, fusion of a hybridoma 
cell line with immune spleen cells; whereby a bispecific antibody producing trioma cell 
is obtained (116). The main advantage of biologically produced bsMAbs is that they 
are synthesized, assembled and secreted by the same process as the native 
immunoglobulins. Quadromas and triomas are infinite sources of bispecific antibodies. 
A disadvantage of this procedure is that it is relatively time-consuming and that some 
hybridomas are difficult to fuse (110). In addition, bsMAbs may be difficult to purify, 
due to the fact that the functional bsMAb is 1 of the 10 different species that can be 
produced in quadroma and trioma cells (117). 
Bispecific antibodies and radioimmunotargeting 
The idea to use antitumor χ antichelate bispecific antibodies was based on studies of 
Reardan eta/. (118) and Goodwin etat. (119). They produced monoclonal antibodies 
against metal chelates. In mice with a KHJJ mouse tumor, antichelate MAb and n i l n -
BLEDTA II chelate were injected simultaneously. i n ln-BLEDTA II was specifically 
bound by circulating antichelate antibody. Significant higher uptake in the tumor was 
observed compared with 111ln-BLEDTA II alone, due to nonspecific uptake of the 
antichelate antibody-^'ln-BLEDTA II complex in the tumor (119). In later studies, it 
was shown that uptake of radiolabeled chelate in the tumor could also be enhanced 
when the antichelate MAb and the radiolabeled chelate were administered sequentially 
(120). 
Stickney et al. (121) developed a two-step system based on an anti-CEA χ anti-
, nln-Bz-EDTA Fab' χ Fab' bsMAb and "Mn-EOTUBE (a hydroxyethyl thiourido 
derivative of Bz-EDTA). The radiolabeled chelate together with 3 цд carrier bsMAb (to 
prolong the plasma retention time of inln-EOTUBE) was administered 24 h after 
injection of 14 цд bsMAb. Tumor uptake and tumor-to-blood ratios were higher with 
the EOTUBE chelate. Tumor-to-blood ratios increased upto 11 at 48 h p.i. (121). 
Le Doussal et al. (122) demonstrated that pretargeting could be improved using 
bivalent chelates instead of monovalent chelates, leading to 2-fold higher tumor-to-
nontumor ratios compared to monovalent chelates (122). The higher tumor uptake of 
bivalent chelates was attributed to the preferential binding of radiolabeled bivalent 
chelate to cell-bound bsMAb compared with circulating bsMAb. In the tumor the 
bivalent chelate might interact simultaneously with t w o bsMAbs, resulting in 
increased affinity (122). In contrast, Goodwin et al. (123) found 2-fold lower tumor 
uptake of bivalent chelates compared with monovalent chelates using a two-step 
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approach based on an antichelate MAb and radiolabeled DOTA. This was attributed to 
the crosslinking of bivalent chelate with circulating antichelate MAb and clearance of 
these complexes via the liver (123). In addition to higher uptake in the tumor of the 
radiolabeled chelate, retention in the tumor might be prolonged using bivalent 
chelates. Theoretical calculations have indicated that the rate of loss of radiolabel 
from a tumor would be 20x slower for a bivalent hapten than for a monovalent hapten 
(124). 
The influence of different parameters on the two-step protocol was studied in 
detail in mice with A375 melanoma tumors by Le Doussal et al. (122). In the first 
step G7A5-734 F(ab')2-Fab' bispecific antibody was administered, followed by
 l 1 1 ln-di-
In-DTPA-TL. The highest tumor uptake was observed when the interval between 
F(ab')2-Fab' bsMAb and chelate injections was 24-48 h. The protein dose of the 
bsMAb influenced 111ln-di-ln-DTPA-TL uptake in the tumor, with the highest tumor 
uptake observed at a dose of 3 pg. In addition, with increasing chelate concentration, 
the uptake in the tumor expressed as %ID/g tumor decreased. Maximum tumor-to-
nontumor ratios were observed using 1-10 pmol radiolabled chelate (122). Compared 
with directly labeled F(ab')2, tumor-to-blood ratios were similar at 48 h p.i. However, 
tumor-to-blood ratios increased faster with the two-step approach. Compared with the 
directly labeled F(ab')2, lower uptake of radiolabeled chelate in the tumor was 
observed in the two-step approach (1 22). 
Goodwin et al. (120,123,125) found high amounts of radiolabeled chelate in 
blood due to binding of radiolabeled chelate to circulating antichelate antibody. This 
could be overcome by introduction of a background reduction step. Binding of 
radiolabeled chelate to circulating antibody could be reduced 38-fold by administration 
of chelate covalently bound to a slowly diffusable serum protein (transferrin) shortly 
before injection of the radiolabeled chelate (120). In the three-step protocol tumor 
uptake was reduced to one third. Tumor-to-blood ratios, however, increased 13-fold 
due to the very efficient clearance of radiolabeled chelate from the circulation (120). 
This so-called chase technique was also used by Schuhmacher et al. (125) to improve 
tumor-to-blood ratios. Results depended on the amount of chase injected. With 
increasing amounts of chase injected, the amount of radiolabeled chelate decreased in 
the blood and increased in the tumor (in contrast with the lower tumor uptake 
observed by Goodwin et al. (120)). The interval between administration of chase 
agent and chelate also influenced the biodistribution of the radiolabeled chelate. When 
the interval was 1 h or longer, lower amounts of radiolabeled chelate were observed in 
all tissues, including the tumor (125). 
In 1991 Stickney et al. (121) described a two-step system to image patients 
with recurrent or metastatic colorectal carcinoma. Patients received 20-40 mg Fab'-
Fab' anti-CEA χ anti-ln-Bz-EDTA bsMAb, followed by a second injection 4 days later 
with 25 nmol radiolabeled EOTUBE chelate in combination with 0.1-5 mg bsMAb as 
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carrier protein. Radioactivity levels were low in the background tissues. High tumor-to-
nontumor ratios were observed as early as 4 h p.i. Twenty out of 21 known lesions 
were detected. Besides this, nine new lesions were identified (121). 
In patients with primary colorectal tumors Le Doussal et al. (126) studied various 
parameters of the two-step protocol (Fab'-Fab' anti-CEA χ anti-ln-DTPA bsMAb and 
111ln-di-ln-DTPA-TL bivalent chelate), such as the interval between the two injections, 
the protein dose of bispecific antibody and the dose of hapten. At higher bispecific 
antibody protein dose extravasation and elimination of radiolabeled chelate was 
decreased, whereas the residence time and the tÄP of the chelate increased. At longer 
time intervals between both injections, extravasation of chelate increased. However, 
tumor uptake of radiolabeled chelate was not influenced. Finally, at higher chelate 
doses the fraction of hapten distributed in tissues increased. Lower relative uptake of 
chelate in the tumor and lower amounts in the circulation were seen at higher chelate 
dose levels (126). On the basis of these data the optimal two-step protocol was 
defined as follows: an interval of 4-5 days between the injection of the bsMAb and 
that of the radiolabeled chelate, a protein dose of 0.1 mg/kg of the bsMAb and an 
amount of 0.1 nmol/kg of the bivalent chelate (126). Using this two-step protocol 12 
out of 13 lesions were detected, with lower uptake in normal organs and increased 
uptake ratios compared with imaging with directly labeled F(ab')2 (126). 
The optimized anti-CEA χ antichelate bispecific antibody two-step system as 
described by Le Doussal et al. (126), has also been used for radioimmunodetection of 
medullary thyroid cancer (127), recurrent colorectal cancer (128) and non-small-cell 
lung cancer (129). In patients with primary, recurrent, or suspected recurrent 
medullary thyroid carcinoma, primary tumors as well as small extra- and intrahepatic 
metastases were imaged with good quality. New lesions were found in patients 
suspected of recurrent tumor. Uptake of radiolabeled chelate in the tumor lesions 
varied between 2.7 and 139 %ID/kg. Tumor uptake was > 3 0 %ID/kg when antigen 
expression was high and the percentage of cancer cells in the tumor was > 7 0 % 
(127). In patients with recurrent colorectal cancer extrahepatic lesions were clearly 
imaged: only one lesion was missed (peritoneal carcinomatosis). Imaging of large, 
necrotic intrahepatic lesions was not reliable, since the tumor-to-background ratio for 
these lesions was only 1.1 (128). In patients with primary non-small-cell lung cancer 
the two-step protocol was used to establish mediastinal involvement (129). The 
sensitivity of detecting the primary lesion was 7 5 % (9 out of 12 patients). At the 
mediastinum level sensitivity and specificity were 6 6 % (2 out of 3) and 8 9 % (8 out of 
9). No relationship was observed between CEA antigen expression and uptake of the 
radiolabeled chelate in the tumor, however, such a relationship might exist for the 
tumor-to-blood ratio (129). 
The same investigators are now developing a similar approach for 
radioimmunotherapy. In mice with colorectal cancer xenografts they compared the 
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radioimmunotherapeutic efficacy of 131l-di-ln-DTPA-TL after priming with anti-CEA χ 
anti-DTPA bsMAb with l31l-anti-CEA IgG, both at MTD (111 MBq versus 12 MBq). 
Tumor growth delay was significantly longer compared with 131l-lgG (53 versus over 
150 days). Hematologic and overall toxicity of both treatments were equivalent (130). 
In several clinical studies human antimouse antibodies were elicited after the 
administration of bsMAb (7 out of 11 patients (126) and 4 out of 9 patients (128)). 
Due to the presence of these human antimouse antibodies, a second injection of 
bispecific antibody might be less successful due to rapid clearance of the bispecific 
antibody as a result of formation of immune complexes with the human antimouse 
antibodies. The immunogenicity of murine bsMAbs may be overcome by using 
humanized bsMAbs. Bruynck er al. (131) have produced an anti-CEA χ anti-DTPA 
humanized bispecific MAb by consecutively transfecting the humanized genes of the 
anti-CEA Mab and the chimerized genes of the anti-DTPA MAb into eucaryotic BHK 
cells. 
These data indicate that with antitumor χ antichelate bsMabs and radiolabeled 
chelates high tumor-to-nontumor ratios are observed shortly after injection of the 
radiolabeled chelate, which is beneficial for radioimmunotargeting. In addition, 
prolonged tumor growth delay is seen in radioimmunotherapy studies. 
S U M M A R Y 
Various approaches aiming to improve tumor-to-nontumor ratios in 
radioimmunotargeting have been tested in animal models as well as in cancer patients. 
Some of these approaches seem to be more useful in the context of 
radioimmunodetection, while others are more appropriate for radioimmunotherapy. 
Some approaches aim to enhance the tumor localization of radiolabeled Mabs. 
Second generation antibodies, cocktails of antibodies, antibody protein dose, and 
more stable radiolabeling methods improve the outcome of radioimmunotargeting. In 
addition, regional administration of the radiolabeled antibody can enhance the tumor 
uptake of radiolabeled MAb. However, for this approach tumors need to be confined 
to accessible or locoregional areas. Administration of external irradiation or 
hyperthermia gave rise to significantly higher tumor uptake. However, this approach 
can only be applied in limited cases. Finally, administration of biological response 
modifiers resulted in enhanced antigen expression and in enhanced tumor uptake. 
Tumor-to-nontumor ratios can also be increased by improving the clearance of 
radiolabeled Mab from nontarget tissues. For antibodies labeled with metallic 
radionuclides, introduction of an metabolizable linkage resulted in increased tumor-to-
nontumor ratios. This approach seems to improve mainly tumor-to-liver ratios. The 
beneficial effect of antibody fragments on tumor-to-nontumor ratios in 
radioimmunodetection protocols has been well established. However, for therapeutic 
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applications, the optimal antibody form remains to be established. For radioiodinated 
antibodies, administration of a background reducing agent (e.g., second antibodies or 
avidin) might improve the therapeutic efficacy of radiolabeled MAb, because of 
reduced background activity. Increased therapeutic efficacy might also be achieved 
using pretargeting approaches (e.g., avidin-biotin interaction, antitumor χ antichelate 
bispecific antibodies) since there is reduced toxicity of radiolabeled chelate or 
increased tumor growth delay compared to directly labeled MAbs. The first preclinical 
and clinical results justify further investigations of bispecific antitumor χ antichelate 
antibodies in animal models as well as patients. 
Pretargeting approaches seem to be a promising way to optimize 
radioimmunodetection and radioimmunotherapy. The studies in this thesis focus on 
optimization of an antitumor χ antichelate bispecific antibody based pretargeting 
protocol in mice with renal cell carcinoma xenografts. 
REFERENCES 
1. Fujimori K, Covell DG, Fletcher JE, Weinstein J N . A modeling analysis of monoclonal antibody 
percolation through tumors a binding-site barrier. J Nucl M e d , 1 9 9 0 , 3 1 : 1191-1198 
2 Muraro R, Kuroki M, Wunderl ich D, Poole DJ, Colcher D, Thor A, Gremer JW, Simpson JF, 
Molinolo A, Noguchi P, Schlom J . Generation and characterization of B72.3 second generation 
monoclonal antibodies reactive w i t h the tumor-associated glycoprotein 72 antigen. Cancer Res, 
19Θ8, 4 8 : 4 6 8 8 - 4 5 9 6 
3 Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J . 
Radioimmunolocahzation of human carcinoma xenografts w i t h B72.3 second generation 
monoclonal antibodies. Cancer Res, 1 9 8 8 , 4 8 : 4 5 9 7 - 4 6 0 3 
4. Gallinger S, Reilly RM, Kirsh JC, Odze RD, Schmocker BJ, Hay K, Polihroms J , Damani MT, 
Shpitz B, Stern HS. Comparative dual label study of f irst and second generation antitumor-
associated glycoprotein-72 monoclonal antibodies in colorectal cancer pat ients. Cancer Res, 
1 9 9 3 , 5 3 : 2 7 1 - 2 7 8 
5 Hansen H J , Goldenberg D M , Newman ES, Grebenau R, Sharkey RM. Characterization of second-
generation monoclonal antibodies against carcinoembryomc ant igen. Cancer, 1 9 9 3 , 7 1 : 3 4 7 8 -
3 4 8 5 
6. J u w e i d M, Sharkey RM, Behr T, Swayne LC, Rubin A D , Hanley D, Herskovic T, Markowitz A, 
Siegel J , Goldenberg D M . Targeting and initial radioimmunotherapy of medullary thyroid 
carcinoma w i t h ' 3 1 l- labeled monoclonal antibodies to carcinoembryomc antigen Cancer Res, 
1 9 9 5 , 5 5 : 5 9 4 6 s - 5 9 5 1 s 
7. Kitamura K, Takahashi T, Kotani T, Miyagaki N, Yamaoka N, Tsurumi H, Noguchi A, Yamaguchi 
T. Local administrat ion of monoclonal antibody-drug conjugate: a n e w strategy to reduce the 
local recurrence of colorectal cancer. Cancer Res,1992, 5 2 : 6 3 2 3 - 6 3 2 8 
8 Rowlmson-Busza G, Bamias A, Krausz T, Epenetos AA. Uptake and distr ibution of specific and 
control monoclonal antibodies in subcutaneous xenografts fo l lowing intratumor injection. Cancer 
Res, 1 9 9 1 , 5 1 : 3 2 5 1 - 3 2 5 6 
9 Riva Ρ, Arista A, Franceschi G, Frattarelli M, Stunale C, Riva N, Casi M , Rossitti R. Local 
t reatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled w i t h 
, 3 1 l : comparison of the results obtained in recurrent and newly diagnosed tumors Cancer Res, 
1 9 9 5 , 5 5 : 5 9 5 2 s - 5 9 5 6 s 
10 Ine RF, M o r t o n DL. Regression of cutaneous metastatic melanoma by intralesional injection w i t h 
human monoclonal ant ibody to ganghoside GD2. Proc Natl Acad Sci USA, 1 9 8 6 , 8 3 : 8 6 9 4 - 8 6 9 8 
11 Pectasides D, Stewart S, Courtenay-Luck N, Ramplmg R, Munro A J , Krausz T, Dhokia B, Snook 
D, Hooker G, Durbin H, Taylor-Papadimitnou J , Bodmer WF, Epenetos AA. Antibody-guided 
irradiation of malignant pleural and pericardial effusions. Br J Cancer, 1 9 8 6 , 5 3 : 727-732 
12. Wahl RL, Liebert M , Headington J , Wilson BS, Shulkin BL, Johnson JW, Mallette S, Natale RB, 
34 
Chapter 1 
Coon W, East M, Davenport R, Brown MB, Niederhuber JT, Swanson NA. Lymphoscintigraphy in 
melanoma, initial evaluation of a low protein dose monoclonal antibody cocktail. Cancer Res, 
1 9 9 0 , 5 0 : 941s-948s 
13 Mulshine JL, Carrasquillo JA, Weinstein JN, Keenan A M , Reynolds JC, Herdt J, Bunn PA, 
Sausville E, Eddy J, Cotehngam JD, Perentesis P, Pinsky C, Larson S M . Direct intralymphatic 
injection of radiolabeled " Ί η - Τ Ί Ο Ι in patients with cutaneous T-cell lymphoma. Cancer Res, 
1 9 9 1 , 5 1 : 6 8 8 - 6 9 5 
14 Roos JC, Derksen EJ, van Lingen A, Postma B, van der Hoeven J J M , den Hollander W, van Loon 
M, Meijer S, Teule GJJ. Qualitative and quantitative kinetics of submucosally administered 
antibody fragments in patients with rectal carcinoma: the detection of lymph node metastasis in 
relation to local tracer diffusion. Nucl Med Biol, 1 9 9 1 , 1 8 : 5 9 - 6 3 
15. Bamias A, Bowles M J , Krausz T, Williams G, Epenetos AA. Intravesical administration of indium-
111 -labelled HMFG2 monoclonal antibody in superficial bladder carcinomas. Int J Cancer, 1 9 9 3 , 
5 4 : 8 9 9 - 9 0 3 
16 Ward BG, Wallace K. Localization of the monoclonal antibody HMFG2 after intravenous and 
intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian 
cancer xenografts. Cancer Res, 1 9 8 7 , 4 7 : 4 7 1 4 4 7 1 8 
17 Rowlinson G, Snook D, Busza A, Epenetos AA. Antibody-guided localization of intraperitoneal 
tumors following intraperitoneal or intravenous antibody administration. Cancer Res, 1 9 8 7 , 4 7 : 
6 5 2 8 - 6 5 3 1 
18 Moseley KR, Battaile A, Knapp RC, Haisma HJ. Localization of radiolabeled F(ab')2 fragments of 
monoclonal antibodies in nude mice bearing intrapentoneally growing human ovarian cancer 
xenografts Int J Cancer, 1 9 8 8 , 4 2 3 6 8 - 3 7 2 
19 Tibben JG, Massuger LFAG, Boerman OC, Borm GF, Claessens RAMJ, Corstens FHM. Effect of 
the route of administration on the biodistnbution of radioiodinated OV-TL 3 F(ab')2 in 
experimental ovarian cancer. Eur J Nucl Med, 1 9 9 4 , 2 1 : 1 1 8 3 - 1 1 9 0 
20 Ward BG, Mather SJ, Hawkins LR, Crowther ME, Shepherd JH, Granowska M, Britton KE, Slevin 
ML. Localization of radioiodme conjugated to the monoclonal antibody HMFG2 in human ovarian 
carcinoma assessment of intravenous and intraperitoneal routes of administration. Cancer Res, 
1 9 8 7 , 4 7 : 4 7 1 9 - 4 7 2 3 
21 Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson S M , Schlom 
J. Complementation of intracavitary and intravenous administration of a monoclonal antibody 
(B72.3) in patients with carcinoma Cancer Res, 1 9 8 7 , 4 7 . 4 2 1 8 - 4 2 2 4 
22 Boerman OC, Sharkey RM, Wong GY, Blumenthal RD, Aninipot RL, Goldenberg D M . Influence of 
antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing 
GW-39 human tumor. Cancer Immunol Immunother, 1 9 9 2 , 3 5 : 1 2 7 - 1 3 4 
23 Fenwick JR, Philpott GW, Connett J M . Biodistribution and histological localization of anti-human 
colon cancer monoclonal antibody (MAb) 1A3: the influence of administered MAb dose on tumor 
uptake. Int J Cancer, 1 9 8 9 , 4 4 : 1 0 1 7 - 1 0 2 7 
24 Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS. Improved delivery of 
radiolabeled anti B1 monoclonal antibody to Raji lymphoma xenografts by predosmg with 
unlabeled anti-B1 monoclonal antibody. Cancer Res, 1 9 9 2 , 5 2 : 6 3 7 - 6 4 2 
25 Wahl RL, Wilson BS, Liebert M, Beierwaltes W H High-dose, unlabeled, nonspecific antibody 
pretreatment: influence on specific antibody localization to human melanoma xenografts. Cancer 
Immunol Immunother, 1 9 8 7 , 2 4 : 2 2 1 2 2 4 
26 Carrasquillo JA, Abrams PG, Schroff RW, Reynolds JC, Woodhouse CS, Morgan AC, Keenan 
A M , Foon KA, Perentesis P, Marshall S, Horowitz M, Szymendera J, Englert J, Oldham RK, 
Larson SM. Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 
anti-melanoma monoclonal antibody. J Nucl Med, 1 9 8 8 , 2 9 : 3 9 - 4 7 
27 Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson S M , 
Warnaar SO, Fleuren GJ, Oettgen HF, Old LJ. Antibody localization in human renal cell 
carcinoma· a phase I study of monoclonal antibody G 2 5 0 . J Clin Oncol, 1 9 9 3 , 1 1 : 7 3 8 - 7 5 0 
28 Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GON, Witjes JA, Koenders EB, 
Oyen WJG, Buijs W C A M , Debruyne FMJ, Corstens FHM, Oosterwijk E. Targeting of renal cell 
carcinoma with iodine 131-labeled chimeric monoclonal antibody G 2 5 0 . J Clin Oncol, 1 9 9 7 , 15: 
1 5 2 9 - 1 5 3 7 
29 Sharkey RM, Primus FJ, Shochat D, Goldenberg D M . Comparison of tumor targeting of mouse 
monoclonal and goat polyclonal antibodies to carcinoembryonic antigen in the GW-39 human 
tumor-hamster host model. Cancer Res, 1 9 8 8 , 4 8 : 1 8 2 3 - 1 8 2 8 
30 Gaf far SA, Pant KD, Shochat D, Bennett SJ, Goldenberg D M . Experimental studies of tumor 
35 
Experimental approaches to improve tumor to nontumor ratios of radiolabeled monoclonal antibodies 
radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and 
colon-specific antigen-p (CSAp). Int J Cancer, 1981, 27: 101-105 
31. Greiner JW, Guadagni F, Noguchi Ρ, Pestka S, Colcher D, Fisher PB, Schlom J. Recombinant 
interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science, 1987, 
235: 895-898 
32 Guadagni F, Schlom J, Pothen S, Pestka S, Greiner JW. Parameters involved in the enhancement 
of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol 
Immunother, 1988, 26: 222-230 
33. Kuhn JA, Beatty BG, Wong JYC, Esteban JM, Wanek PM, Wall F, Buras RR, Williams LE, Beatty 
JD. Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res, 1991, 5 1 : 
2335-2339 
34. Greiner JW, Dansky Ullmann C, Nieroda C, Qi C-F, Eggensperger D, Shimada S, Steinberg SM, 
Schlom J. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody 
(131I-CC49) when given in combination with γ-interferon. Cancer Res, 1993, 53: 600-608 
35. Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JU. Interferon-induced changes in 
pharmacokinetics and tumor uptake of lnln-labeled antimelanoma antibody 96.5 in melanoma 
patients. J Natl Cancer Inst, 1988, 80: 160-165 
36 Murray JL, Macey DJ, Grant EJ, Rosenblum MG, Kasi LP, Zhang H-Z, Katz RL, Rieger PT, 
LeBherz D, Bhadkamkar V, Greiner JW, Schlom J, Podoloff DA. Enhanced TAG-72 expression 
and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer 
patients following α-interferon treatment. Cancer Res, 1995, 55: 5925s-5928s 
37 Greiner JW, Guadagni F, Goldstein D, Smalley RV, Borden EC, Simpson JF, Molinolo A, Schlom 
J. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression 
of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J 
Clin Oncol, 1992, 10: 735-746 
38 Folli S, Pèlegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, Lejeune F, Mach J-P. Tumor-
necrosis factor can enhance radio-antibody uptake in human oclon carcinoma xenografts by 
increasing vascular permeability. Int J Cancer, 1993, 53: 829-836 
39. LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A, Epstein AL Enhanced 
tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. 
Cancer Res, 1991, 51 : 2694-2698 
40. Nakamura K, Kubo A. Effect of interleukm-2 on the biodistribution of technetium-99m-labelled 
anti-CEA monoclonal antibody in mice bearing human tumour xenografts. Eur J Nucl Med, 1994, 
21 : 924-929 
41. DeNardo G, DeNardo S, Kukis D, Diril H, Suey C, Meares С. Strategies for enhancement of 
radioimmunotherapy. Nucl Med Biol, 1991, 18: 633-640 
42 Kalofonos H, Rowlinson G, Epenetos AA. Enhancement of monoclonal antibody uptake in human 
colon tumor xenografts following irradiation. Cancer Res, 1990, 50: 159-163 
43 Gridley DS, Smith ТЕ, Liwnicz BH, McMillan PJ. Pilot study of monoclonal antibody localization 
in subcutaneous and intracranial lung tumor xenografts after proton irradiation. Anticancer Res, 
1994, 14: 2493-2500 
44 Gridley DS, Slater JB, Slater JM. Evaluation of pre-irradiation on monoclonal antibody 
localization in colon tumor xenografts expressing a cell-associated antigen. Anticancer Res, 
1995, 15. 99-104 
45. Cope DA, Dewhirst MW, Friedman HS, Bigner DD, Zalutsky MR. Enhanced delivery of a 
monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local 
hyperthermia. Cancer Res, 1990, 50: 1803-1809 
46. Wilder RB, Langmuir VK, Mendonca HL, Gons ML, Knox SJ. Local hyperthermia and SR 4233 
enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic 
adenocarcinoma xenografts. Cancer Res, 1993, 53: 3022-3027 
47 Hosono MN, Hosono M, Endo К, Ueda R, Onoyama Y. Effect of hyperthermia on tumor uptake 
of radiolabeled anti-neural cell adhesion molecule antibody in small-cell lung cancer xenografts. J 
Nucl Med, 1994, 35: 504-509 
48 Mittal BB, Zimmer AM, Sathiaseelan V, Rosen ST, Radosevich JA, Rademaker AW, Saini A, 
Pierce MC, Webber DI, Spies SM. Effects of hyperthermia and iodine-131-labeled 
anticarcinoembryonic antigen monoclonal antibody on human tumor xenografts in nude mice. 
Cancer, 1992, 70· 2785-2791 
49 Zalutsky MR, Noska MA, Colapinto EV, Garg PK, Bigner DD. Enhanced tumor localization and in 
vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tn-n-
butylstannyllbenzoate. Cancer Res, 1989, 49: 5543-5549 
36 
Chapter 1 
50 Hnatowich DJ, Layne WW, Childs RL, Lanteigne D, Davis MA, Griffin TW, Doherty PW. 
Radioactive labeling of antibody: a simple and efficient method. Science, 1983, 220: 613-615 
51 Cole WC, DeNardo SJ, Meares CF, McCall MJ, DeNardo GL, Epstein AL, O'Brien HA, Moi MK. 
Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med, 
1987, 28: 83-90 
52 Esteban JM, Schlom J, Gansow OA, Atcher RW, Brechbiel MW, Simpson DE, Colcher D. New 
method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of 
athymic mice bearing human colon carcinoma xenografts. J Nucl Med, 1987, 28: 861-870 
53 Kozak AW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghaus R, Gansow OA, Waldmann TA. 
Nature of the bifunctional chelating agent used for radioimmunotherapy with yttnum-90 
monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer 
Res, 1989, 49: 2639-2644 
54 Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, McMurry TJ, Gansow OA, 
Pastan I, Paik CH, Carrasquillo JA. Evaluation of the serum stability and in vivo biodistribution of 
CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med, 1994, 
35: 882-889 
55 Roselli M, Schlom J, Gansow OA, Brechbiel MW, Mirzadeh S, Pippin CG, Milenio DE, Colcher D. 
Comparative biodistribution studies of DTPA-denvative bifunctional chelates for radiometal 
labeled monoclonal antibodies. Nucl Med Biol, 1991, 18. 389-394 
56 Vogel C-Α, Bischof-Delaloye A, Mach J-P, Pèlegrin A, Hardman N, Delaloye B, Buchegger F. 
Direct comparison of a radioiodmated intact chimeric anti-CEA MAb with its F(ab')2 fragment in 
nude mice bearing different human colon cancer xenografts. Br J Cancer, 1993, 68: 684-690 
57 Kojima S, Suzuki N, Shimura N, Kubodera A, Kubota K, Yamaguchi T, Takabashi T, Oyamada H. 
Comparative study of intact A7 MoAb and F(ab')2 fragments for radioimmunoimaging of human 
colon cancer in nude mice. Nucl Med Biol, 1993, 20: 243-248 
58 Massuger LFAG, Boerman OC, Corstens FHM, Verheijen RHM, Claessens RAMJ, Poels LG, van 
den Broek WJM, Kenemans P. Biodistribution of iodine-125 and mdium-111 OV-TL 3 intact 
antibodies and F(ab')2 fragments in tumor-bearing athymic mice Anticancer Res, 1991, 11: 
2051-2058 
59 Andrew SM, Pimm MV, Perkins AC, Baldwin RW. Comparative imaging and biodistribution 
studies with an anti-CEA monoclonal antibody and its F(ab')2 and Fab fragments in mice with 
colon carcinoma xenografts. Eur J Nucl Med, 1986, 12: 168-175 
60 Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, Whitlow M, Snoy P, 
Schlom J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv 
derived from the pancarcinoma monoclonal antibody CC49. Cancer Res, 1991, 5 1 : 6363-6371 
61 Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and 
radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments 
in nude mice bearing human colonic tumor xenografts. Cancer Res, 1990, 50: 2330-2336 
62 Buist MR, Kenemans P, den Hollander W, Vermorken JB, Molthoff CFM, Burger CW, Helmerhorst 
ThJM, Baak JPA, Roos JC. Kinetics and tissue distribution of the radiolabeled chimeric 
monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients. Cancer 
Res, 1993, 53: 5413-5418 
63 Murray JL, Rosenblum MG, Zhang H-Z, Podoloff DA, Kasi LP, Curley SA, Chan JC, Roh M, Hohn 
DC, Brewer H, Cunningham JE, Thompson LB, Bhadkamkar V, Pmsky CM, Fogler WE. 
Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen 
monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. Cancer, 1994, 
73: 850-857 
64 de Bree R, Roos JC, Quak JJ, den Hollander W, van den Brekel MWM, van der Wal JE, Tobi H, 
Snow GB, van Dongen GAMS. Clinical imaging of head and neck cancer with technetium-99m-
labeled monoclonal antibody E48 IgG or F(ab')2. J Nucl Med, 1994, 35: 775-783 
65 Mach J-P, Chatal J-F, Lumbruso J-D, Buchegger F, Forni M, Ritschard J , Berche C, Douillard J-Y, 
Carrel S, Herlyn M, Steplewski Z, Koprowski H. Tumor localization in patients by radiolabeled 
monoclonal antibodies against colon carcinoma. Cancer Res, 1983, 43: 5593-5600 
66 Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM. Comparison of therapeutic efficacy and 
host toxicity of two different '3,l-labelled antibodies and their fragments in the GW-39 colonic 
cancer xenograft model. Int J Cancer, 1989, 44: 292-300 
67 Pedley RB, Boden JA, Boden R, Dale R, Begent RHJ. Comparative radioimmunotherapy using 
intact or F(ab')2 fragments of
 1Э'І anti-CEA antibody in a colonic xenograft model. Br J Cancer, 
1993, 68: 69-73 
68 Stem R, Blumenthal R, Sharkey RM, Goldenberg DM Comparative biodistribution and 
37 
Experimental approaches to improve tumor-to-nontumor ratios of radiolabeled monoclonal antibodies 
radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human 
tumor xeonografts. Cancer, 1 9 9 4 , 7 3 : 8 1 6 - 8 2 3 
69 Sharkey RM, Blumenthal RD, Behr T M , Wong GY, Haywood L, Forman D, Griffiths GL, 
Goldenberg D M . Selection of radioimmunoconjugates for the therapy of well-established or 
micrometastatic colon carcinoma. Int J Cancer, 1 9 9 7 , 7 2 : 4 7 7 - 4 8 5 
70 Blumenthal RD, Sharkey RM, Haywood L, Natale A M , Wong GY, Siegel JA, Kennel SJ, 
Goldenberg D M . Targeted therapy of athymic mice bearing GW-39 human colonic cancer 
micrometastases with ,31l-labeled monoclonal antibodies. Cancer Res, 1 9 9 2 , 52" 6 0 3 6 - 6 0 4 4 
71 Lane D M , Eagle KF, Begent RHJ, Hope-Stone LD, Green AJ, Casey JL, Keep PA, Kelly AMB, 
Ledermann JA, Glaser MG, Hilson AJW Radioimmunotherapy of metastatic colorectal tumours 
with iodine-131-labelled antibody to carcinoembryonic antigen: phase l/ll study with comparative 
biodistribution of intact and F(ab')2 antibodies Br J Cancer, 1 9 9 4 , 7 0 ' 5 2 1 - 5 2 5 
72 Sharkey RM, Goldenberg D M , Vagg R, Pawlyk D, Wong GY, Siegel JA, Murthy S, Levine G M , 
Izon D, Gascon Ρ, Burger К, Swayne LC, Hansen HJ. Phase I clinical evaluation of a new murine 
monoclonal antibody (Mu-9) against colon-specific antigen ρ for targeting gastrointestinal 
carcinomas Cancer, 1 9 9 4 , 73. 8 6 4 - 8 7 7 
73 Goldenberg D M , Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, 
Siegel JA, Izon DO, Burger К, Swayne LC, Belisle E, Hansen HJ, Pinsky CM Targeting, 
dosimetry, and radioimmunotherapy of В cell lymphomas with iodine-131-labeled LL2 
monoclonal antibody. J Clin Oncol, 1 9 9 1 , 9· 5 4 8 - 5 6 4 
74 Paik CH, Yokoyama K, Reynolds JC, Quadri SM, Mm CY, Shin SY, Maloney PJ, Larson S M , 
Reba RC. Reduction of background activities by introduction of a diester linkage between 
antibody and a chelate in radioimmunodetection of tumor. J Nucl Med, 1 9 8 9 , 3 0 : 1 6 9 3 - 1 7 0 1 
75 Paik CH, Quadri SM, Reba RC. Interposition of different chemical linkages between antibody and 
l n l n - D T P A to accelerate clearance from non-target organs and blood. Nucl Med Biol, 1 9 8 9 , 16: 
4 7 5 - 4 8 1 
76 Haseman MK, Goodwin DA, Meares CF, Kaminski MS, Wensel TG, McCall MJ, Levy R. 
Metabolizable " ' I n chelate conjugated anti-idiotype monoclonal antibody for 
radioimmunodetection of lymphoma in mice Eur J Nucl Med, 1 9 8 6 , 12: 4 5 5 - 4 6 0 
77 Quadri SM, Vriesendorp HM, Leichner PK, Williams JR. Evaluation of indium-111- and yttrium-
90-labeled linker-immunoconjugates in nude mice and dogs. J Nucl Med, 1 9 9 3 , 3 4 : 9 3 8 9 4 5 
78 Tibben JG, Massuger LFAG, Claessens RAMJ, Schijf CPT, Pak KY, Strijk SP, Kenemans Ρ and 
Corstens FHM. Tumour detection and localization using technetium-99m-labelled OV TL 3 Fab' 
in patients suspected for ovarian cancer. Nucl Med Commun, 1 9 9 2 , 13 8 8 5 - 8 9 3 
79 Tibben JG, Massuger LFAG, Boerman OC, Claessens RAMJ, Borm GF, Pak KY, Koenders EB, 
Corstens FHM. Decreased kidney uptake of technetium-99m-labelled Fab' fragments in ovarian 
carcinoma bearing nude mice using a cleavable chelator. Nucl Med Biol, 1 9 9 4 , 2 1 : 17-24 
80 Barra« GM, Ryman BE, Boden JA, Keep PA, Searle F, Begent RH, Bagshawe KD. Liposomal 
clearance of antibodies to tumour products: possible improvement of tumour detection Biochem 
Soc Trans, 1 9 8 1 , 9: 5 6 4 - 5 6 5 
81 Begent RHJ, Keep PA, Green AJ, Searle F, Bagshawe KD, Jewkes RF, Jones BE, Barratt G M , 
Ryman BE. Liposomally entrapped second antibody improves tumour imaging with radiolabeled 
(first) antitumor antibody. Lancet, 1 9 8 2 , 7 3 9 - 7 4 2 
82 Sharkey RM, Primus FJ, Goldenberg D M . Second antibody clearance of radiolabeled antibody in 
cancer radioimmunodetection Proc Natl Acad Sci USA, 1 9 8 4 , 8 1 : 2 8 4 3 - 2 8 4 6 
83 Sharkey RM, Mabus J, Goldenberg D M . Factors influencing anti-antibody enhancement of tumor 
targeting with antibodies in hamsters with human colonic tumor xenografts. Cancer Res, 1 9 8 8 , 
4 8 2 0 0 5 - 2 0 0 9 
84 Pedley RB, Dale R, Boden JA, Begent RHJ, Keep PA, Green AJ. The effect of second antibody 
clearance of the biodistribution and dosimetry of radiolabelled anti-CEA antibody in a human 
colonic tumor xenograft model. Int J Cancer, 1 9 8 9 , 4 3 : 7 1 3 - 7 1 8 
85 Goldenberg D M , Sharkey RM, Ford E. Anti-antibody enhancement of iodine-131 anti-CEA 
radioimmunodetection in epxenmental and clinical studies. J. Nucl. Med , 1 9 8 7 , 2 8 1 6 0 4 - 1 6 1 0 . 
86 Stewart JSW, Sivopalenko GB, Hird V, Davies KAA, Walport M , Ritter MA, Epenetos AA. 
Clearance of '3 ,l-labeled murine monoclonal antibody from patients' blood by intravenous human 
anti-munne immunoglobulin antibody. Cancer Res, 1 9 9 0 , 5 0 5 6 3 - 5 6 7 
87 Blumenthal RD, Sharkey RM, Snyder D, Goldenberg D M . Reduction by anti-antibody 
administration of the radiotoxicity associated with 1 3 ll-labeled antibody to carcinoembryonic 
antigen in cancer radioimmunotherapy. J Natl Cancer Inst, 1 9 8 9 , 81 1 9 4 - 1 9 9 
88 Sharkey RM, Boerman OC, Natale A, Pawlyk D, Monestier M , Losman M J , Goldenberg D M . 
38 
Chapter 1 
Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotype 
antibody in tumor-bearing nude mice. Int J Cancer, 1992, 5 1 : 266-273 
89 Paganelli G, Pervez S, Siccardi AG, Rowlinson G, Deleide G, Chioleno F, Malcovati M, Scassettati 
GA, Epenetos AA. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated 
monoclonal antibodies. Int J Cancer, 1990, 45. 1184-1189 
90 Marshall D, Pedley RB, Boden JA, Boden R, Begent RHJ. Clearance of circulating radio-
antibodies using streptavidin or second antibodies in a xenograft model. Br J Cancer, 1994, 69: 
502-507 
91. Kobayashi H, Sakahara H, Hosono M, Yao Z-S, Toyama S, Endo К, Konishi J. Improved 
clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a 
"chase" without decreased accumulation in the target tumor. J Nucl Med, 1994, 35: 1677-1684 
92 Marshall D, Pedley RB, Melton RG, Boden JA, Begent RHJ. Galactosylated streptavidin for 
improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody. Br J 
Cancer, 1995, 7 1 . 18-24 
93 Kobayashi H, Sakahara H, Endo К, Yao Z-S, Toyama S, Konishi J. Repeating the avidin "chase" 
markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the 
excretion of additional background radioactivity. Eur J Cancer, 1995, 31 A: 1689-1696 
94 Hawkins GA, McCabe RP, Kim C-Η, Subramanian R, Bredehorst R, McCullers GA, Vogel C-W, 
Hanna MG Jr, Pomato N. Delivery of radionuclides to pretargeted monoclonal antibodies using 
dihydrofolate reductase and methotrexate in an affinity system Cancer Res, 1993, 53: 2368-
2373 
95 Bos ES, Kuijpers WHA, Meesters-Winters M, Pham DT, de Haan AS, van Doornmalen AM, 
Kaspersen FM, van Boeckel САА, Gougeon-Bertrand F. In vitro evaluation of DNA-DNA 
hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res, 1994, 54· 
3479-3486 
96 Mardirossian G, Lei K, Rusckowski M, Chang F, Qu Τ, Egholm M, Hnatowich. In vivo 
hybridization of technetium-99m-labeled peptide nucleic acid (PNA). J Nucl Med, 1997, 38: 907-
913 
97 Rusckowski M, Qu Τ, Chang F, Hnatowich DJ. Pretargeting using peptide nucleic acid. Cancer, 
1997, 80 2699-2705 
98 Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotm for imaging 
applications. J Nucl Med, 1987, 28: 1294-1302 
99 Saga T, Weinstein JN, Jeong JM, Heya T, Lee JT, Le Ν, Paik CH, Sung C, Neumann RD. Two-
step targeting of experimental lung metastases with biotinylated antibody and radiolabeled 
streptavidin Cancer Res, 1994, 54: 2160-2165 
100 Yao Z, Zhang M, Kobayashi H, Sakahara H, Nakada H, Yamashina I, Konishi J. Improved 
targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal 
antibodies through an avidin chase. J Nucl Med, 1995, 36 837-841 
101 Axworthy DB, Fritzberg AR, Hylandes MD, Mallett RW, Theodore LJ, Gustavson LM, Su F-M, 
Beaumier PL, Reno JM. Preclinical evaluation of an anti-tumor monoclonal antibody/streptavidin 
conjugate for pretargeted ^Y radioimmunotherapy in a mouse xenograft model. J Immunother, 
1994, 16· 41 
102 Axworthy DB, Beaumier PL, Bottino BJ, Goshorn S, Mallett RW, Stone DM, Su F-M, Theodore 
LJ, Yau EK, Reno JM. Preclinical optimization of pretargeted radioimmunotherapy components: 
high efficiency, curative 90Y delivery to mouse tumor xenografts. Tumor Targeting, 1996, 2: 
156-157 
103 Kalofonos HP, Rusckowski M, Siebecker DA, Sivopalenko GB, Snook D, Lavender JP, Epenetos 
AA, Hnatowich DJ. Imaging of tumor in patients with indium-111-labeled biotm and streptavidin-
conjugated antibodies: preliminary communication J Nucl Med, 1990, 3 1 . 1791-1796 
104 Paganelli G, Belloni С, Magnani Ρ, Zito F, Pasini A, Sassi I, Meroni M, Mariani M, Vignali M, 
Siccardi AG, Fazio F. Two-step tumour targetting in ovarian cancer patients using biotinylated 
monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med, 1992, 19 322-329 
105 Paganelli G, Magnani Ρ, Zito F, Villa E, Sudati F, Lopalco L, Rossetti C, Malcovati M, Chioleno F, 
Seccamani E, Siccardi AG, Fazio F. Three step monoclonal antibody tumor targeting in 
carcinoembryonic antigen-positive patients Cancer Res, 1991, 5 1 : 5960-5966 
106 Magnani Ρ, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, Koch Ρ, Maecke H, Brancato R, 
Siccardi A, Fazio F. Quantitative comparison of direct antibody labeling and tumor pretargeting in 
uveal melanoma J Nucl Med, 1996, 37: 967-971 
107 Sharkey RM, Karacay H, Griffiths GL, Anmipot R, McBride W, Goldenberg DM, Hansen HJ. 
Increasing tumor uptake of ln-111 biotin in a two-step pretargeting approach- importance of 
39 
Experimental approaches to improve tumor to nontumor ratios of radiolabeled monoclonal antibodies 
endogenous biotin J Nucl Med, 1997, 38: 233P 
108 Rusckowski M, Fogarasi M, Fritz B, Hnatowich DJ Effect of endogenous biotin on the 
applications of streptavidin and biotin in mice. Nucl Med Biol, 1997, 24: 263-268 
109 Nolan 0, O'Kennedy R. Bifunctional antibodies: concept, production and applications. Biochim 
Bhophys Acta, 1990, 1040: 1-11 
110 Songsivilai S, Lachmann PJ. Bispecific antibody: a tool for diagnosis and treatment of disease. 
Clin Exp Immunol, 1990, 79: 315-321 
111. DeJonge J, Brissmck J, Heirman C, Demanet C, Leo C, Moser M, Thieleman К. Production and 
characterization of bispecific single-chain antibody fragments. Mol Immunol, 1995, 32: 1405-
1412 
112 Glennie MJ, McBnde HM, Worth AT, Stevenson GT. Preparation and performance of bispecific 
F(ab'y)2 antibody containing thioether-lmked Fab'y fragments. J Immunol, 1987, 139: 2367-237. 
113 LeDoussal J-M, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of 
radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody 
conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med, 
1989, 30: 1358-1366 
114 Cook AG, Wood PJ. Chemical synthesis of bispecific monoclonal antibodies: potential 
advantages in immunoassay systems. J Immunol Meth, 1994, 171: 227-237 
115. Suresh MR, Cuello AC, Milstein С Advantages of bispecific hybridomas in one-step 
immunocytochemistry and immunoassays. Proc. Natl. Acad. Sci. USA, 1986, 83: 7989-7993. 
116 Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature, 1983, 
305: 537-540 
117 Staerz UD, Bevan MJ. Hybrid hybridoma producing a bispecific monoclonal antibody that can 
focus effector T-cell activity. Proc Natl Acad Sci USA, 1986, 83: 1453-1457 
118 Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, 
Bartholomew RM, Frincke JM. Antibodies against metal chelates. Nature, 1985, 316: 265-268 
119 Goodwin DA, Meares CF, David GF, McTigue M, McCall MJ, Frincke JM, Stone MR, 
Bartholomew RM, Leung JP. Monoclonal antibodies as reversible equilibrium carriers of 
radiopharmaceuticals Nucl Med Biol, 1986, 13: 383-391 
120 Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted 
immunoscintigrapy of murine tumors with indium-111 -labeled bifunctional haptens J Nucl Med, 
1988, 29: 226-234 
121 Stickney DR, Anderson LD, Slater JB, Ahlem CN, Kirk GA, Schweighardt SA, Frincke JM. 
Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal 
carcinoma. Cancer Res, 1991, 5 1 : 6650-6655 
122 LeDoussal J-M, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of 
indium-111 -labeled bivalent hapten to human melanoma mediated bispecific monoclonal 
antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res, 1990, 50: 3445-3452 
123 Goodwin DA, Meares CF, Watanabe Ν, McTigue M, Chaovapong W, Ransone CM, Renn О, 
Greiner DP, Kukis DL, Kronenberger SI. Pharmacokinetics of pretargeted monoclonal antibody 
2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) 
in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. Cancer 
Res, 1994, 54: 5937-5946 
124. Goodwin DA, Meares CF, McTigue M, Chaovapong W, Diamanti CI, Ransone CH, McCall MJ. 
Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J Nucl Med, 
1992, 33: 2006-2013 
125 Schuhmacher J, Klivényï G, Matys R, Stadler M, Regiert Τ, Hauser G, Doll J, Maier-Borst W, 
Zoller M. Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate 
suitable for immunoscintigraphy with positron emission tomography. Cancer Res, 1995, 55: 
115-123 
126 LeDoussal J-M, Chetanneau A, Gruaz-Guyon A, Martin M, Gautherot E, Lehur P-Α, Chatal J-F, 
Delaage M, Barbet J Bispecific monoclonal antibody-mediated targeting of an indium-111-
labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy 
and immune response. J Nucl Med, 1993, 34. 1662-1671 
127 Peltier P, Curtet C, Chatal J-F, LeDoussal J-M, Daniel G, Aillet G, Gruaz-Guyon A, Barbet J, 
Delaage M. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-
indium-111 -labeled DTPA dimer. J Nucl Med, 1993, 34: 1267-1273 
128 Chetanneau A, Barbet J, Peltier P, Le Doussal JM, Gruaz-Guyon A, Bernard AM, Resche I, 
Rouvier E, Bourguet P, Delaage M, Chatal JF Pretargetted imaging of colorectal cancer 
recurrences using an '"In-labelled bivalent hapten and a bispecific antibody conjugate. Nucl Med 
40 
Chapter 1 
Commun, 1994, 15: 972-980 
129. Vuillez JPh, Moro D, Brichon PY, Rouvier E, Brambilla E, Barbet J, Peltier Ρ, Meyer Ρ, Sarrazin R, 
Brambilla Ch. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a 
bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111 -labeled DTPA dimer. J Nucl 
Med, 1997, 38: 507-511 
130. Gautherot E, Bouhou J, Le Doussal J-M, Manetti C, Martin M, Rouvier E, Barbet J. Therapy for 
colon carcinoma xenografts with bispecific antibody-targeted, ¡odine-131 -labeled bivalent 
hapten. Cancer, 1997, 80: 2618-2623 
131. Bruynck A, Seemann G, Bosslet К. Characterisation of a humanised bispecific monoclonal 
antibody for cancer therapy. Br J Cancer, 1993, 67: 436-440 
41 
Experimental approaches to improve tumor-to-nontumor ratios of radiolabeled monoclonal antibodies 
42 
Chapter 2 
DEVELOPMENT AND CHARACTERIZATION OF ANTI-RENAL 
CELL CARCINOMA X ANTI-DTPA BISPECIFIC MONOCLONAL 
ANTIBODIES FOR TWO-PHASE TARGETING OF RENAL CELL 
CARCINOMA 
Marion H.G.C. Kranenborg, Otto С. Boerman, Jeannette С. Oosterwijk-
Wakka, Mirjam CA. de Weijert, Frans H.M. Corstens, Egbert Oosterwijk 
Cancer Research, 1995, 55: 5864s-5867s 
Development and characterization of anti RCC χ anti DTPA bispecific monoclonal antibodies 
ABSTRACT 
To test a two-step approach for radioimmunotargeting of renal cell cancer, qudroma cells 
secreting antichelate χ anti renal cell carcinoma bispecific antibodies (bsMAbs) were obtained 
by somatic cell fusion Five monoclonal antibodies (MAbs) against the chelate 1,4,7-
tnazaheptane-N,N',N"-pentaacetic acid (DTPA) were produced and characterized Competitive 
binding assays indicated that the anti DTPA antibodies reacted with DTPA chelated with 
indium, yttrium, chromium, iron, or zinc The affinity constants of the anti DTPA antibodies 
for 1 , 1 ln DTPA ranged from 0 19 to 0 23 nM ' Using different chelates, a remarkable chelate 
specificity of the anti-DTPA antibodies was demonstrated The chelates recognized by the 
antibodies DTInl, DTIn2, and DTIn4 share a N(N")-diacetic acid group, whereas the chelates 
recognized by DTIn3 share a N'-acetic acid group, suggesting the presence of different 
essential structures within the DTPA molecule that determine the reactivity of the antibodies 
Five anti-DTPA antibody-producing hybridomas were used for somatic cell fusion with 
hybridoma G250 directed against renal cell carcinoma, resulting in three bispecific antibody-
producing quadroma cell lines The bsMAbs were purified from ascites fluid using protein A 
affinity chromatography followed by hydroxylapatite chromatography and/or cation exchange 
chromatography Of the total IgG amount present in the ascites fluid 10-15% represented the 
bispecific antibodies These bispecific antibodies will allow testing and optimization of a two-
step approach for radioimmunotargeting of chelated radionuclides 
INTRODUCTION 
Although radiolabeled antitumor antibodies can target tumors selectively in vivo, 
optimal visualization is delayed for several days, because the antibody has to clear 
from the blood pool and normal tissues. In addition to obscuring visualization of 
tumors, sustained levels of radiolabeled antibody in the blood and normal tissues 
increase toxicity to nontarget tissues and limit the amount of radioactivity that can be 
administered in radioimmunotherapy 
The efficacy of radioimmunodetection or radioimmunotherapy might be optimized 
by: (a) enhancing tumor uptake, or (b) reducing background activity. The use of 
antibody fragments with faster blood clearance (1-3) or antiantibodies to reduce 
serum levels of circulating antibody (4-6) has resulted in reduction of background 
activity. 
Alternatively, reduction of background activity might be accomplished by 
pretargeting protocols In these, the antitumor antibody is administered and allowed to 
clear from the circulation, after which the radionuclide is given as a low-molecular-
weight ligand. The main advantage of these protocols is the very rapid excretion of 
the small ligand when not targeted to the tumor. The avid interaction between biotm 
and (strept)avidin has been exploited in such a multistep approach (7-10). 
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Analogously, pretargeting protocols may make use of bispecific antibodies and 
radiometal-labeled chelates. In this approach, the tumor is pretargeted with bispecific 
antibodies reactive with a tumor-associated antigen and with a radiolabeled chelate. 
The feasibility of this approach has been shown in studies in nude mouse models 
(11,12) and in immunoscintigraphy studies in colon carcinoma (13,14) and in 
medullary thyroid cancer patients (15). The marked reduction of the background 
activity and the good retention of the radionuclide in the tumor observed in these 
studies suggests that this approach could also be used for radioimmunotherapeutic 
purposes. 
Bispecific antibodies can be produced either by: (a) chemical coupling of two 
antibody fragments; or (b) fusion of two hybridoma cell lines, resulting in quadromas 
(16). Chemical production of bispecific antibodies suffers from batch-to-batch 
variation, whereas quadromas are infinite sources of bispecific antibodies. In addition, 
the fusion technique results in quadromas that synthesize, assemble, and secrete 
bispecific antibodies by the same process as native immunoglobulins. 
To investigate the possibilities of a two-phase radioimmunotargeting protocol, 
we have produced hybridomas secreting MAbs specific for the chelate DTPA and 
fused these to a hybridoma producing a MAb recognizing a renal cell carcinoma-
associated antigen. In this report, we describe the isolation and characterization of 
anti-DTPA MAbs, the production of quadromas, and the purification of bsMAbs. 
MATERIALS AND METHODS 
Antibodies and chelates 
Production of protein-chelate conjugates 
Keyhole limpet hemocyanin (KLH) (Pierce, Rockford, IL) and bovine serum albumin 
(BSA) (Sigma Chemical Co., St. Louis, MO) were conjugated with the cyclic anhydride 
of DTPA (Sigma) according to Hnatowich et al. (17). After PD 10 (Pharmacia, Uppsala, 
Sweden) chromatography to remove unreacted DTPA, excess lnCI3 (Merck, 
Darmstadt, Germany) or YCI3 (Aldrich Chemical Co., Milwaukee, Wl) was added. Free 
ln3+ or Y3+ was removed by PD10 column chromatography. 
BSA, fibrinogen (ICN Biochemicals, Costa Mesa, CA) and calf lens protein (a kind 
gift from Dr. W. de Jong, University of Nijmegen, Nijmegen, The Netherlands) were 
conjugated with isothiocyanato-benzyl DTPA (ITC-Bz-DTPA) (kindly provided by Dr. G. 
Griffiths, Immunomedics, Morris Plains, NJ) according to the method of Ruegg et al. 
(18). BSA and calf lens protein were conjugated with ITC-Bz-1,4,7,10-
tetraazadodecane-N,N',N",N'"-tetraacetic acid (DOTA) (kindly provided by Dr. O.A. 
Gansow, National Cancer Institute, Bethesda, MD) according to the method of Ruegg 
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et al (18) 
Preparation of 111ln-DTPA 
Five μΙ 1 1 l lnCI 3 (Mallinckrodt, Petten, The Netherlands) and 2 μΙ lnCI3 (2 5 ng/μΙ) were 
diluted in 50 μΙ 40 mM HCl and mixed with 850 μΙ aqueous DTPA solution (0 05 
μς/σιΙ) and 100 μΙ 0.1 M sodium acetate buffer (pH 6 0), resulting in a final pH of 3.0. 
Following 30 mm of incubation at room temperature, the solution was neutralized 
with 17 μΙ 0.1 M NaOH. Complexmg of l n 3 + was assessed by paper chromatography 
on Whatman 1 paper with methanol.water (55 -45) as an eluent. The specific activity 
of the l11ln-DTPA was 25 9-29.6 GBq/μητιοΙ. 
Anti-DTPA antibodies 
BALB/c mice were immunized with an emulsion of 50 μg KLH-DTPA-ln or KLH-DTPA-
Y in complete Freund's adjuvant (Sigma) Animals received boosters of antigen mixed 
with incomplete Freund's adjuvant. Three days after an intravenous boost of antigen, 
spleen cells were harvested and fused with Sp2/0-Ag14 myeloma cells (19) as 
described by Lane (20). Culture supernatants of resulting clones were analyzed for 
anti-DTPA reactivity using a direct antigen-binding enzyme linked immunosorbent 
assay (ELISA). Cells of clones reactive with BSA-DTPA-ln or -Y were subcloned at 
least twice in soft agarose (30 g/l; agarose type VII; Sigma) containing RPMI 1640 
medium with hypoxanthine-thymidme supplement (GIBCO-BRL, Gaithersburg, MD). 
Production of bispecific monoclonal antibodies 
Enzyme-deficient hybridomas were isolated to enable selection of fused cells (21) 
Hypoxanthine guanine phosphonbosyl transferase deficiency was introduced in the 
anti-DTPA Mab-producing hybridomas by 8-azaguanidine (Sigma) selection. The anti-
renal cell carcinoma MAb G250 was used as the antitumor antibody in these studies. 
MAb G250 and its subclass variants are directed against the renal cell carcinoma-
associated antigen G250 that is expresssed homogeneously in 7 5 % of renal cell 
carcinomas, whereas expression in normal tissues is restricted to gastric mucosal cells 
and cells of the larger bile ducts (22). MAb G250 has shown excellent targeting of 
renal cell carcinoma in patients (23). Thymidine kinase-deficient hybridoma G250 
variants were isolated by bromodeoxyundine (Boehnnger Mannheim, Mannheim, 
Germany) selection. Anti-DTPA hybridomas were fused with hybridoma G250 at a 1:1 
ratio and seeded in soft agarose containing Low-Protein Hybridoma Medium (GIBCO-
BRL) Growing colonies were picked, grown in suspension, and tested for the 





In all the assays described in this section, the following conditions were used, unless 
indicated otherwise. Wells of 96-well microtiter plates (Costar, Cambridge, MA) were 
coated overnight at 4°C, and remaining protein binding sites were blocked for 1 h with 
50 mM phosphate buffer (pH 7.4)/ 150 mM NaCI/ BSA (5 g/liter). Wells were rinsed 
with the same buffer. Peroxidase activity was revealed using 3,3' ,5,5'-
tetramethylbenzidine (Merck)/ hydrogen peroxide for 10-20 min and A was determined 
at 450 nm. 
Direct antigen-binding assay 
Wells coated with 400 ng BSA-DTPA, 600 ng fibrinogen-ITC-Bz-DTPA, or 300 ng calf 
lens protein-ITC-Bz-DOTA were incubated with the culture supernatant, washed, and 
incubated with peroxidase-conjugated rabbit antimouse immunoglobulins (Dakopatts, 
Glostrup, Denmark). 
Competitive antigen-binding assay 
Wells were coated with BSA-DTPA-ln. Serially diluted Cr-DTPA, Fe-DTPA, Zn-DTPA, 
Y-DTPA, or In-DTPA was added simultaneously with anti-DTPA tissue culture 
supernatant. After 3 h of incubation, wells were washed and incubated with 
peroxidase-conjugated rabbit antimouse immunoglobulins. 
Double-specificity ELISA 
Wells coated with 400 ng BSA-DTPA-ln were incubated with serially diluted 
quadroma tissue culture supernatant, washed, and incubated with biotinylated 
NUH82. NUH82 (lgG1) is an internal-image, anti-idiotype MAb resembling MAb G250 
antigen with an affinity-binding constant of 8.2 nM'1 for MAb G250 (24). Wells were 
incubated with a streptavidin-biotinylated horseradish peroxidase complex (Amersham, 
Little Chalfont, England). This assay assured measurement of bispecific antibodies 
with functional DTPA- and G250-binding pockets only. The detection limit was 
determined to be 100 ng bsMAb/ml. 
Determination of isotypes 
The isotypes of the anti-DTPA MAbs were determined in an ELISA with mouse 
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subclass IgG-specific antisera (Southern Biotechnology Associates, Inc., Birmingham, 
AL). 
Determination of affinity constants 
Affinity constants for n i ln-DTPA were determined by Scatchard analysis (25). 
Microtiter wells coated with rabbit antimouse immunoglobulins (Dakopatts) were 
incubated with excess anti-DTPA MAb or bsMAb. Increasing amounts of 11,ln-DTPA 
were added, and after 1 h at room temperature, wells were washed and counted. 
Purification of monoclonal antibodies 
Ascites fluids were cleared by centrifugaron and diluted 1:1 in 3 M NaCI/ 1.5 M 
glycine (pH 8.9) and subjected to protein A affinity chromatography. Immunoglobulins 
were eluted by sequential application of 0.1 M sodium citrate buffers (pH 6.0, 5.0, 
4.0, and 3.0). 
Cation exchange chromatography was performed on a mono-S HR 5/5 column 
(Pharmacia). Protein A-punfied material was dialyzed against 40 mM NaAc (pH 5 2) 
and loaded on the cation exchange column. Material was eluted with a 0-400 mM 
linear LiCI gradient. 
For hydroxylapatite (Bio-Rad Laboratories, Richmond, CA) purification, protein A-
punfied material was dialyzed against 10 mM sodium phosphate (pH 6.8). The bound 
immunoglobulins were eluted with a linear ionic gradient ranging from 10 to 300 mM 
sodium phosphate (pH 6.8). 
RESULTS 
Anti-DTPA antibodies 
Fusion of spleen cells from mice immunized with In- or Y-DTPA derived KLH with 
Sp2/0-Ag14 myeloma cells resulted in hybridoma cells secreting immunoglobulins 
reactive with BSA-DTPA-ln and BSA-DTPA-Y No reactivity was observed with BSA, 
indicating recognition of DTPA. After subcloning, five hybridomas were selected: 
DTInl (lgG2a), DTIn2 (IgGD, DTIn3 (IgGD, DTIn4 (lgG1), and DTY4 (lgG2a). 
Metal selectivity of the anti-DTPA antibodies 
To study whether the binding of DTPA was influenced by chelation of different 
metals, competitive antigen-binding ELISAs were performed. For all anti-DTPA MAbs, 
with the exception of DTIn3, In-DTPA was the best competitor for BSA-DTPA-ln 
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binding, irrespective of the origin of the anti-DTPA MAb; i.e., even DTY4, isolated 
after immunization with KLH-DTPA-Y, showed superior binding of In-DTPA. However, 
all metal-DTPA chelates, including Y-DTPA, competed for BSA-DTPA-ln binding. For 
DTIn3, Cr-DTPA was the best competitor for BSA-DTPA-ln binding, but all chelates 
competed for BSA-DTPA-ln binding. As an example, the competitive antigen-binding 
assay of DTIn2 is shown in Figure 1. 
10 9 8 7 6 5 4 3 
negative log concentration chelate 
FIGURE 1. Competitive antigen binding assay of DTIn2. The amount of DTIn2 bound to the solid-
phase-coated BSA-DTPA-ln is plotted versus the concentration of the competing chelate added. 
Chelate specificity of anti-DTPA antibodies 
The fine specificity of the anti-DTPA MAbs was determined in direct antigen-binding 
assays. All antibodies reacted with protein-conjugated In-DTPA. In addition, DTIn l , 
DTIn2, DTIn4, and DTY4 reacted with protein-conjugated ITC-Bz-DOTA. DTIn3 and 
DTY4 reacted with protein-conjugated-ITC-Bz-DTPA. BSA-DTPA binding of DTIn3 and 
DTY4 could be completely inhibited with 1,4-diazabutane-N,N'-tetraacetic acid 
(EDTA). 
Affinity constants of anti-DTPA antibodies 
Based on Scatchard analysis the affinity constants of the anti-DTPA MAbs for binding 
111ln-DTPA ranged from 0.19 to 0.23 n M \ The affinity constants of bsMAb G250 χ 
DTY4 and bsMAb G250 χ DTInl were comparable to the parental antibodies DTY4 
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and DTIn l , respectively (Table 1). 
TABLE 1 
Affinity constants for binding i n ln-DTPA 






G250 χ DTY4 0.28 
G250 χ DTIn2 ND 
G250 χ DTInl 0.24 
* ND = not determined 
Production of bispecific monoclonal antibodies 
Fusion of hypoxanthine guanidine phosphoribosyl transferase-deficient anti-DTPA 
hybridoma cells with thymidine kinase-deficient hybridoma G250 resulted in viable 
quadroma colonies. Quadromas G250 (IgGI) χ DTY4, G250 (IgGD χ DTIn2 and G250 
(IgGD χ DTInl produced bsMAbs, as evidenced by reactivity in the double-specificity 
ELISA. Fusion of G250 (lgG2b) with DTIn3 and G250 (IgGD with DTIn3 resulted in 
quadroma cells that did not produce detectable levels of bsMAbs, as judged by the 
double-specificity assay. The IgG molecules produced by the quadroma G250 (lgG2b) 
χ DTIn3 were partly characterized. IgG molecules with functional G250-binding 
pockets and nonfunctional DTIn3-binding pockets were produced, as well as IgG 
molecules with intact DTIn3 sites and nonfunctional G250 sites, as determined in 
ELISAs determining solid-phase binding to either NUH82 or BSA-DTPA using anti-lgG1 
or anti-lgG2b as the tracer antibody, respectively. 
Purification of antibodies 
BsMAb G250 χ DTY4 was purified from ascites fluid using protein A chromatography 
followed by cation exchange chromatography (Fig. 2). Protein Α-bound bispecific IgG 
was eluted at pH 5.0 (Fig. 2A) and subjected to cation exchange chromatography. 
Application of a LiCI gradient resulted in four protein peaks (Fig. 2B) which were 
analysed for G250 χ DTY4 activity. Bispecific G250 χ DTY4 antibody eluted at 223 
mM LiCI. The cation exchange-purified material represented 10-15% of the IgG eluted 
from the protein A column. The protein peak eluting at 206 mM LiCI contained 
immunoglobulins with intact IgGI χ lgG2a heavy-chain pairing, as shown by a mixed-
isotype ELISA, but incorrect heavy-light chain pairing, as shown by the negative 
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FIGURE 2. Purification of bsMAb G250 χ DTY4 using protein A affinity chromatography (A) followed 
by cation exchange chromatography (B). A: protein Α-bound material was eluted by sequential 
application of 0.1 M sodium citrate buffers (pH 6.0, 5.0, 4.0, and 3.0). B: cation exchange-bound, 
protein A-punfied material was eluted using a 0-400 mM LiCI gradient in 40 mM NaAc (pH 5.2). The 
peaks containing bsMAb are indicated by the solid bar. 
BsMAb G250 χ DTIn2 was purified from ascites using protein A chromatography 
followed by hydroxylapatite chromatography and cation exchange chromatography. 
After protein A chromatography, the material eluting at pH 6.0 contained bsMAb. This 
material separated into four peaks on hydroxylapatite chromatography, with the 
bsMAb eluting at 133 mM phosphate. Additional separation of bsMAb from 
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contaminants was achieved by cation exchange chromatography, with G250 χ DTIn2 
activity eluting at 165 mM LiCI. The cation exchange chromatography-purified 
material represented 10-1 5% of the initial amount of protein Α-bound IgG. 
BsMAb G250 χ DTInl was purified from ascites fluid using protein A affinity 
chromatography followed by cation exchange chromatography. Protein A-bound 
bispecific IgG eluted at pH 5.0 and was subjected to cation exchange 
chromatography. This material separated into seven peaks, with the bsMAb eluting at 
276 mM LiCI. The cation exchange chromatography-purified material represented ΙΟ­
Ι 5% of the protein Α-bound IgG. 
DISCUSSION 
Two-step strategies using bsMAbs may optimize radioimmunotargeting of tumors in 
vivo. The main advantage of this approach is the very rapid excretion of the low-
molecular-weight radiolabeled ligand when not targeted to the tumor. Several 
preclinical and clinical studies have shown that two-phase targeting results in high 
tumor-to-nontumor ratios shortly after injection of the radiolabel (11-15). To 
investigate the possibilities of two-phase radioimmunotargeting, we have developed 
five hybridomas producing MAbs reactive with DTPA and fused these with the 
hybridoma G250, producing a MAb reactive with renal cell carcinoma, to obtain 
bsMAbs. 
The affinity constants of the anti-DTPA MAbs for binding '"In-DTPA were in the 
same order of magnitude (0.19-0.23 nM 1) as reported for other antichelate MAbs 
(12,26). 
All anti-DTPA MAbs reacted also with DTPA loaded with different metals. For all 
anti-DTPA MAbs, with the exception of DTIn3, In-DTPA was bound most efficiently, 
irrespective of the immunogen used (KLH-DTPA-ln or KLH-DTPA-Y). In the competitive 
binding assays, the affinity for binding In-DTPA was 10-100-fold higher than the 
affinity for binding DTPA loaded with other metals. Similar results have been obtained 
by Reardan et al. (26) and Bosslet et al. (27). They showed that the affinity of their 
antichelate antibodies for chelates labeled with indium was at least 100-fold higher 
than for chelates labeled with other metals. Involvement of l n 3 + in the antibody-
antigen interaction may cause the higher affinity of the MAbs for the l n 3 + labeled 
chelates (28). 
The anti-ln-DTPA MAbs displayed a remarkable chelate specificity. The chelates 
recognized by DTIn l , DTIn2, and DTIn4 (DTPA and ITC-Bz-DOTA) share a N(N")-
diacetic acid group, whereas the chelates recognized by DTIn3 (DTPA, ITC-Bz-DTPA 
and EDTA) share a N'-acetic acid group, suggesting the presence of different essential 
structures within the DTPA molecule that determine the reactivity of the anti-ln-DTPA 
MAbs. For the anti-Y-DTPA MAb DTY4 (reacting with DTPA, ITC-Bz-DTPA, ITC-Bz-
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DOTA and EDTA) the recognized structure is unclear. The broad reactivity of the 
M Abs makes them suitable for imaging (using n i ln-DTPA or 99mTc-DTPA) as well as 
therapy (with 90Y-DTPA or 90Y-DOTA). 
Because of these characteristics, all anti-DTPA MAbs were used for production 
of bsMAbs. Three of five quadroma fusions resulted in quadromas actually secreting 
bsMAbs. Fusion of isotype-mismatched or isotype-matched hybridomas G250 and 
DTIn3 did not result in the production of functional bsMAb. Therefore, it seems that 
for successful assembly of bsMAb, factors other than the isotype of the parental 
antibodies are important. 
Individual purification protocols were developed for every bsMAb. BsMAb G250 
χ DTY4 was purified using protein A affinity chromatography followed by cation 
exchange chromatography. The amount of bsMAb obtained after cation exchange 
chromatography was 10-15% of the total amount of IgG present in the ascites fluid. 
BsMAb G250 χ DTIn2 was purified by protein A affinity chromatography followed by 
hydroxylapatite chromatography and cation exchange chromatography. Similarly, 
bsMAb G250 χ DTIn2 also represented 10-15% of the total amount of IgG present in 
the ascites fluid. After protein A affinity chromatography and cation exchange 
chromatography, bsMAb G250 χ DTInl was shown to be 10-15% of the amount of 
IgG present in the ascites fluid. This is in concordance with total random association 
of the two heavy and light chains (provided that the heavy and light chains of both 
parents are expressed codominantly) as suggested by Suresh et al. (29). 
We have developed five anti-DTPA MAbs reactive with a broad range of chelated 
metals. Fusion of the anti-DTPA-producing hybridomas with the G250 hybridoma 
resulted in three quadroma cell lines producing bsMAbs. These purified bsMAbs will 
allow testing and optimization of a two-phase targeting protocol in nude mice models. 
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ABSTRACT 
Antibodies preferentially can direct radionuclides to solid tumors However, antibody uptake in 
tumors is often highly heterogeneous This heterogeneity may be overcome by increasing 
antibody protein dose The biodistnbution of increasing protein doses of radioiodinated anti-renal 
cell carcinoma (RCC) monoclonal antibodies (MAbs) G250 and RC 38 was studied in mice with 
NU-12 or SK-RC-52 RCC xenografts In addition, MAb affinity constants and antigen densities 
(Scatchard analysis) and MAb processing (internalization) were determined in vitro. The relative 
uptake of G250 in NU-12 tumors was very high at low protein doses (125 percent injected dose 
per g (%ID/g)), but decreased at higher doses, suggesting tumor saturation Indeed, saturation 
of G250 antigen occurred at 3 μg protein In this model, 9,200 G250 determinants per NU-12 
cell could be targeted, which is only 6 1 % of the 150,000 G250 determinants per NU-12 cell as 
determined in vitro. The RC 38 uptake in NU-12 tumors remained constant up to the 10 μg dose 
level (40 %ID/g) and decreased at higher doses. RC 38 antigens were saturated at 25 μg of RC 
38 With RC 38, 15% of the available RC 38 antigens per NU-12 tumor cell were targeted In 
contrast, G250 uptake in SK-RC-52 tumors was very low at low antibody dose (4 %ID/g at 1 
μg) and increased with increasing protein dose These differences in G250 biodistribution might 
be related to differences in the processing of G250 by the tumor cells Our studies show that 
some RCC tumors can be saturated with anti-RCC MAbs at low (25 μg) to very low (3 μg) 
protein doses At nonsaturated doses relatively high tumor uptake can be achieved Surprisingly, 
in NU-12 tumors only 6 1 and 15% of the available antigenic sites were targeted at the 
saturating dose levels with G250 and RC 38, respectively. 
INTRODUCTION 
Monoclonal antibodies against tumor-associated antigens have been used successfully 
to direct radionuclides preferentially to solid tumors (1-3). However, in general 
intratumor antibody uptake is highly heterogeneous and not all tumor regions are 
targeted adequately. This heterogeneous uptake might hamper the therapeutic 
applications of MAbs. A number of parameters have been identified that may explain 
this heterogeneity, e.g., heterogeneous blood supply, high interstitial pressure, 
heterogeneous antigen expression, local necrosis and locally enhanced vascular 
permeability (4) The heterogeneous delivery of antibody in tumors may also be 
explained by antibody retention as a result of the successful binding to antigen on the 
tumor cell surface near blood vessels, (/ e , the hypothesized binding site barrier) (5) 
The heterogeneous antibody delivery to tumors may be overcome by using 
antibody fragments (4). Yokota et al have shown that intact IgG is concentrated in 
the region of or immediately adjacent to tumor blood vessels, whereas single chain Fv 
was distributed more evenly throughout the tumor mass (6). Secondly, in a 
mathematic model Fujimori et al suggested that antibody penetration can be 
56 
Chapter ЗА 
enhanced by lowering the affinity constant of the antibody or by increasing the 
antibody dose (5). Autoradiographic studies have shown that at higher antibody 
protein dose or lower affinity, MAbs distributed more evenly in tumors xenografted in 
nude mice (7). 
In studies in RCC patients the uptake of the anti-RCC MAb G250 differed 
dramatically within and between tumors (8,9). To assess this variation in tumor 
uptake, the effects of antibody protein dose on tumor uptake in nude mice with RCC 
tumors were studied. 
MATERIALS AND METHODS 
Antibody preparation and radiolabeling 
The anti-RCC MAb G250 (lgG1) is directed against the RCC-associated antigen G250. 
This antigen is expressed in 75% of RCCs, whereas expression in normal tissues is 
restricted to gastric mucosal cells and cells of the larger bile ducts (10). The G250 
antigen is homologous with the MN antigen, a recently cloned human tumor-
associated protein (11). The anti-RCC MAb RC 38 (lgG1) is directed against human 
aminopeptidase-A. This antigen is expressed in 9 5 % of RCCs and in 6 0 % of 
metastatic RCC lesions. RC 38 antigen is expressed in adult kidney and in several 
other normal tissues (12). The anticarcinoembryonic antigen MAb MN-14 (lgG1), 
which is not reactive with RCC, was used as a control antibody (13). 
Antibodies were radioiodinated with 1 2 5 l (Amersham International, 
Buckinghamshire, UK) or l 3 1 l (Nordion Europe, Fleurus, Belgium) using the iodogen 
method (14). In all preparations > 9 5 % of the radioactivity was associated with the 
antibodies as determined by instant thin layer chromatography. 
The immunoreactive fraction of , 2 b l-G250, 131I-RC 38 and 1 3 , I-MN-14 essentially 
was determined as described by Lindmo et al. using SK-RC-52 RCC cells, NU-12 RCC 
cells and LS180 colon carcinoma cells, respectively (15). The immunoreactive fraction 
of 125I-G250 was > 8 5 % , the immunoreactive fraction of 131I-RC 38 was > 7 0 % and the 
immunoreactive fraction of 131I-MN-14 was > 9 5 % . 
RCC xenografts and cell lines 
The NU-12 RCC xenograft was established from a primary tumor by serial 
subcutaneous (s.c.) transplantation in nude mice (16). From this established tumor 
NU-12 also was propagated in vitro. The RCC cell line SK-RC-52 was derived from a 
mediastinal metastasis of a primary RCC (17). 
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Biodistribution studies 
RCC tumors were initiated in 6-week-old BALB/c nu/nu mice. NU-12 was transplanted 
serially by implanting viable tumor specimens (1-2 mm3) s.c. in the flank of the mice. 
SK-RC-52 cells were trypsinized, washed in saline, and 2x106 cells were injected s.c. 
into the flank of the mice. Experiments began when tumors weighed 0.02-0.5 g. Each 
group contained 3-5 mice. To study the biodistribution at different antibody protein 
doses (0.3, 1 ,3 , 10, 30, or 100 цд/апітаі) increasing amounts of unlabeled antibody 
were added to the radioiodinated antibody preparation. 1 2 5I-G250 and 1 3'I-MN-14 or 
125I-G250 and 131I-RC 38 were coinjected intravenously (i.V.) and after 3 days the 
biodistribution of the radiolabeled antibodies was determined. The amount of activity 
in the whole tumor and tissues (blood, muscle, liver, kidney, and spleen) was 
determined by gamma-counting together with an injection standard. The %ID/g, the 
absolute amount of antibody bound per g of tumor, and the tumor-to-blood ratios 
were calculated. Statistical analysis was performed using one-way analysis of 
variance, with Bonferroni posttest correction for multiple comparisons. 
Scatchard analysis 
The affinity constant for the G250 antigen and the number of binding sites per NU-12 
or SK-RC-52 cell were determined by Scatchard analysis on single cell suspensions of 
cultured cell lines (18). In addition, Scatchard analysis was performed for the MAb RC 
38 on NU-12 cells. 
Immunohistochemistry 
RCC tumors were snap frozen in isopentane. Cryostat sections (4 ц т ) were fixed for 
10 min in acetone. G250 antigen expression was determined using mouse/human 
chimeric MAb G250 (a gift from Dr. S.O. Warnaar, Centocor BV, Leiden, The 
Netherlands) followed by rabbit antihuman Fc-peroxidase (DAKO A/S, Glostrup, 
Denmark). RC 38 antigen expression was determined using the MAb RC 38 and rabbit 
antimouse-peroxidase (DAKO A/S) sequentially. Peroxidase activity was revealed 
using 3-3'-diaminobenzidine/0.03% hydrogen peroxide (Fluka Chemie, Bornem, 
Belgium). 
Retention and processing of G250 in vitro 
The internalization and degradation rate of 125I-G250 by NU-12 and SK-RC-52 cells 
was measured in vitro essentially as described by Kyriakos et al. (19). Briefly, 
confluent NU-12 or SK-RC-52 cells were incubated for 2 h at 37°C with 7.5 or 3.8 ng 
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of 1 2 5I-G250 in 200 μΙ tissue culture medium, respectively. To determine nonspecific 
binding, a large excess unlabeled G250 was added to control wells. After washing to 
remove unbound 1 2 5I-G250, the cells were cultured from 0 to 24 h in 200 μΙ culture 
medium at 37°C. Supernatant fluids were collected at various timepoints and 
trichloroacetic acid (TCA)-precipitable (large fragments of G250 or intact G250) and 
non-TCA-precipitable (internalized and subsequently processed G250) activity was 
determined. The cells were washed twice and collected by solubilization with 2 M 
NaOH. Solubilized cells, TCA-precipited culture medium, and TCA-supernatant fluid 
were counted in a shielded well-type gamma counter. 
RESULTS 
Biodistribution of 125I-G250 in mice with NU-12 tumors 
The effect of increasing G250 antibody protein dose on tumor uptake and tumor-to-
blood ratios was determined in nude mice with a NU-12 tumor. MN-14 was used as a 
control antibody. Injection of 0.3 or 1 μg of the MAb G250 resulted in very high 1 2 S I -
G250 tumor uptake (approximately 125 %ID/g) (Fig. 1A). However, at higher protein 
doses the tumor uptake gradually decreased and was significantly lower compared 
with the uptake at the 0.3 and 1 μg dose levels, suggesting antigen saturation in the 
tumor. The uptake of 1 3 1I-MN-14 in the tumors was similar at each dose level 
investigated (2.79 ± 0.67 %ID/g). The tumor uptake of 1 2 5I-G250 was significantly 
higher than 1 3 1I-MN-14 at each dose level, indicating specific G250 tumor uptake. The 
amount of 1 2 5I-G250 in the blood at 0.3 μg injected dose was significantly lower 
compared with 10 and 30 μg G250 (Table 1). The amount of 1 2 5I-G250 in muscle, 
liver, spleen, and kidneys was not influenced by the G250 antibody dose (Table 1). 
Tumor-to-blood ratios > 1 0 were obtained only at the 0.3 and 1 μg dose levels. At 
higher protein dose levels the tumor-to-blood ratios were significantly lower compared 
with those at the 0.3 and 1 μg dose levels (Table 1). 
The absolute amount of specifically accumulated G250 at the tumor site was 
calculated at every dose level (Fig. 2A). The specific tumor uptake was defined as the 
amount of G250 {цд) that accumulated per g of tumor at a particular protein dose, 
minus the amount of irrelevant MN-14 antibody present in the tumor at that protein 
dose. A linear increase of the absolute amount of G250 targeted to the tumor was 
observed up to 3 цд G250, after which point a plateau was reached. Thus, tumor 
saturation was achieved at the 3 μg dose of the MAb G250, because absolute 
amounts of G250 accumulating specifically in the tumor did not increase at higher 
dose levels. Approximately 2.3 μg G250 can be targeted per g NU-12 tumor at the 
saturating antibody dose level. 
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FIGURE 1. Tumor uptake of 125I-G250 m NU-12 and SK-RC-52 tumors (A) and tumor uptake of 131I-RC 
38 in NU-12 tumors (B) at protein doses varying from 0.3 to 100 цд/mouse. Error bars represent 
standard deviation (n = 3-5). 
Biodistribution of 131I-RC 38 in NU-12 xenografts 
To determine whether the G250 antigen saturation at a relatively low protein dose 
level in NU-12 tumors was an antibody specific phenomenon, the biodistribution of 
the RC 38 MAb was determined in the NU-12 model at various protein doses. Uptake 
of 131I-RC 38 in the tumor was similar at 1, 3, and 10 цд of RC 38 (Fig. 1B). 
However, when 30 цд RC 38 was injected the %ID/g lowered significantly, and at 
100 цд RC 38 the uptake was significantly lower compared with doses of 1, 3, and 
10 цд, indicating saturation of the RC 38 antigen. Specific targeting of RC 38 in the 
tumor was demonstrated by the significant higher 131I-RC 38 uptake compared with 
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131I-MN-14 uptake. The relative amount of 131I-RC 38 in the blood, muscle, liver, 
kidneys, and spleen remained constant over the entire dose range (Table 1). 
Calculation of the absolute amounts of RC 38 accumulating in the tumors 
showed a bindingcurve with an apparent plateau at > 1 0 0 цд RC 38, indicating 
saturation of RC 38 antigen in the tumor (Fig. 2B). Extrapolation of the data indicated 
that RC 38 antigen saturation in the tumor occurred at a dose of approximately 25 цд 
of the RC 38 antibody. At this saturation level approximately 7.5 цд RC 38 was 
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FIGURE 2. The absolute amount of ,25I-G250 (A) and 131I-RC 38 (B) specifically accumulating ¡η NU-12 
tumors. Error bars represent standard deviation (n = 5). 
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TABLE 1 
Biodistribution of G250 and RC 38 anti-RCC antibodies at different protein doses in 
























Uptake (%ID/g) and tumor-to-blood ratio (TBR) for different protein doses 
M9 
9.36 ± 1.07 
0.95 ±0.32 
123.9 ± 2 0 . 0 
3.07 10.29 
2.79 + 0.58 
2.32 ±0.29 
13.19 ± 0 . 6 6 
1 M9 Зцд 
Mab G250 in mice 
11.73 ± 1.44 
1.09 ±0.17 
131.6 ± 14.4 
4.33 ±0.32 
3.65 ±0.39 
2.87 ± 0.62 
11.86 ± 2.63 
12.57 ± 1.9 
1.49 ±0.48 
76.84 + 23.8 
4.68 ± 0 . 9 8 
4.01 ± 0 . 5 8 
3.46 ± 0.74 
6.25 ± 1.07 
MAb RC 38 in mice 
9.74 ± 2.29 
0.70 ±0.17 
44.42 ± 14.8 
2.43 ± 0.68 
2.52 ±0.48 
2.36 ±0.94 
3.96 ± 2.24 
8.63 ± 0 . 7 8 
0.72 ±0.064 
50.30 ± 9 . 1 4 
2.58 ±0.81 
2.13 + 0.30 
2.20 + 0.78 
5.91 ± 1.59 
10 цд 30 цд 
with NU-12 tumor 
1 3 . 3 3 ± 0 . 8 6 
0.86 ± 0.050 
25.86 + 0.65 
4.71 ± 0 . 7 9 






4.46 ± 0.41 
3.90 + 0.21 
3.40 ± 0.46 
0.69 ± 0.03 
ι with NU-12 tumor 
10.58 ± 2 . 0 0 
0.80 ± 0 . 1 3 
33.67 ± 4.64 
3 . 1 3 ± 0 . 5 1 
3.09 + 0.42 
2.30 1 0 . 4 4 
3.32 ± 0 . 9 4 
9.36 ± 1.33 
0.68 ±0.078 
22.27 ± 2.09 
3.07 ±0.75 
2.86 + 0.42 
2.06 ±0.69 
2.43 + 0.55 
MAb G250 in mice with SK-RC-52 tumor 
0.39 + 0.17 
0.08 ± 0.02 
3.57 ± 2.05 
0.46 ± 0.28 
0.26 ± 0 . 0 4 
0.18 ±0.01 
1 1 . 2 9 ± 9 . 1 4 
1.42 ± 0 . 3 8 
0.40 ± 0 . 1 6 
6.08 ± 1.39 
1.61 ±0.16 
0.54 ± 0 . 0 9 
0.42 + 0.02 
4.56 ± 1.73 
2.61 ± 2.49 
0.32 ± 0 . 2 3 
7.84 ± 6 . 9 3 
1.76± 1.51 
0.92 + 0.76 


















0.60 ± 0 . 1 2 
10.79 ± 1.67 
3.26 ± 0 . 5 3 
2.82 ± 0 . 2 8 
1.65 ± 0 . 0 6 
1.32 ± 0 . 2 2 
Biodistribution of 125I-G250 in SK-RC-52 xenografts 
To investigate whether the G250 antigen saturation observed in the NU-12 model 
was unique for this particular tumor, a similar G250 protein dose escalation study was 
performed in the SK-RC-52 tumor model. In this model the biodistribution of 1 2 5I-G250 
was completely different compared with the NU-12 model. In contrast to the high 
G250 uptake in the NU-12 tumors, very low G250 tumor uptake was observed at low 
protein dose levels in the SK-RC-52 model (Fig. 1A). Tumor uptake increased to 
10.79 %ID/g at 100 цд injected dose. The uptake of 1 3 1I-MN-14 in the tumor 
remained constant (2.65 ± 0.82 %ID/g) over the entire dose range. At the 1 цд dose 
the %ID/g of 1 2 5I-G250 and '3 1I-MN-14 were not significantly different in the tumor, 
whereas at higher dose levels the amount of 1251-G250 in the tumor was significantly 
higher. In addition, 1 2 5I-G250 blood levels were extremely low (0.39 ± 0.17 %ID/g) at 
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the lowest protein dose investigated (1 цд) (Table 1). The amount in the blood 
increased to 8.21 ± 0.68 %ID/g at the 100 цд dose level. 
Scatchard analysis 
·&. 
0 05 0 10 0 15 
specific binding (nM) 
td 
ω 
0 0 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 
specific binding (nM) 
0 15 
0 05 0 10 0 15 
specific binding (nM) 
FIGURE 3. Scatchard analyses of 125I-G250 binding to NU-12 cells (A), 125I-G250 binding to SK-RC-52 
cells (B), and 131I-RC 38 binding to NU-12 cells (C). 
Scatchard analysis of G250 binding revealed that the number of antigenic sites per 
cell varied for both cell lines. SK-RC-52 cells contained 600,000 sites per cell and NU-
12 contained 150,000, with a similar affinity constant (Ka) (0.96 nM"
1 versus 1.2 
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nM 1 ) (Fig. 3). The number of RC 38 binding sites on NU-12 cells was 200,000, 
which was similar to the number of G250 binding sites on these cells. The Ka of RC 
38 (0.19 nM 1 ) was 6.3-fold lower than the Ka of G250 (Fig. 3). 
Immunohistochemistry 
The intratumoral distribution of the G250 antigen was determined in NU-12 and SK-
RC-52 xenografts. Membraneous G250 antigen expression was observed in > 7 0 % of 
the cells in both xenografts. The RC 38 antigen was expressed on the membrane in 
approximately 8 0 % of the cells in the NU-12 tumor. 
Retention and processing of G250 bound to tissue culture cells 
In Figure 4 the retention and processing of G250 by RCC cells is shown. At 24 h 
most of the 1 2 5I-G250 was cell-associated for both cell lines. Processing of G250 was 
not very rapid because < 2 0 % of G250 was processed by the cells at 24 h. However, 
processing of G250 (i.e., internalization and degradation of the antibody and 
subsequent excretion of the radiolabel) by SK-RC-52 cells was faster than processing 
by NU-12 cells (17% versus 8% non-TCA-precipitable activity at 24 h). 
DISCUSSION 
The MAb G250 has been used successfully to direct 1 3 1 l to RCC tumors in RCC 
patients (8,9). However, intratumor uptake was highly heterogeneous, which might 
hamper the therapeutic applications of the MAb G250 (8). Heterogeneity in antibody 
distribution may be overcome by increasing the antibody dose (5). In the current study 
the effect of antibody protein dose on the biodistribution of anti-RCC MAbs in nude 
mice bearing RCC xenografts was investigated. 
G250 antibody uptake in NU-12 tumors was very high at the lowest injected 
doses (approximately 125 %ID/g). However, at doses exceeding 1 цд the %ID/g 
gradually decreased with apparent tumor saturation occuring at a dose of 3 цд. High 
tumor-to-blood ratios were achieved at the lowest protein doses, mainly due to the 
high tumor uptake at these dose levels. Although tumor saturation has been 
described, saturation at this low antibody dose level is uncommon. Boerman et al. and 
Fenwick et al. observed saturation of antigens at doses > 100 μg using anti-colon 
carcinoma antibodies in animals with a GW-39 colon carcinoma xenograft (20,21). 
The animal data obtained with the NU-12 model are strikingly in line with the human 
data obtained in a Phase I antibody dose escalation study using radioiodinated 
chimerized MAb G250 in RCC patients: at lower protein doses relatively high tumor 
uptake was observed, whereas at doses > 1 0 mg, 10-fold lower tumor uptake was 
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observed, suggesting that saturation of available G250 epitopes occurred when 
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FIGURE 4. Retention and processing of 125I-G250 bound to NU-12 cells (A), and SK-RC-52 cells (B). 
Percentage of total cpm retained by the cells (-0-), TCA-precipitable supernatant (-Δ-), and non-TCA-
precipitable supernatant (-D-) are displayed. 
To determine whether the observed G250 tumor saturation was unique for the 
G250 antigen, we tested another anti-RCC MAb. For the RC 38 MAb tumor saturation 
was also observed. However, the level of antigen saturation was different for both 
antibodies (3 μg for G250 versus 25 цд for RC 38). The maximum amount of G250 
bound in the tumor at the saturation dose level was 3-fold lower than the maximum 
amount of RC 38 bound in the tumor (2.3 versus 7.5 цд/д). This might be explained 
by the somewhat lower number of G250 antigenic sites per NU-12 cell and/or the 
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somewhat higher Ka of G250. 
Using anti-RCC MAb A6H, Sands et al. (22) and Palme et al. (23) also found high 
tumor uptake in RCC nude mouse models, which was attributed to the increased 
tumor permeability in RCC compared with non-RCC (22). In our study we observed 
high tumor uptake with G250 and moderately high uptake with RC 38 in the same 
NU-12 model, indicating that other factors also play a role in RCC tumor uptake of 
MAbs. 
The biodistribution of G250 also was investigated in another RCC model to 
determine whether the observed G250 saturation was specific for the particular model 
used. In the SK-RC-52 model the biodistribution of G250 was completely different. 
Three days after injection of low protein doses extremely low blood and low tumor 
levels were found. In contrast, in nontumor bearing mice 1 2 5I-G250 blood levels were 
independent from G250 dose (approximately 10.7 %ID/g), indicating that the SK-RC-
52 tumor had a major effect on the biodistribution of G250. Despite low tumor 
uptake, high tumor-to-blood ratios were obtained at the lowest protein dose levels due 
to the extremely low G250 blood levels. Tumor saturation was not observed as a 
result of the rapid clearance of G250 in SK-RC-52 tumor-bearing mice. 
What might explain the extreme differences in the biodistribution of G250 in 
these different tumor models? Internalization of G250 by the tumor cells may cause 
rapid processing and subsequent excretion of radioiodinated G250 in the SK-RC-52 
model. G250 was degraded slightly faster by SK-RC-52 cells compared with NU-12 
cells as determined by the antibody processing assay. It is possible that in vivo this 
difference in antibody processing is more pronounced, thereby explaining the very low 
amounts of G250 in the tumor and in the circulation in mice with SK-RC-52 tumors. 
Vascular permeability, which can be determined using an irrelevant antibody (22), may 
determine the absolute antibody tumor uptake. Because the biodistribution of the 
control IgG in the models studied was similar, it is unlikely that the different 
biodistribution of G250 can be attributed to vascular permeability differences. 
Different antigen distribution also does not appear to play a role: approximately 70-
8 0 % of the tumor cells expressed G250 antigen in both tumors. Another explanation 
might be that G250 antigen density drives the G250 MAb targeting. However, no 
relation between the number of G250 sites per cell and tumor uptake was obvious. 
SK-RC-52 contained a 4-fold higher number of antigenic sites per cell, whereas in vivo 
very low tumor uptake was observed at low antibody doses. Alternatively, shedding 
of G250 antigen might be more prominent in SK-RC-52 tumors, causing differences in 
tumor targeting. However, in tissue culture supernatant fluid from NU-12 and SK-RC-
52 cells no G250 antigen could be detected (data not shown). 
From the amount of G250 specifically bound per g of NU-12 tumor at the 
saturation dose the number of antibody molecules targeted per tumor cell were 
calculated. Assuming 109 cells per g of tumor, 2.3 цд of G250 specifically bound per 
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g of tumor represents 9,200 antibody molecules per cell. In contrast, Scatchard 
analysis on cultured cells demonstrated the presence of 150,000 antigenic sites per 
NU-12 cell. Provided that expression levels in vivo are similar, this would indicate that 
only 6 . 1 % of the antigenic determinants present were accessible for G250 antibody 
binding in the xenografted tumor. With RC 38 only 30,000 of 200,000 of the RC 38 
sites (15%) were targeted at maximum tumor uptake. 
It is interesting to note that tumor saturation also was observed at relatively low 
G250 protein dose levels (>25 mg) in G250-treated RCC patients. Injection at 
saturated G250 levels (25 or 50 mg) resulted in a tumor uptake of 0.0015 %ID/g. 
This would mean that 1,500-3,000 G250 epitopes per cell were targeted in these 
patients. These numbers are strikingly similar to the numbers calculated for our NU-12 
model. 
These studies indicate that some RCC tumors can be saturated at relatively low 
antibody protein doses. At nonsaturated dose levels, very high tumor uptake and very 
high tumor-to-blood ratios can be achieved. At maximum tumor uptake only a minority 
(6.1 and 15%, respectively) of the antigenic determinants in the tumor were targeted 
in the experimental NU-12 RCC tumor. 
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ABSTRACT 
In radioimmunotherapy of solid tumors substantial gain might be achieved by carefully 
selecting the radionuclide and the linker connecting it to the antibody. In contrast to 1 3 1 l , 
radiometals such as 90Y and 1,1ln may be retained in the tumor cell after internalization of the 
antibody, thereby enhancing the radiation dose to the tumor. The physical properties of 186Re 
with 1.08 MeV beta-emission (71%) and 137 keV gamma-emission (10%) seem ideal for 
radioimmunotherapy. In this study we investigated in nude mice with subcutaneous (s.c.) 
renal cell carcinoma (RCC) xenografts the biodistribution and the retention in the tumor of 
la6Re-MAG3 labeled monoclonal antibody (MAb) G250 as compared to 11,ln-DTPA-G250, to 
125I-G250 and to 13,I-MN-14 (nonspecific control MAb). Radiolabeled antibody preparations 
were intravenously (i.v.) injected. Seventy-two h postinjection (p.i.) biodistribution of the 
radiolabel was determined. Blood levels of all MAb G250 preparations were remarkably low 
(mean: 2.38, 1.40 and 1.43 percent of the injected dose per g (%ID/g) for 1 2 5 l , l n l n and 186Re, 
respectively) whereas blood levels of MAb MN-14 were significantly higher (mean: 12.3 
%ID/g), indicating tumor processing of MAb G250. Retention of n i l n in the tumor was 
significantly higher than of '86Re and ' 2 5 l , whereas retention in the tumor of 18eRe and 125l did 
not differ significantly. Conclusion: In contrast to other radiometals such as 111ln and 90Y, 
186Re is not retained in the tumor cell. Therefore 186Re has no additional advantage for 
radioimmunotherapy with respect to retention in the tumor. 
INTRODUCTION 
Radioimmunotherapy with radiolabeled monoclonal antibodies is a promising, however 
still experimental therapy modality in the management of cancer. Recent studies have 
shown that radioimmunotherapy in hematological malignancies can lead to complete 
and lasting responses in the majority of patients (1-3). Results in patients with solid 
tumors however, have been less successful (4). A series of factors have been 
identified that potentially could explain the limited efficacy of radioimmunotherapy of 
solid tumors, e.g., immunogenicity of murine antibodies (HAMA), low tumor uptake, 
heterogeneous distribution of the antibody within a tumor and relative insensitivity of 
solid tumors to radiation. Chimeric or humanized antibodies have shown to be much 
less immunogenic (5-7). Methods to enhance uptake, retention and radiation 
sensitivity have been investigated intensively. For instance, alpha-interferon has been 
reported to enhance expression of particular tumor-associated antigens (8,9). 
Enhanced antigen expression may lead to increased uptake of the antibody. 
Furthermore, high affinity second generation antibodies have shown higher uptake in 
the tumor (10). Administration of radiosensitizers may lead to a higher therapeutic 




Since the introduction of radioimmunotherapy, the majority of clinical trials has 
been carried out with 13 ll-labeled antibodies because 1 3 1 l is a cheap, readily available 
radionuclide that can be easily linked to antibodies. Nevertheless, 1 3 1 l is not the ideal 
radionuclide for radioimmunotherapy: its beta-emission is of a relatively mild energy 
{EmM: 0.6 MeV, 89%) with a range of only a few cell diameters and its gamma-
emission is of relatively high energy (364 keV, 81%) causing an undesired high 
whole-body radiation. In addition, once the antibody has been internalized by the 
tumor cell, the 131l-label is rapidly released, thereby reducing the radiation dose to the 
tumor. 
Several other radionuclides, such as 30Y and 186Re, have been proposed as 
alternatives for 1 3 1 l since they have more optimal physical characteristics for 
application in radioimmunotherapy. Press et al. (12) showed that 90Y, like 1 n l n , is 
better retained in the tumor following metabolization of the antibody. However, 90Y is 
a pure β emitter (Emax: 2.28 MeV, 100%) and thus the localization of the radionuclide 
can not be followed scintigraphically. A further disadvantage of 90Y is the specific 
incorporation in bone tissue when released from the antibody. As a result, the 
radiation delivered to the bone marrow limits the dose of radioactivity that can be 
administered safely. The physical properties of 186Re seem to be ideal for 
radioimmunotherapy: it has a half-life of 89.3 h, beta-emission energies of 1.08 MeV 
(71%) and 0.9 MeV (21%) and its 10% abundance gamma-radiation of 137 keV 
(gamma-energy similar to 9 9 mTc) is ideal for scintigraphic imaging. 
Once a radiolabeled antibody is internalized by the tumor cell, it is degraded 
enzymatically in the lysosomes. Small-molecular-weight components, formed 
following enzymatic degradation are less easily released from lysosomes (13,14). 
From this perspective it is often hypothesized that radiometals - whether or not linked 
to a chelator - are retained in the lysosomes (15-17). Therefore 186Re, like n i l n and 
90Y, might show lysosomal retention after internalization of the antibody. However, 
the outcome of several studies indicated that such retention depends on the choice of 
radiometal and labeling method (15,18). Based on the known retention of positively 
charged compounds (19) other investigators have hypothesized, and indeed provided 
evidence, that residualization in the lysosomes occurs when molecules are positively 
charged (20). 
Shih et al. (15) and Sharkey et al. (18) have studied the fate of 188Re-labeled 
antibodies after processing of the antibody by the tumor cells. The results of these 
studies did not show a favorable retention of 188Re compared to radioiodinated 
antibodies. However in both studies a direct method to link 188Re to the antibody was 
used as described by Griffiths et al. (21). Both studies revealed a significant instability 
of the radioimmunoconjugate. It was concluded that the observed instability might 
have contributed to the poor retention of 188Re in the tumor cells. To overcome this 
problem, a method to stably label antibodies with 186Re has been developed using S-
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benzoylmercaptoacetyltriglycerine (MAG3) as a chelator (22). 
In the present study we investigated whether '86Re has an additional advantage 
for radioimmunotherapy in terms of intratumoral residualization after processing of the 
radiolabeled antibody by the tumor. The tumor model that was used has been well 
characterized previously and appeared suitable to study the processing of the antibody 
G250 by the tumor (23). 
MATERIALS AND METHODS 
Murine monoclonal antibodies G250 and MN-14 
The generation, the characteristics and the reactivity of murine MAb G250 have been 
described earlier (24). Briefly, MAb G250 is reactive with the antigen G250 which is 
expressed in all clear cell RCCs and in the majority of non-clear cell RCC. Expression 
in normal organs is restricted to the gastric mucosal cells and the larger bile ducts. 
Recently, the G250 antigen has been cloned and was found to be homologous with 
the MN antigen which is expressed in cervical carcinomas (25). 
The anti-carcinoembryonic antigen MAb MN-14 (lgG1) (26), not reactive with the 
G250 antigen, was used as a control antibody. 
Nude mouse tumor model 
The RCC cell line SK-RC-52 was derived from a mediastinal metastasis of a primary 
RCC (27). SK-RC-52 cells were trypsinized, washed in saline, and 1.5x106 cells were 
injected s.c. into the right flank of 6-week-old BALB/c nu/nu mice. Experiments were 
initiated 10 weeks after inoculation of tumor cells (tumor weight: 0.1-0.8 g). 
Conjugation, radiolabeling and quality control 
The monoclonal antibodies G250 and MN-14 were radioiodinated with 125l (Amersham 
International, Buckinghamshire, UK) and with 13,l (Nordion Europe, Fleurus, Belgium) 
respectively, according to the iodogen method (28). Specific activity of the 
radiolabeled preparations were 281 MBq125 l/mg G250 and 185 MBq 131l/mg MN-14. 
The conjugation of DTPA (Sigma Chemical Co., St. Louis, MO) to MAb G250 and 
the determination of the number of DTPA ligands was carried out as described by 
Hnatowich et al. (29). The DTPA-MAb G250 was purified by extensive dialysis 
against 0.1 M citrate buffer pH 5.0. The purified DTPA-MAb G250 conjugate 
(DTPA:MAb G250 ratio 2 : 1 , cone : 1.0 mg MAb G250/ml) was radiolabeled with 
111lnCI3 (Mallinckrodt, Petten, The Netherlands) via citrate transchelation. The specific 
activity of the final preparation was 255 MBq n i l n /mg MAb G250. 
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The labeling of the MAG3 chelate with 186Re and the conjugation of the 
radioactive chelate to the MAb G250 was essentially carried out essentially as 
described by Visser et al. (22). Briefly, 80 nmol MAG3 was labeled with 185 MBq 
18eRe (10 min, 100°C). Following derivation of MAG3 with 2,3,5,6-tetrafluorphenol 
(TFP, 100 mg/ml in MeCN/H20 9:1), the
 186Re-MAG3-TFP was purified on a Sep-Pak 
C1 8 cartridge (Waters, Milford, MA) and subsequently reacted with 200 μ<ι MAb 
G250. The conjugated 186Re-MAG3-G250 was then purified on a PD-10 column 
(Pharmacia, Woerden, The Netherlands). Overall labeling efficiency was 5 0 % resulting 
in a specific activity of 92 MBq 1B6Re/mg MAb G250. 
In all preparations more than 9 5 % of the radioactivity was associated with the 
antibodies as determined by instant thin layer chromatography (ITLC). The 
¡mmunoreactive fractions of 125 l-G250, l1 l ln-DTPA-G250 and 186Re-MAG3-G250, 
determined on SK-RC-52 RCC cells as described by Lindmo et al. (30), were 90%, 
75% and 76%, respectively. 
In vitro stability of radiolabeled antibodies 
The stability of radiolabeled antibody preparations was tested in serum at 37°C for 30 
hours. At several time points post labeling ( 1 , 4, 20 and 30 h), the amount of free 
radiolabel was determined by ITLC. 
Biodistribution studies 
Thirty-six mice were divided in 3 groups of 12 mice, receiving either 186Re-MAG3-
G250 (3 цд per mouse), 111ln-DTPA-G250 (3 цд per mouse) or a combination of 1 2 5 l -
G250/1 3 1I-MN-14 (3 цд/3 цд per mouse). All antibody preparations were injected i.v. 
via the tail vein of the mice (0.2 ml/mouse). At 72 h p.i.mice were killed via cervical 
dislocation under ether anesthesia and biodistribution of the radiolabel was 
determined. The amount of radioactivity in the tumor and in the normal tissues (blood, 
muscle, lung, spleen, liver, kidneys and intestines) was determined in a gamma-
counter (1480 Wizard 3", Wallac Oy., Turku, Finland) along with an injection 
standard. The %ID/g and the tumor-to-blood ratios were calculated. Statistical 
analysis was performed using one-way analysis of variance, wi th Bonferroni posttest 
correction for multiple comparisons. Differences with a p-value < 0 . 0 5 were 
considered to be significant. 
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RESULTS 
In vitro stability of radiolabeled antibodies 
All radiolabeled antibody preparations were stable in serum. With each preparation 
less than 5% of the radiolabel was released from the antibody during the investigated 
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FIGURE 1. Serum stability of radiolabeled antibody preparations in time. 
Biodistribution 
The biodistribution of 1 2 5I-G250, i n ln-DTPA-G250 and 186Re-MAG3-G250 was studied 
and compared to the biodistribution of the nonspecific antibody MN-14 (Fig. 2). At 72 
h p.i. blood levels of all MAb G250 preparations were very low with a mean of 2.4 ± 
1.9, 1.4 ± 1.0 and 1.4 ± 1.5 %ID/g for 1 2 5I-G250, 1 l l ln-DTPA-G250 and ia6Re-MAG3-
G250, respectively. In contrast, blood levels of the nonspecific antibody 131I-MN-14 
were significantly higher (p< 0.0001) (mean 12.3 + 2.1 %ID/g), indicating 
metabolization of the MAb G250 by the tumor cells. 
Mean tumor uptake of 11 lln-DTPA-G250 was 18.6 ± 6.2 %ID/g which was 
significantly higher (p<0.01) than the mean tumor uptake of all other preparations 
(10.7 ± 5.2 %ID/g for 1 2 5I-G250, 5.9 ± 4.5 %ID/g for 186Re-MAG3-G250 and 4.6 ± 
1.5 %ID/g for 1 3 1I-MN-14). Mean tumor uptake of 1 2 5I-G250 was significantly higher 











from 18eRe-MAG3-G250 uptake. 
Tumor-to-blood ratios were calculated for each antibody preparation (Fig. 2, right 
panel). The highest tumor-to-blood ratio was obtained with 111ln-DTPA-G250: 16.4. 
Although the mean tumor uptake of 1 2 5I-G250 was higher than the mean tumor 
uptake of 186Re-MAG3-G250, the tumor-to-blood ratios of both preparations were 
similar (6.6 and 5.3, respectively). The lowest tumor-to-blood ratio was obtained with 
1 3 Ί-ΜΝ-14: 0.4. 
Uptake of '2 5I-G250 and 188Re-MAG3-G250 in normal organs was similarly low: 
blood levels (%ID/g) of 1 2 5 l and 186Re were higher than the uptake of these radiolabels 
in the normal organs, except for uptake of 186Re-MAG3-G250 in the liver (mean: 2.5 ± 
0.8 %ID/g). 11lJn-DTPA-G250 showed significantly higher uptake (p<0.001) in the 
spleen, kidneys, liver and intestines as compared to 1 2 5I-G250 and 1B6Re-MAG3-G250. 
Uptake of n i ln-DTPA-G250 in the liver was almost as high as uptake in the tumor 
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FIGURE 2. Biodistribution (%ID/g) and tumor-to-blood ratios of 125I-G250, n,ln-DTPA-G250, 18eRe-
MAG3-G250 and 13,I-MN-14 72 h postinjection. 
Effect of tumor weight on MAb G250 tumor retention 
Additionally, the effect of tumor weight on antibody retention was investigated for 
each radiolabeled antibody. For all MAb G250 preparations tumor uptake decreased 
with increasing tumor weight. In contrast, 1 3 1I-MN-14 uptake in the tumor was fairly 
constant regardless of tumor weight. A scatterplot of the tumor uptake of each 
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preparation in relation to turnor weight is shown in Figure 3. Regression analysis 
(exponential curve fit) showed a clear correlation between MAb G250 tumor uptake 
and tumor size: correlation coefficients (r) were 0.65, 0.90, and 0.85 for 1 2 5I-G250, 
1 1 lln-DTPA-G250 and 18eRe-MAG3-G250, respectively. No correlation was found 
between 1 3 1I-MN-14 tumor uptake and tumor size (r: 0.32). 
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FIGURE 3. Scatterplots of the tumor uptake of 125!-G250, 1l1ln-DTPA-G250, 'e6Re-MAG3-G250 and 
131I-MN-14 in relation to tumor weight. Corresponding correlation coefficients (exponential curve fit): 
0.65, 0.90, 0.85 and 0.32. 
DISCUSSION 
Up to now, radioimmunotherapy of solid tumors with monoclonal antibodies has not 
fulfilled expectations as raised in the early 1980s. Nevertheless, the results of several 
radioimmunotherapy trials in patients still indicate its therapeutic potential (4,31). In 
order to enhance the effect of radioimmunotherapy optimization of the approach 
seems obligatory. Conceivable aspects include treatment design (single versus 
multiple dose treatment), additional measures to reduce toxicity (bone marrow 
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support, GM-CSF administration), enhancement of tumor uptake, choice of antibody 
form (whole IgG, F(ab)2, or Fab fragments, bispecific antibodies) and choice of 
radionuclide. 
An ¡deal radionuclide for radioimmunotherapy should match the following 
characteristics: easy radiochemistry, formation of a stable radioimmunoconjugate 
when linked to the antibody, suitable half-life, effective beta-radiation, imagable 
gamma-radiation with limited abundance and retention in the tumor cell after 
internalization of the antibody in the tumor cell. 186Re is one of the radionuclides that 
meets most of these criteria. 
Several investigators have studied the fate of radiolabeled antibodies after 
processing of the radioimmunoconjugate by the tumor and focused especially on the 
tumor retention of radiometals such as 1 1 l ln , 1B6'18eRe and
 90Y. A study that elegantly 
investigated the processing of radiolabeled antibodies in vitro was performed by Shih 
et al. (15) who investigated the fate of antibodies labeled with 188Re (direct labeling), 
,n ln-DTPA and seven different forms of 125l after internalization in vitro. This study 
showed a favorable retention of 111ln in the tumor cells compared to the retention of 
all ,25l labeled antibody preparations. Tumor cell retention of 188Re was similarly low to 
that of ,25l and it was suggested that the limited retention could be attributed to the 
observed instability of the 188Re-antibody conjugate. Another conclusion from this 
study was that retention most likely is an effect of lysosomal entrapment, which is in 
accordance with the results of other investigators (13). Further evidence supporting 
the hypothesis that high uptake in the tumor resulted from retention in the lysosomes 
came from subcellular fractionation studies: Press et al. (12) showed enhanced 
lysosomal retention of 11l ln and 90Y labeled antibodies in several internalizing 
carcinoma cell lines and Duncan et al. (32) provided similar findings for 1l1ln-DTPA-
octreotide. 
As discussed above, the lack of retention of 188Re (15,18) in a tumor cell might 
be a result of instability of the radiolabeled antibody preparation when a direct labeling 
method is used. Thus, formation of a stable radioimmunoconjugate might result in 
enhanced tumor retention. As shown, stable 186Re-antibody preparations can be 
obtained when MAG3 is used as a chelator. However, the results of the study 
presented here clearly show that 186Re is not retained in the tumor cell after 
processing of the 186Re-MAG3-G250. In accordance with the results of other 
investigators we found an enhanced tumor retention of 111ln-DTPA-G250, whereas 
125I-G250 did not show enhanced tumor retention. The very low blood levels of all 
G250 preparations and the much higher blood levels of the nonspecific antibody MN-
14 - similar to blood levels of this antibody when used in a non-internalizing tumor 
model (23) - indisputably indicate processing of the antibody. Furthermore, it was 
shown that in the tumor model that was used, retention of the radiolabel decreases 
with increasing tumor size, which might be explained by the higher processing 
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capacity of larger tumors compared to smaller ones: following internalization the 
radiolabel is released from the tumor cell and thus the tumors with the highest 
processing capacity release the radiolabel more rapidly than tumors with a lower 
processing capacity. 
Conclusion: Although 186Re still might prove a superior and very useful isotope 
for radioimmunotherapy purposes, it does not show an additional advantage to 1 3 1 l in 
terms of tumor retention after processing of the antibody. 
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Infection imaging with a multistep approach 
ABSTRACT 
Antibodies accumulate nonspecifically in infectious foci due to the locally increased vascular 
permeability. This study describes a method of infection imaging in which 99mTc-
diethylenetnaminepentaacetic acid (99mTc DTPA) is trapped at the target by a previously 
administered anti DTPA monoclonal antibody, DTInl Rats with Staphylococcus aureus-\n1ected 
calf muscle were injected intravenously (i.v ) with DTInl. Two to 24 h after the DTInl injection, 
"Tc-DTPA was injected i.v In separate experiments, excess DTInl was cleared from the 
circulation 2 h after injection with bovine serum albumin (BSA)-DTPA-ln, galactosylated BSA-
DTPA-ln, goat antimouse IgG or avidm Additionally, the effect of DTInl dose on 99mTc-DTPA 
abscess uptake was determined in a three-step protocol The distribution of the radiolabels was 
studied by gamma-counting of dissected tissue and gamma camera imaging Priming with DTInl 
resulted in specific retention of 99mTc DTPA in the abscess Such 99mTc-DTPA abscess uptake 
was not dependent on the interval between the DTInl and the 99mTc-DTPA injection· Optimal 
99mTc-DTPA abscess uptake was already achieved within a 2-h time span between the DTInl 
and DTPA injections However, relatively high 99mTc-DTPA background was observed due to 
slowly clearing DTInl-99mTc-DTPA complexes. Background reduction with various agents had a 
prominent effect on DTInl as well as 99mTc-DTPA biodistribution. The best reduction was 
obtained using BSA-DTPA-ln. Optimal 99mTc-DTPA abscess uptake in the three-step protocol 
was obtained at higher DTInl doses (>100 μg). Infectious foci in a rat model can be imaged 
earlier with extremely low background levels after priming with DTInl, followed by BSA-DTPA-
ln and imaging with 39mTc-DTPA, as compared with directly labeled IgG. 
INTRODUCTION 
Scintigraphic imaging of focal infection is currently performed with various agents, such 
as 67Ga-citrate, radiolabeled leukocytes or ^In-labeled human IgG (1,2). Large proteins 
such as IgG and human serum albumin localize nonspecifically in infectious and 
inflammatory foci due to the locally enhanced vascular permeability (3,4). Although 
labeled IgG is a convenient radiopharmaceutical, its relatively slow blood clearance, 
which causes persistently high background activity, interferes with the early diagnosis 
of infection and inflammation (5) 
Reduction of background activity may be accomplished by pretargeting protocols. 
In these methods, the infectious focus is pretargeted and the radionuclide is 
administered afterwards as a low-molecular-weight ligand. The small ligand is rapidly 
excreted when not targeted to the infectious focus. Streptavidm and biotin have been 
used in such multistep approaches (6-8). Rusckowski et al (8) pretargeted mice with 
Escherichia coll infection with cold streptavidm and injected 1 1 lln-biotin 3 h later. Higher 
abscess-to-background ratios were obtained compared with 11 lln-streptavidin or 1 1 1 ln-
IgG. Similar results were observed in tumor pretargeting studies using antichelate 
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antibodies and radiometal labeled chelates (9-12). 
In this study, we investigated a multistep strategy for rapid infection imaging using 
an anti-DTPA monoclonal antibody (MAb) as the pretargeting agent and 99mTc-DTPA as 
the targeting radiopharmaceutical. 
MATERIALS AND METHODS 
Radiopharmaceuticals 
^Tc-fgG 
Human nonspecific IgG in kit form (Technescan-HIG; Mallinckrodt Medical B.V., Petten, 
The Netherlands) was labeled with 750 MBq 9 9 mTc eluate according to the 
manufacturer's instructions. 
Monoclonal antibodies 
The production of anti-DTPA MAb DTInl (lgG2a), reacting with DTPA loaded with 
different metals, has been described (13). The affinity constant for 99mTc-DTPA was 
approximately 0.2 n M ' \ which is similar to that for 1 l1ln-DTPA (13). The lgG2a 
switchvariant of MAb G250 (14) was used as a non-DTPA-binding control antibody. 
DTInl and G250 were labeled with 1 2 5 l (Amersham International, Buckinghamshire, UK) 
using the lodogen method (15). 
Biotinylated DTIn 1 
DTInl was conjugated with NHS-LC-biotin (Pierce, Rockford, IL). Briefly, 0.8 mg DTInl 
and 740 цд NHS-LC-biotin in 50 mM sodium phosphate pH 7.5 were incubated for 16 h 
at 4°C. Thereafter, unreacted biotin was removed by PD10 (Pharmacia LKB Technology, 
Uppsala, Sweden) chromatography. Each DTInl molecule contained 18 biotins as 
determined by the method of Green (16). In vivo, the 99mTc-DTPA binding capacity of 
biotinylated DTInl and DTInl were similar. 
BSA-DTPA-ln 
BSA (Sigma Chemical Co., St. Louis, MO) was conjugated with the cyclic anhydride of 
DTPA (Sigma) in a 1:20 molar ratio as described by Hnatowich et al. (17). After PD10 
chromatography to remove unreacted DTPA, excess lnCI3 (Merck, Darmstadt, Germany) 
was added. Five DTPA molecules were conjugated per BSA molecule as determined by 
the ITLC method described by Hnatowich et al. (17). 
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Galactosylated BSA-DTPA-ln 
BSA-DTPA-ln was galactosylated essentially as described by Marshall et al. (18). To 
36.5 mg dry activated galactose 10 mg BSA-DTPA-ln (5 mg/ml in 25 mM sodium 
borate, pH 8.5) were added and allowed to react for 2 h. PD10 chromatography was 
used to remove unreacted galactose. Thirty-two galactose molecules were conjugated 
per BSA-DTPA-ln molecule as determined by the method of Dubois et al. (19). 
""•Tc-DTPA 
A kit containing 1 mg DTPA, 0.6 mg calcium nitrate and 0.05 mg stannous sulphate 
(pH 5.0) was radiolabeled with a fresh 99mTc eluate. 
Animal studies 
Animal Model 
A S. aureus calf muscle abscess was induced in young, male Wistar rats according to 
the method of Oyen et al. (3). Experiments were initiated 24 h after the S. aureus 
inoculation. All radiopharmaceuticals were intravenously injected. 
Biodistribution Studies 
Rats were injected intraperitoneal^ with a phénobarbital overdose, bled by cardiac 
puncture and killed. Tissues were dissected and weighed. The activity in tissues and 
injection standards was measured in a shielded well scintillation gamma counter and 
expressed as the percentage of injected dose per g (%ID/g). From these data abscess-
to-blood ratios (ABR) and abscess-to-contralateral muscle ratios (AMR) were calculated. 
In all experiments, groups of five rats were used. 
Immunoscintigraphy 
Groups of four rats were anesthesized (nitrous oxide/oxygen/halothane) and placed 
prone on a gamma camera (Orbiter, Siemens, Hoffman Estates, IL) equipped with a low-
energy, parallel hole collimator. Images (400,000 counts per image) were obtained up to 
2 h postinjection (p.i.) and stored in a 256x256 matrix. The ¡mages were analyzed by 
drawing regions of interest over the whole animal, the abscess and the contralateral calf 
muscle (background). The abscess-to-background ratios and abscess-to-whole body 
ratios were calculated. 
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Targeting of infections with 99mTc-lgG 
Each rat was injected with 25 цд 99mTc-lgG (750 MBq/mg). The rats were killed, and the 
biodistribution was determined 4, 8 and 24 h after injection. 
Two-phase targeting of infections 
Each rat was injected with 100 цд DTInl (3 MBq/mg) or 100 цд 125I-G250 (4 MBq/mg). 
Twenty-four h later, the rats received 7.5 MBq 99mTc-DTPA (0.2 цд) and 2 h later 
biodistribution studies were performed. 
Optimization of time between DTInl and DTPA injection 
DTInl (100 μg labeled with 300 kBq 125l) was injected into each rat. 99mTc-DTPA (0.2 
μg labeled with 7.5 MBq) was injected at 2, 6 or 24 h. Radiolabel biodistributions were 
determined 2 h p.i. 
Three-step targeting of infections 
Ten rats were injected with 100 μg DTIn l . Two h later, 5 of the 10 rats received 500 
μg BSA-DTPA-ln. All rats received 15 MBq 99mTc-DTPA (1.4 цд) 30 min later, and 
images were obtained up to 120 min p.i. As control, a third group of rats received 7.5 
MBq 99mTc-DTPA (0.7 μg) only. Images were obtained up to 20 min p.i. 
The three-phase targeting protocol was also studied in a biodistribution 
experiment. Ten rats received 300 μg DTInl labeled with 370 kBq 1 2 5 l . After 2 h, 5 of 
the 10 rats received 650 μg BSA-DTPA-ln. Rats in both groups received 4 MBq " T c -
DTPA (4 μg) 2.5 h after the first injection, and biodistribution was determined 1 h later. 
Comparison of background-reducing agents 
Four background-reducing agents were studied in the three-step protocol: BSA-DTPA-ln, 
galactosylated BSA-DTPA-ln (gal-BSA-DTPA-ln), goat antimouse IgG (GAM-IgG; rat 
serum absorbed; Southern Biotechnology Associates Inc., Birmingham, AL) and avidin 
(Sigma). Rats were injected with 30 μg DTInl (labeled with 2 MBq 125l) or 30 цд 
biotinylated DTInl (labeled with 3 MBq 1 2 BI). Two h later, a 10-fold molar excess of 
background-reducing agents was injected (assuming an antibody blood level of 4 %ID/g 
and a total blood volume of 12 ml (3)). Thirty min later, 4 MBq 99mTc-DTPA (3.5 μg) 
were injected. The biodistribution was determined 30 min p.i. 
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Antibody dose optimization 
Increasing amounts of 125l-DTIn1 (10-900 μg per rat, labeled with 370 kBq 125l) were 
injected. Two h later, BSA-DTPA-ln was injected into each rat at a calculated 10-fold 
molar excess. Thirty min later, each rat was injected with 4 MBq 99mTc-DTPA (3.3 цд), 
and 99mTc-DTPA biodistribution was determined 1 h p.i. 
Statistical Analysis 
All mean values are ± SD. Statistical analysis was performed using one-way analysis of 
variance, with Bonferroni posttest correction for multiple comparisons. 
RESULTS 
Two-phase targeting of infections 
Priming rats with DTInl for 24 h had a profound effect on the 99mTc-DTPA 
biodistribution (Fig. 1). Whereas almost no differences in the biodistribution between 
DTInl and G250 were observed (data not shown), 99mTc-DTPA activity was 
significantly higher in DTInl primed rats in all examined tissues with the exception of 













blood muscle abscess lungs spleen kidneys liver 
FIGURE 1. Biodistribution of 9 9 mTc-DTPA after DTInl (solid bars) or G250 (hatched bars) priming. Twenty-
four h after antibody injection, rats were injected w i t h 9 9 mTc-DTPA, and 9 9 mTc-DTPA biodistribution was 
determined 2 h later. 
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Optimization of the time between DTInl and DTPA injection 
In Table 1, biodistribution of 125l-DTIn1 is shown 4, 8 and 26 h after injection. The 
%ID/g 125l-DTIn1 in the blood decreased with time. More importantly, the l25l-DTIn1 
uptake in the abscess was similar up to 26 h after injection. Neither ABR nor the AMR 
of '25l-DTIn1 improved with time. 
The %ID/g 99mTc-DTPA in blood decreased significantly with increasing intervals 
between the DTInl and DTPA injections (Table 1). The 99mTc-DTPA uptake in other 
organs and in the abscess was not significantly affected by the interval between the 
DTInl and 99mTc-DTPA injections. The ABR slightly improved from 0.27 at the 6-h 
interval to 0.46 at the 24-h interval between the DTInl and 99mTc-DTPA injections. No 
significant differences were observed in 99mTc-DTPA AMRs. Optimal abscess uptake of 
99mTc-DTPA had been achieved during the 2 h between the DTInl and DTPA injections. 
However, due to the high DTInl blood levels, 99mTc-DTPA background levels remained 
high. 
TABLE 1 











4 h p.i. 
3.17 + 0.17 
0.10 ±0.02 
0.83 + 0.22 
0.67 ± 0.05 
0 82 ±0.08 
0.48 ± 0.04 
0.26 ± 0.06 
8 96 ± 3.07 
,25l-DTIn1 (%ID/g or ratio; 
8 h p.i. 
2.45 ±0.15 




0.47 ± 0.08 
0.36 ±0.15 
10.26 ±2.10 
mean values ± SD) 





0.43 ± 0.06 
0.23 ±0.04 
0.44 + 0.07 
6.44 ±0.17 
Biodistribution of 99mTc-DTPA 2 h p.i. at different intervals between DTInl and 

























0.20 ± 0.09 
0.27 + 0.14 
7.43 ± 2.27 
24-h interval 
0.97 ±0.16 
0.08 ± 0.01 




0.46 ± 0.06 
5.83 ±0.16 
To clarify the role of the two-step strategy, biodistribution studies with 99mTc-lgG 
were performed (Table 2). High background levels were also observed with 99mTc-lgG. 
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The AMR was significantly higher using 99mTc-lgG, but no significant differences were 
observed in ABRs when 99mTc-lgG 4 h p.i. was compared with 99mTc-DTPA in the two-
phase protocol with a 2-h timespan. Early imaging of infectious foci, in terms of ABRs, 
was not improved using this two-step protocol. 
TABLE 2 















8.21 ± 1.81 
0.98 ± 0.08 
0.35 ±0.05 
12.72 ±2.54 









24 h p.i. 




6.96 ± 2.66 
0.40 ± 0.06 
0.69 ± 0.06 
8.09 ±0.55 
Three-step targeting of infectious foci 
FIGURE 2. Images of rats wi th a S. aureus infection in the left calf muscle imaged at 10 min p.i. of 99mTc-
DTPA using the two-phase protocol (DTIn l , " T c - D T P A ; rats 1 and 2) or the three-phase protocol 
(DTIn l , BSA-DTPA-ln, " "Tc -DTPA; rats 3 and 4). 
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The effect of BSA-DTPA-ln on 99mTc-DTPA abscess uptake and whole-body distribution 
was studied scintigraphically. Administration of BSA-DTPA-ln resulted in a marked 
change in whole-body distribution of 99mTc-DTPA (Fig. 2). With the two- and three-step 
protocols, the abscesses were clearly visualized. However, a notable decrease of 
circulating 99mTc-DTPA was observed in BSA-DTPA-ln treated rats. With the three-step 
protocol, the abscess-to-background ratio increased to 14.8 ± 3.1 2 h after 99mTc-
DTPA injection. Due to the rapid excretion of the nontargeted " T c - D T P A , the abscess 
uptake as percentage of residual activity increased up to 16.3% 2 h after 99mTc-DTPA 
injection. In contrast, rats receiving 99mTc-DTPA only showed minimal abscess uptake 
(2.3% ± 0.3% of whole-body activity 20 min p.i.) and the abscess-to-background ratio 
did not exceed 2. 
blood muscle abscess liver kidneys spleen lungs 
FIGURE 3. Comparison between the three-phase protocol (DTInl, BSA-DTPA-ln, DTPA; solid bars) and 
the two-phase protocol (DTInl, DTPA; hatched bars). Biodistribution of "Tc-DTPA 1 h after injection is 
shown. Biodistribution of 125l-DTIn1 3.5 h after injection is shown in the inset. 
In the biodistribution experiment, striking differences between two- and three-step 
protocols were observed. A decrease in 99mTc-DTPA uptake was seen in blood (17-fold 
reduction), abscess (1.9-fold decrease) and other organs of rats treated with BSA-
DTPA-ln (Fig. 3). More importantly, the 93mTc-DTPA ABR was significantly higher in 
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three-phase protocol rats (1.97 ± 0.42 versus 0.22 ± 0.03; p < 0 . 0 0 1 ) , whereas the 
AMR was not different. The %ID/g l25l-DTIn1 in blood, kidneys and lungs significantly 
decreased, whereas a significant increase was seen in the liver and spleen, indicating 
DTIn1-BSA-DTPA-ln complexation and subsequent metabolization (Fig. 3 inset). The 
amount of 125l-DTIn1 in the abscess was similar in both pretargeting protocols. 
The three-step approach resulted in significant improvement of the ABR for " T c -
IgG 4 h p.i. (1.97 ± 0.42 versus 0.35 ± 0.05; p < 0 . 0 0 0 1 ) . 
Comparison of different background-reducing agents 
All agents effectively reduced the %ID/g 99mTc-DTPA in the blood (Table 3). BSA-DTPA-
In had the most prominent effect on 99mTc-DTPA blood levels, with a 5.6-fold reduction 
compared with the two-step protocol. Only slightly (but significantly) decreased " T c -
DTPA abscess uptake was observed after injection of BSA-DTPA-ln or gal-BSA-DTPA-
In. Lower 99mTc-DTPA levels were observed in the liver and spleen using BSA-DTPA-ln 
or in the liver using gal-BSA-DTPA-ln. Higher 99mTc-DTPA levels were observed in the 
spleen after GAM-IgG injection and in the liver and spleen after avidin injection. The 
99mTc-DTPA ABR significantly improved using avidin (2.7-fold), BSA-DTPA-ln (3.6-fold) 
or GAM-IgG (3.7-fold). 
TABLE 3 
Comparison of different background reducing agents 




















0.08 ± 0.004 
1.00 + 0.21 
0.68 + 0.10 




0.93 ± 0 22 
1.07 ± 0 . 1 2 ' 
1.25 ± 0 . 1 1 ' 
,25l-DTIn1 (%ID/g; 
1.90±0.10' 
0.07 + 0.005 
0 . 5 4 ± 0 . 1 4 ' 
3.28 ± 0 . 1 9 ' 
0.46 ± 0 . 0 3 ' 
mean value + SD) 
0.57 ± 0 . 0 6 ' 
0.11 ± 0 . 0 1 ' 
0.56 + 0.05' 
2.67 ± 0 . 0 8 ' 
2.63 ± 0 . 4 2 ' 
Biodistribution of "Tc-DTPA (%ID/g or ratio; mean value ± 
2.25 ±0.20 
0.08 ± 0.003 
0.56 + 0.11 
0.45 ±0.06 
0.29 ±0.17 
0.25 ± 0.04 
7.29 ± 1.49 
0.40 ± 0.04* 
0.07 ± 0.01 
0.36 ±0.09* 
0.15 ± 0 . 0 2 ' 
0.11 + 0 . 0 1 ' 
0.90 + 0.26' 
5.17 ± 0 . 8 6 ' 
1.16 ± 0 . 0 8 ' 
0.0810.01 
0.39 ± 0 . 0 9 ' 




0.51 ± 0 . 0 4 ' 
0.08 ± 0.01 
0.47 ± 0.05 
0.50 ± 0.04 
1.78 + 0.29* 
0.92 ± 0 . 0 9 ' 
6.06 ±0.75 
0.82 + 0.09' 
0.11 ± 0 . 0 1 * 
0.59 ± 0 . 0 7 ' 
1.99±0.19' 
2.71 ± 0 . 5 4 ' 
SD) 
0.72 ± 0 . 0 9 ' 
0.08 ± 0.01 
0.48 ± 0.08 
0.76 ± 0.06' 
1.34 + 0.30' 
0.67 ±0.07' 
5.89 ± 1.01 
* Significant difference as compared w i t h two-phase protocol [i.e., DTInl ) at p < 0 . 0 5 
' Significant difference as compared w i t h two-phase protocol at ρ < 0.01 
* Significant difference as compared w i t h two-phase protocol at ρ < 0.001 
No significant differences were observed between DTInl and biotmylated DTInl; only DTInl results are shown 
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After injection of avidin, gal-BSA-DTPA-ln or GAM-IgG, 125l-DTIn1 blood levels 
significantly decreased compared to the two-phase protocol (Table 3). Injection of BSA-
DTPA-ln did not reduce 125l-DTIn1 blood levels. Elevated levels of 12Sl-DTIn1 in liver and 
spleen were observed after BSA-DTPA-ln, avidin or GAM-IgG injection, indicating 
removal of complexed DTInl by cells of the mononuclear phagocyte system. After gal-
BSA-DTPA-ln injection, l25l-DTIn1 was cleared through the liver, indicating that the 
galactose moiety directed the gal-BSA-DTPA-ln-DTIn1 complexes to the liver. 
Antibody dose escalation studies 
The amount of DTInl in all organs in terms of protein mass increased linearly with 
increasing amounts injected DTInl (data not shown), indicating that saturation was not 
reached. 
Biodistribution data for 99nTc-DTPA after priming with various doses of DTInl are 
shown in Fig. 4. The %ID/g in the abscess was significantly higher at £300 цд 
compared with 100 μg (0.31 ± 0.05 versus 0.19 ± 0 . 0 1 ; p < 0 . 0 5 ) . Consequently, the 
ABR and AMR significantly increased when increasing the DTInl dose from 100 to 300 
μg (ABR: 0.88 ± 0.03 versus 1.79 ± 0.30 (p<0.05); AMR: 5.63 ± 1.71 versus 8.79 
± 2.25 (p<0.05)), indicating that 300 цд per rat was the optimal dose. 
125 
blood muscle abscess liver kidneys spleen lungs ABR AMR 
FIGURE 4. Biodistribution of "Tc-DTPA after priming with increasing DTInl doses and chasing with a 
10-fold molar excess BSA-DTPA-ln. Two h after DTInl injection, BSA-DTPA-ln was injected, and DTPA 
was injected 30 mm later Biodistribution data were obtained 1 h after DTPA injection. 
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DISCUSSION 
The development of an imaging technique to localize acute infection within a few hours 
is of great clinical importance (20). Using radiopharmaceuticals such as 111ln-lgG and 
99mTc-lgG a relatively long time (^24 h) is needed before a final diagnosis can be made 
(5). This is mainly related to slow blood clearance, resulting in slower increase of target-
to-background ratios (3). We investigated whether a pretargeting protocol could 
overcome this drawback. 
We evaluated the potential of an anti-DTPA MAb combined with radiolabeled 
DTPA for multistep targeting of infectious foci. After pretargeting with DTInl , the 
abscess was visualized with 99mTc-DTPA. DTPA abscess uptake was based on antibody-
antigen interaction because priming with G250 did not result in any specific 99mTc-DTPA 
uptake. Given the hyperemia and increased vascular permeability in acute infections, 
optimal abscess uptake of 99mTc-DTPA was achieved within a 2-h time interval between 
the DTInl and DTPA injections, since accumulation of DTInl in the abscess was very 
rapid 
However, relatively high background activity was seen due to slow clearance of 
99mTc-DTPA-DTIn1 complexes formed in the circulation. The two-phase protocol 
revealed no significant improvement in comparison to directly labeled 99mTc-lgG at early 
time points. 
To reduce the complexation of 99mTc-DTPA with circulating DTInl , BSA-DTPA-ln 
was injected. This markedly changed the whole-body distribution of the subsequently 
injected 99mTc-DTPA The imaging studies showed only minor amounts of 99mTc-DTPA in 
the circulation, whereas the abscess was clearly visualized. 
Four different background-reducing agents were compared. Immune complexes 
formed between DTInl and avidin, GAM-IgG or BSA-DTPA-ln should be cleared through 
the liver and spleen (9,21-25). DTInl-Gal-BSA-DTPA-ln complexes should be cleared 
through the hepatic asialoglycoprotein receptor (26) Avidin and GAM-IgG do not 
interfere with the antigen-binding site of DTInl , whereas BSA-DTPA-ln and gal-BSA-
DTPA-ln do Each of the background-reducing agents significantly reduced the amount 
of 99mTc-DTPA in the blood The enhanced 99mTc-DTPA liver and spleen uptake seen 
with avidin and GAM-IgG most likely represents 99mTc-DTPA entrapment by DTInl 
complexes not yet metabolized. In contrast, reduced amounts of "Tc -DTPA were 
observed in the spleen and/or liver with gal-BSA-DTPA-ln and BSA-DTPA-ln, indicating 
efficient blocking of the DTPA-binding site. Significantly decreased 99mTc-DTPA abscess 
uptake was observed with BSA-DTPA-ln and gal-BSA-DTPA-ln This reduced abscess 
uptake resulted from blocking of DTInl antibody in the abscess or blockage of 
circulating DTInl (thereby reducing the number of circulating DTInl-DTPA complexes 
contributing to 99mTc-DTPA abscess uptake) These data suggest that 99mTc-DTPA 
binding to prelocalized DTInl plays an important role in 99mTc-DTPA abscess uptake, in 
92 
Chapter 4 
view of the slight reduction in the amount of 99mTc-DTPA in the abscess after BSA-
DTPA-ln injection. 
The best reduction of 99mTc-DTPA background was obtained with BSA-DTPA-ln: A 
5.6-fold reduction of 99mTc-DTPA blood level was achieved with a concomittant 3.5-fold 
increase in the ABR. The use of a background-reducing agent that can block the DTInl 
antigen binding site does not hamper the targeting of infectious foci with 99mTc-DTPA. 
Therefore, the behavior of BSA-DTPA-ln in these studies was superior to the other 
background-reducing agents. 
Goodwin et al. used a similar background reduction approach to image tumors in 
mice (9). A three-step protocol was designed using an anti-BLEDTA IV antibody, a 
human transferrin-chelate conjugate and n iln-BLEDTA IV. Due to the background 
reduction step, decreased l ,1ln-BLEDTA IV tumor uptake and increased tumor-to-blood 
ratios were observed similar to our observations. In their study of mice with E. coli 
infection, Rusckowski et al. demonstrated that infection imaging could be improved, in 
terms of ABR and AMR, using streptavidin pretargeting and radiolabeled biotin (8). 
With our three-step strategy, rapid imaging of infectious foci was achieved: High 
abscess-to-background ratios were obtained within 30 min p.i. of DTPA and 3 h after 
the first injection. The three-phase targeting protocol may potentially improve the 
infection imaging at earlier times after tracer injection in humans. A limitation to this 
approach might be the development of a HAMA response after administration of DTInl . 
For clinical studies, a humanized DTInl antibody is preferable. Immunogenicity of the 
background-reducing agent can be minimized by the use of a human serum protein as a 
carrier. The immunogenicity of (strept)avidin (6) might hamper the use of the 
(strept)avidin-biotin system for infection imaging in humans, especially since a human 
equivalent of (strept)avidin is not available. 
A potential drawback to the three-step method is the relatively large DTInl protein 
dose needed in humans. The use of multivalent DTPA might facilitate the use of lower 
DTInl doses in view of the higher affinity of antichelate antibodies for multivalent 
chelates compared to monovalent chelates (11). 
In conclusion, three-phase targeting of infectious foci results in early imaging with 
low background levels as compared to two-phase targeting protocols or directly labeled 
nonspecific IgG. 
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ABSTRACT 
The specificity of antibodies offers unique opportunities to target tumors with radionuclides 
However, due to the slow clearance of radiolabeled antibody, relatively high background is 
observed in nontarget organs Pretargeting protocols using bispecific monoclonal antibodies 
(bsMAbs) and radiolabeled chelates may overcome this problem We have evaluated the anti-
renal cell carcinoma (RCC) χ anti-diethylenetriammepentaacetic acid (DTPA) bsMAb G250 χ 
DTInl for two-step targeting of RCC tumors in nude mice Tumor uptake of 111ln-DTPA was 
similar up to a 3-day interval between bsMAb and 11,ln-DTPA injections and decreased 
thereafter The effect of G250 χ DTInl protein dose was studied. High tumor uptake was 
seen at 1 to 4 μg, whereas at higher doses uptake decreased Tumor was saturated with 15 
μg bsMAb. At the saturating bsMAb dose the ,11ln-DTPA amount was varied High tumor 
uptake was observed at a 10-fold molar excess 11,ln-DTPA, whereas at higher excess uptake 
decreased After priming with 15 цд bsMAb and targeting with a 10-fold molar excess " Ί η -
DTPA the biodistribution of m l n DTPA was studied for 1 to 48 h after injection Good tumor 
retention of 1,lln-DTPA was observed, while the radiolabel cleared rapidly from the blood 
Consequently, tumor-to-blood ratios increased with time to 500 at 24 h after injection In 
conclusion, RCC xenografts can be targeted efficiently using G250 χ DTInl and '"In DTPA 
However, this requires careful tuning of bsMAb protein dose and "1ln-DTPA dose Using the 
optimal protein dose and "Ίπ-DTPA dose, high "'In DTPA tumor uptake and tumor-to-blood 
ratios can be obtained, thus providing good perspectives for diagnostic and therapeutic use in 
humans. 
INTRODUCTION 
Monoclonal antibodies against tumor-associated antigens have been used successfully 
to direct radionuclides preferentially to solid tumors (1,2). However, due to the slow 
clearance of radiolabeled antibody from the blood and normal tissues, optimal 
visualization of the tumor is delayed for several days. In addition, sustained levels of 
radiolabeled antibody in the blood and normal tissues increase toxicity to nontarget 
tissues and limit the amount of radioactivity that can be administered in 
radioimmunotherapy. The efficacy of radioimmunodetection or radioimmunotherapy 
might be enhanced by improving the localization of radiolabeled MAbs in tumors or by 
reduction of the background activity (3). Several approaches have been tested to 
enhance the clearance of radiolabeled MAbs, e g, the use of antibody fragments, 
metabohzable chelating agents, biochemically modified MAbs, second antibodies or 
plasmapheresis (3). 
Reduction of background activity might also be achieved by pretargeting 
approaches. In these, the antitumor antibody and the radionuclide are administered 
separately, / e , when the antibody has cleared from the circulation, the radionuclide is 
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given as a low-molecular-weight ligand. This ligand is very rapidly excreted when not 
bound to pretargeted antibody. The avid interaction between streptavidin and biotin 
has been exploited in pretargeting approaches (4,5). Alternatively, pretargeting 
protocols can also be based on bispecific antibodies and radiometal-labeled chelates. 
In these, the tumor is pretargeted with a bispecific antibody reactive with a tumor-
associated antigen and with a radiolabeled chelate. The feasibility of this approach has 
been shown in animal studies (6-10) and in radioimmunoscintigraphy studies in colon 
carcinoma (11) and medullary thyroid cancer patients (12), in which markedly reduced 
background activity and good retention of the radiolabeled chelate in the tumor were 
observed. 
We have described the production and characterization of a series of anti-RCC χ 
anti-DTPA bsMAbs (13). Here, we describe two-phase targeting of RCC in nude mice 
with RCC xenografts. We have investigated the influence of the interval between 
bsMAb and 111ln-DTPA injections, the protein dose of bsMAb, the dose of 111ln-DTPA 
and the duration of 1 l l ln-DTPA binding in the tumor. 
MATERIALS AND METHODS 
Antibody preparation and radiolabeling 
The anti-RCC MAb G250 (IgGD is directed against the RCC-associated antigen G250. 
This antigen is expressed in 7 5 % of RCCs, whereas expression in normal tissues is 
restricted to gastric mucosal cells and cells of the larger bile ducts (14). 
The anti-DTPA MAbs DTInl (lgG2a) and DTY4 (lgG2a) specifically recognize 
DTPA loaded with different metals (13). 
The production and characterization of the bispecific anti-RCC χ anti-DTPA MAb 
G250 χ DTInl has been described (13). In short, hypoxanthine guanine 
phosphoribosyl transferase-deficiency was introduced in the DTInl-producing 
hybridoma by 8-azaguanidine selection. Thymidine kinase-deficient hybridoma G250 
was isolated by bromodeoxyuridine selection. DTInl hybridoma was fused with 
hybridoma G250 at a 1:1 ratio and seeded in soft agarose. Growing colonies were 
picked, grown in suspension and tested for the production of bsMAb by a double-
specificity ELISA. G250 χ DTInl was purified from ascites fluid using protein A 
affinity chromatography followed by cation exchange chromatography. 
Antibodies were labeled with 1 2 5 l (Amersham International, Buckinghamshire, UK) 
using the iodogen method (15). More than 9 5 % of the radioactivity was associated 
with the antibodies as determined by instant thin layer chromatography (ITLC). The 
immunoreactivity of '2 5I-G250 and 1 2 5I-G250 χ DTInl was determined using one 
concentration of antibody and serial dilutions of the SK-RC-52 RCC cell line as 
described by Lindmo et al. (16). Immunoreactivity of 1 2 5I-G250 was higher than 8 5 % 
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and of 12SI-G250 χ DTInl higher than 8 0 % . 
Preparation of inln-DTPA 
"'InClg (18.5 MBq/ml; Mallinckrodt, Petten, The Netherlands) (15 μΙ) and 45 μΙ 40 
mM HCl were mixed with 1020 μΙ aqueous 0.12 μΜ DTPA solution and 120 μΙ 1.0 M 
sodium citrate buffer (pH 4.0). Following 60 min of incubation at room temperature, 
20 μΙ 0.1 M NaOH were added. Cold In-DTPA was prepared as follows: to 60 μΙ lnCI3 
(0.11 mM in 40 mM HCl) 1020 μΙ 0.12 mM aqueous DTPA solution and 120 μΙ 1 M 
sodium citrate buffer (pH 4.0) were added. After 60 min incubation at room 
temperature, 20 μΙ 0.1 M NaOH were added. Before injection in animals, i n ln-DTPA 
and In-DTPA were mixed to achieve the desired specific activity. More than 9 8 % of 
the n i l n was complexed by the DTPA as assessed by ITLC with methanokwater 
(55:45) as an eluent. 
Scatchard analysis 
The affinity constants of G250 and G250 χ DTInl for the G250 antigen and the 
number of binding sites per cell were determined by Scatchard analysis (17) on NU-12 
RCC cells. 
Biodistribution studies 
The NU-12 RCC xenograft was established from a primary tumor by serial subcutane 
(s.с.) transplantation in nude mice (18). The primary tumor consisted of large solid 
fields of large clear cells. The NU-12 xenograft largely resembled the original tumor 
(18). From the established tumor, NU-12 was also propagated in tissue culture. NU-
12 tumors were initiated in 6-week-old BALB/c nu/nu mice. NU-12 was serially 
transplanted by implanting viable tumor specimens (1-2 mm3) s.c. in the flank of the 
mice. All groups contained 4 or 5 mice. All radiopharmaceuticals were injected 
intravenously. The amount of radiolabel in the tumor and tissues (blood, muscle, liver, 
kidney and spleen) was determined by gamma-counting against an injection standard. 
From these biodistribution data the percentage injected dose per g (%ID/g), and the 
tumor-to-blood ratios were calculated. All data are given as mean values ± SD. 
Statistical analysis was performed using one-way analysis of variance, with Bonferroni 
posttest correction for multiple comparisons. Data were considered to be significantly 
different if the p-value was below 0.05. 
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Two-phase targeting of NU-7 2 tumors 
Mice were injected with 1 μg '2 5I-G250, ,25I-DTY4 or 1 2 5I-G250 χ DTIn l , and the 
biodistribution of the radiolabel was determined 7 days after injection. A separate 
group of mice received 1 μg unlabeled G250, DTY4 or G250 χ DTInl and 7 days 
postinjection (p.i.) 0.05 pmol l l 1 ln-DTPA was injected. Biodistribution of 1 l1ln-DTPA 
was determined 1 h thereafter. 
Optimization of the interval between G250 χ DTInl and 111ln-DTPA injections 
Mice were injected with 6 μg G250 χ DTIn l . After 1, 3 and 7 days a 10-fold molar 
excess 111ln-DTPA was injected, assuming a total blood volume of 2 ml and G250 χ 
DTInl blood levels of 15, 12 and 7 %ID/g, respectively. Biodistribution of l11ln-DTPA 
was determined 1 h p.i. 
Protein dose escalation of G250 χ DTInl 
To study the biodistribution at different protein doses ( 1 , 2, 4, 6, 9, 12, 18 and 36 
цд/гпоиэе) increasing amounts of unlabeled G250 χ DTInl were added to 1 2 5I-G250 χ 
DTInl . Three days p.i. the biodistribution of 1 2 5I-G250 χ DTInl was determined. In a 
separate experiment, mice were primed with 2 to 50 цд G250 χ DTIn l . After 3 days 
a 100-fold molar excess 1 l1ln-DTPA was injected (assuming a blood level of 12 %ID/g 
at each antibody dose level) and biodistribution of l11ln-DTPA was determined 1 h p.i. 
Effect of the "Ίη-DTPA dose 
Mice were injected with 15 цд G250 χ DTIn l , followed 3 days later by a 10-, 100-, 
or 250-fold molar excess , 1 lln-DTPA (based on 12 %ID/g G250 χ DTInl in the 
circulation). Biodistribution of the n i l n label was determined 1 h after 111ln-DTPA 
injection. 
Tumor retention of '"/n-DTPA 
Mice were injected with 15 цд G250 χ DTInl and 3 days later with a 10-fold molar 
excess 1 l1ln-DTPA (based on 12 %ID/g G250 χ DTInl in the circulation). 
Biodistribution was determined 1, 3, 6, 24 and 48 h p.i. 
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RESULTS 
Scatchard analysis 
Scatchard analysis of MAb G250 binding revealed that 1 50,000 antibody molecules 
were bound per NU-12 cell. The affinity constant for binding antigen was 1.2 n M 1 . 
The Ka of G250 χ DTInl was 6-fold lower compared with the Ka of G250 (0.20 nM"
1). 
With G250 χ DTIn l , a 2-fold higher number of antibody molecules were bound per 
NU-12 cell (325,000). 
The affinity constants of the anti-DTPA M Abs DTY4 and DTInl and the bsMAb 
G250 χ DTInl for binding 111ln-DTPA were similar (0.22, 0.23 and 0.24 n M 1 , 
respectively) (13). 
Two-phase targeting of NU-12 tumors 
The in vivo behavior of bsMAb G250 χ DTInl was compared with antibody G250 as 
well as the anti-DTPA MAb DTY4 in nude mice with a NU-12 tumor. The 
biodistribution of 1 цд 1 2 6I-G250, 125I-DTY4 and 1 2 5I-G250 χ DTInl 7 days p.i. was 
similar in all organs (data not shown) with the exception of the tumor. The tumor 
uptake of , 2 5I-G250 (102.9 ± 31.1 %ID/g) and '2 6I-G250 χ DTInl (27.6 ± 6.1 %ID/g) 
was significantly higher than that of 125I-DTY4 (2.3 ± 0.5 %ID/g), indicating specific 
uptake of the first two antibodies in the tumor. In addition, 1 2 5I-G250 tumor uptake 
was significantly higher than 1 2 5I-G250 χ DTInl uptake. 
The amount of 111ln-DTPA in blood, muscle, liver, kidneys and spleen of mice 
primed with G250, DTY4 or G250 χ DTInl were similar (data not shown). However, 
i n ln-DTPA tumor uptake differed significantly: the amount of n i ln-DTPA in G250 
primed mice (0.006 ± 0.004 %ID/g) was significantly lower compared with DTY4 
(0.2 ± 0.005 %ID/g) and G250 χ DTInl (0.4 ± 0.07 %ID/g) primed mice, whereas the 
amount of n i ln-DTPA in G250 χ DTInl primed mice was significantly higher than in 
DTY4 primed mice. These data indicate that i n ln-DTPA is specifically trapped by the 
pretargeted bsMAb G250 χ DTInl in the tumor. 
Optimization of interval between G250 χ DTInl and 11lln-DTPA injections 
To evaluate whether the interval between G250 χ DTInl and n i ln-DTPA injections 
influenced i n ln-DTPA tumor targeting, animals were primed with 6 цд bsMAb 
followed by n i ln-DTPA 1, 3 or 7 days later. The amount of n i ln-DTPA in the tumor 
and the tumor-to-blood ratios were not significantly different at a 1-, 3- or 7-day 
interval between G250 χ DTInl and 111ln-DTPA injections (Table 1), but the amount 
of l n ln-DTPA in the tumor tended to decline and the tumor-to-blood ratio tended to 
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increase at the 7-day interval. In all other tissues the amount of 111ln-DTPA after 7 
days of pretargeting with bsMAb was significantly lower compared with 1 and 3 days 
pretargeting. Tumor uptake at the 7-day interval (2.60 ± 0.65 %ID/g) was higher than 
that observed in the preceding section at a 7-day interval (0.4 ± 0.07 %ID/g), due to 
the higher amounts of bsMAb and 111ln-DTPA that were injected. For further studies a 
3-day interval was chosen because of the higher 111ln-DTPA tumor uptake observed 
compared with the 7-day interval. 
TABLE 1 
Effect of interval between G250 χ DTInl and i n ln-DTPA injections on n i ln-DTPA 
biodistribution 













4.61 ± 1.51 
0.72 10.17 
4.17 ±0.45 
1.13 ± 0.16 
1.51 ±0.57 
determined 1 h p.ι. of 111 In-DTPA 
3-day 
2.98 ± 0 . 8 5 
0.29 ± 0 . 1 4 
5.25 ±2.11 
0.93 ±0.21 
4.88 ± 0 . 7 6 
0.92 ±0.31 
1.73 + 0.18 
7-day 
1.09 ±0.61 
0.12 ± 0 . 0 6 
2.60 ± 0 . 6 5 
0.26 ± 0 . 1 2 
1.98 ± 0 . 5 4 
0.27 ± 0 . 1 6 
2.78 + 0.99 
Protein dose escalation of G250 χ DTInl 
Table 2 shows the tumor uptake of 1 2 5I-G250 χ DTInl (3 days p.i.) at different 
antibody protein doses. At the lowest bsMAb protein doses ( 1 , 2 and 4 цд), 
approximately 30 %ID was targeted per g tumor, whereas at higher dose levels a 
gradual decrease was observed in tumor uptake, indicating saturation of the G250 
antigen in the tumor. The %ID/g in the tumor at 1 цд was significantly higher than at 
9, 12, 18 and 36 цд, and at 2 and 4 цд was significantly higher than at 18 and 36 
μg. At 1, 2 and 4 цд, G250 χ DTInl tumor-to-blood ratios of 2.4 to 3 were achieved 
3 days p.i., whereas at higher doses tumor-to-blood ratios gradually decreased. The 
amount of 1 2 5I-G250 χ DTInl in the blood, muscle, liver, spleen and kidneys was not 
influenced by the protein dose injected (Table 2). 
The amount of G250 χ DTInl that accumulated specifically in the tumor was 
calculated at all dose levels (Fig. 1). The specific tumor uptake was defined as the 
amount of G250 χ DTInl (цд) that accumulated per g of tumor at a particular protein 
dose, minus the amount of non-RCC binding DTY4 antibody that accumulated at that 
protein dose. The bindingcurve showed a plateau at protein doses >18 цд G250 χ 
DTIn l , indicating saturation of G250 antigen in the tumor. Saturation occurred 
approximately at the 1 5 цд dose level, with 1.8 цд G250 χ DTInl bound per g tumor. 
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TABLE 2 
Biodistribution of G250 χ DTInl bsMAb at different antibody protein doses 


















0.92 ± 0 . 1 6 
31.72 ± 3.37 
2.40 ± 0.45 
3.01 ±0.35 
2.40 ± 0.38 
3.02 + 0.21 
Эйд 
10.71 ± 1.83 
0.93 ± 0 . 1 6 
19.38 ± 4 . 8 7 
2.31 ±0.18 
3.19 ±0.42 
2.58 ± 0 . 8 2 
1.87 ±0.58 
2цд 
12.1 ± 1.45 





2.48 ± 0.80 
12 Mg 
12.66 + 0.63 
1.24 + 0.22 
18.61 ± 5 . 7 4 
3.30 + 0.83 
3.85 ±0.41 
3.64 ±0.38 
1.48 + 0.48 
4 цд 
12.23 ± 2.40 
1.09 ± 0.25 
28.61 + 1.70 
2.50 + 0.27 
3.46 ± 0 . 4 1 
2.91 ± 0 . 7 2 
2.43 ± 0 . 5 9 
18 цд 
13.66 ± 1.33 
1.20 ± 0.11 
14.72 ± 4 . 4 7 
3.26 ± 1.02 
4.14 + 0.44 
3.47 ± 0 . 6 5 
1.06 ± 0 . 2 4 
бцд 
11.14 ± 1.00 
0.92 ± 0 . 1 4 
23.21 ± 2.84 
2.40 + 0.30 
3.33 ±0.29 
2.84 + 0.55 
2.14±0.17 
36 дд 
14.75 ± 0 . 0 8 
0.87 ±0.053 
9.81 ± 1.15 
3.02 ± 0 . 5 4 
3.62 ±0.63 
3.23 ±0.49 
0.66 ± 0.047 
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FIGURE 1 . Specific NU-12 tumor uptake of 1 2 5 I-G250 χ D T I n l 3 days p.i. The specific tumor uptake 
was defined as the amount of G 2 5 0 χ D T I n l (цд) that accumulated per g of NU-12 tumor at a 
particular protein dose minus the amount of DTY4 that accumulated at that dose. 
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In a separate experiment the biodistribution of i n ln-DTPA was determined after 
priming with increasing G250 χ DTInl antibody protein doses. In the tumor, the 
amount of n i ln-DTPA increased with antibody dose up to 15 цд G250 χ DTInl (Fig. 
2). At the highest dose of 50 цд the tumor uptake of n i ln-DTPA was lower, again 
indicating saturation of G250 χ DTInl binding in the tumor. The amount of l 1 l ln-DTPA 
in the tumor at 15 цд was significantly higher than at 2 and 5 цд. The amount of 
111ln-DTPA in the blood was not significantly different at 2 and 5 цд G250 χ DTInl 
(Fig. 2). At higher antibody doses, the 1 l1ln-DTPA level in the blood increased 
significantly, indicating that the amount of n i ln-DTPA bound to circulating G250 χ 










blood muscle tumor liver kidneys spleen 
FIGURE 2. Protein dose escalation of G 2 5 0 χ D T I n l . Mice were primed with 2 to 5 0 μg G 2 5 0 χ D T I n l . 
After 3 days a 100-fold molar excess l 1 1ln-DTPA was injected and biodistribution of n , ln-DTPA was 
determined 1 h thereafter. 
Dose escalation of l11ln-DTPA 
At the optimal protein dose of 15 цд bsMAb the effect of the amount of 111ln-DTPA 
was studied. The %ID/g in the tumor and all other organs at a 10-fold excess l 1 1 l n -
DTPA was significantly higher than at a 100- or 250-fold excess, whereas the %ID/g 
was not significantly different for 100-fold or 250-fold excess i n ln-DTPA (Fig. 3). 
Tumor-to-blood ratios at different molar excesses 1 l l ln-DTPA were not significantly 
different. From the %ID/g in the tumor the absolute amount of 1 l l ln-DTPA (ng) bound 
per g tumor was calculated. At 100-fold excess (19.5 ± 3.2 ng l n ln-DTPA/g tumor) 
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tumor than at 10-fold excess (5.0 ± 1.6 ng/g). The 10-fold excess i n ln-DTPA was 
chosen for further experiments, because at that dose level the highest %ID/g of i n l n -
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FIGURE 3. Effect of the n lln-DTPA dose. Mice were injected with 15 цд G250 χ DTIn1, followed 3 
days later by a 10-, 100- or 250-fold molar excess 11'ln-DTPA. One h after 111ln-DTPA injection, 
biodistnbution of the 111ln label was determined. 
Biodistribution of "Ίη-DTPA at various times after injection 
In the above-determined optimal conditions, the retention of 1 l l ln-DTPA by pretargeted 
G250 χ DTInl in the tumor was studied. The tumor uptake of 11lln-DTPA was 
determined at different times p.i. of l l 1 ln-DTPA. From 1 h onwards, 111ln-DTPA 
cleared from all tissues, including the tumor (Fig. 4). However, 1 l1ln-DTPA cleared 
from the blood and nontarget organs much more rapidly than from the tumor. 
Consequently, the tumor-to-blood ratios increased with time up to 500 at 24 h p.i. 
DISCUSSION 
Sustained levels of radiolabeled antibodies in nontarget organs hamper the efficacy of 
radioimmunotargeting, since they limit the amount of radionuclide that can be 
administered. Therefore, pretargeting protocols, aiming at reducing the retention time 
of radiolabel in background organs, have been proposed. In the present study we 
optimized a two-phase protocol for targeting of RCCs using G250 χ DTInl bsMAb and 
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tumor-to-blood blood muscle tumor liver kidneys spleen 
FIGURE 4. Tumor retention of 11lln-DTPA. Mice were injected with 15 цд G250 χ DTIn1 and 3 days 
later with a 10-fold molar excess 111ln-DTPA. Biodistribution was determined 1, 3, 6, 24 and 48 h 
after injection. 
The Ka of G250 χ DTInl for G250 antigen was 6-fold lower than for the parental 
MAb G250. This also has been observed for other bsMAbs: the Ka of bsMAb 
CD3/G250 F(ab')2 was 14.5-fold lower than that of G250 F(ab')2 (19) and the Ka of 
ОС/TR bsMAb was 4- to 7-fold lower than that of the parental MAb (20). These lower 
Ka values may be explained by a monovalent interaction of bsMAb with antigen. The 
number of antibody molecules bound per cell was 2-fold higher for G250 χ DTInl 
than for G250, indicating that binding of G250 to NU-12 cells is bivalent. We have 
shown that Ka of DTIn l , DTY4 and G250 χ DTInl for binding
 i n ln-DTPA were 
similar, indicating that antibody valency does not play a role in the binding of 1 1 1 ln-
DTPA (13). G250 χ DTInl localized specifically in RCC tumors, as demonstrated by 
the higher tumor uptake of G250 χ DTInl as compared with DTY4. However, tumor 
uptake was 3.7-fold lower than that of G250. This might be due to the monovalent 
interaction between G250 χ DTInl and the antigen in the tumor. Boerman et al. (20) 
reported the same finding with anti-ovarian carcinoma MAb MOv-18 and OC/TR 
bsMAb. Robert et al. (21) observed no differences in the biodistribution of bispecific 
and parental antibodies, having similar Ka, which was ascribed to monovalent binding 
of parental F(ab')2 and bsMAb F(ab')2 to the tumor-associated antigen. 
The G250 χ DTInl bsMAb localized in the tumor could be targeted specifically 
with l l 1 ln-DTPA, indicating the feasibility of the two-phase approach. This approach 
was optimized with respect to a series of parameters. 
The amount of 1 l l ln-DTPA targeted to the tumor, and the tumor-to-blood ratios, 
were similar at the 1- and 3-day interval between bsMAb and 111ln-DTPA injections. 
However, when the interval between bsMAb and 111ln-DTPA injections was extended 
to 7 days the uptake of 111ln-DTPA in the tumor tended to decrease. This is probably 
due to clearance of the bsMAb from the tumor. Since high uptake of the bsMAb is a 
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prerequisite for effective targeting of 1 ,1ln-DTPA, we chose an interval of 3 days in 
our further studies. Le Doussal et al. (10) observed maximum tumor uptake and 
maximum tumor-to-nontumor ratios with a 24- to 48-h interval between F(ab')2-Fab' 
bsMAb and mln-di-ln-DTPA-TL chelate injections. At longer intervals the uptake of 
radiolabeled chelate decreased, a finding similar to our observations. 
Tumor uptake of G250 χ DTInl was dependent on the protein dose, with tumor 
saturation occurring at 15 цд bsMAb. We have shown that tumor saturation with the 
parental MAb G250 was obtained at 3 цд (22). The higher protein dose necessary to 
achieve tumor saturation with G250 χ DTInl compared with G250 may be due to the 
lower tumor uptake in terms of %ID/g (caused by the lower Ka of G250 χ DTInl). 
After injection of 3 цд G250, 2.3 цд G250 was specifically bound per g NU-12 tumor 
(22) compared with 1.8 цд G250 χ DTInl at the 15 цд protein dose. The amount of 
111ln-DTPA bound to circulating G250 χ DTInl increased with increasing antibody 
protein dose. In the tumor, the amount of 1 l1ln-DTPA increased with increasing 
antibody protein dose up to 15 цд G250 χ DTIn l . At a dose of 50 цд G250 χ DTIn l , 
no further increase of n , ln-DTPA tumor uptake was observed, again indicating that 
the tumor was saturated at a bsMAb dose of 1 5 цд. 
Dose escalation of 1 l1ln-DTPA at the optimal protein dose of 15 цд revealed that 
with a 10-fold molar excess of i n ln-DTPA the highest %ID/g tumor was obtained. 
With an increase to a >100-fold molar excess of l 1 1ln-DTPA, the amount of 1 l1ln-DTPA 
(ng per g tumor) did not increase, indicating that saturation had occurred. The i n l n -
DTPA excess did not influence the tumor-to-blood ratios. The 10-fold excess n i l n -
DTPA was chosen for further studies, since for radioimmunotargeting studies a high 
%ID/g in the tumor is preferable. For radioimmunotherapeutic protocols, a 100-fold 
molar excess might be preferable, because of the higher absolute amount of 
radionuclide targeted to the tumor. Le Doussal et al. (10) observed the highest tumor 
localization in terms of %ID/g after priming with 13.3 pmol F(ab')2-Fab' bsMAb and 
targeting with 0.2 pmol 1 l l ln-chelate. The best tumor-to-nontumor ratios were 
observed with 1 to 10 pmol 1 n ln-chelate. These data indicate the necessity of carefull 
tuning of the amounts of bsMAb and chelate in two-phase protocols. 
Retention of i n ln-DTPA specifically bound to the previously administered G250 χ 
DTInl decreased with time. From 1 to 3 h p.i., most of the n i ln-DTPA was released 
from the G250 χ DTIn l . However, 11lln-DTPA cleared much more rapidly from the 
blood and nontarget organs than from the tumor. Consequently, the tumor-to-blood 
ratio increased up to 500 at 24 h p.i. The slower release of 1 n ln-DTPA from the tumor 
as compared with the circulation, might be caused by higher bsMAb density in some 
areas of the tumor. If an 111ln-DTPA molecule is released from one bsMAb molecule in 
the tumor, it might be caught by another bsMAb molecule in the vicinity. It might be 
possible to overcome the rapid release of 111ln-DTPA observed in our two-step 
protocol by using multivalent haptens. Goodwin et al. (8) and Le Doussal et al. (9,10) 
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have shown that (bispecific) MAbs are more efficiently targeted by divalent haptens 
than by monovalent haptens. Theoretical calculations indicated that the rate of loss of 
radiolabel from a tumor would be 20x slower for a bivalent hapten than for a 
monovalent hapten (7). With multivalent haptens, crosslinking between two bsMAbs 
might occur (9), leading to prolonged binding of the multivalent hapten. 
At the early time points the amount of ,11ln-DTPA in the blood was relatively 
high, due to binding to circulating G250 χ D T I n l . It might be possible to decrease this 
initial high amount of circulating 111ln-DTPA by administration of a background-
reduction agent {e.g., chelate covalently bound to a serum protein) shortly before 
injection of the radiolabeled chelate (6,23). Goodwin et al. (6) observed 13-fold higher 
tumor-to-blood ratios with a three-step protocol than with the two-step approach. The 
amount of radiolabeled chelate in the blood was decreased by a factor 38: however, 
the tumor uptake of radiolabeled chelate decreased to one third. 
In conclusion, we have shown that RCC xenografts can be targeted efficiently 
with bsMAb G250 χ DTInl followed by l 1 1ln-DTPA. Efficient targeting, however, 
requires fine-tuning of the interval between bsMAb and radiolabeled chelate injections, 
of the amount of bsMAb administered and of the amount of radiolabeled chelate. At 
optimal protein dose and optimal l11ln-DTPA dose, high 111ln-DTPA tumor uptake was 
observed. At 24 h p.i. tumor-to-blood ratios of 500 were achieved. In future studies 
the therapeutic efficacy of this pretargeting protocol will be determined in mice with 
NU-12 tumors using 90Y-DTPA, 186Re-DTPA or radiolabeled multivalent DTPA chelates 
as the targeting radiopharmaceutical. 
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ABSTRACT 
Radiolabeled antibodies can target tumors selectively. However, sustained levels of radiolabel 
in nontarget organs limit their application Pretargeting protocols using bispecific monoclonal 
antibodies (bsMAbs) fundamentally change the pharmacokinetics of the radiolabel We have 
isolated an anti-renal cell carcinoma (RCC) χ anti-diethylenetriaminepentaacetic acid (DTPA) 
bsMAb (G250 χ DTInl) and have successfully used it for two-step radioimmunotargeting of 
NU-12 RCC tumors in nude mice (Kranenborg et al, Int J Cancer, 1998, 75 74-80) Here, we 
report on the further optimization of this two-step approach In our two-step approach l n l n 
DTPA blood levels were relatively high shortly after injection To reduce this binding to 
circulating G250 χ DTInl, BSA-DTPA-ln or IgM-DTPA In was injected, resulting in 24-fold 
increased tumor-to-blood ratios at 1 h postinjection (ρ ι.) However, 1,1ln-DTPA was less well 
retained in the tumor compared with the two-step protocol Subsequently, we studied 
whether multiple 111ln-DTPA injections following pretargeting with bsMAb could enhance 
uptake in the tumor The amount of ,nln-DTPA targeted to the tumor with a second or third 
injection was as high as the amount of l n l n DTPA that localized in the tumor after a first 
injection The absolute amount of l n l n DTPA in the tumor after multiple injections was similar 
to the added amounts of the single injections Finally, we studied whether the use of the 
bivalent chelate 1,1ln-diDTPA FKYK could improve radioimmunotargeting 111ln-diDTPA FKYK 
showed very high tumor uptake (78 %ID/g) 1 h ρ ι compared with 9 %ID/g for 111ln-DTPA 
Moreover, '"In-diDTPA-FKYK was retained in the tumor for at least 7 days Due to the rapid 
clearance from the blood, in the biodistnbution studies tumor-to-blood ratios increased to 
2250 at 72 h ρ ι. In the immunoscintigraphy experiment tumor-to-heart ratios were as high as 
64 at 7 days ρ ι In conclusion, ,nln-diDTPA-FKYK was far superior to ,nln-DTPA in two-step 
radioimmunotargeting Very high tumor uptake and very high tumor to blood ratios were 
observed, thus offering good perspectives for further studies in humans 
INTRODUCTION 
Monoclonal antibodies against tumor-associated antigens have been used successfully 
to direct radionuclides preferentially to solid tumors (1,2). However, due to the slow 
clearance of radiolabeled antibody from the blood and from the normal tissues, 
optimal visualization of the tumor is delayed for several days. In addition, due to the 
sustained levels of radiolabeled antibody in the blood enhanced radiation doses are 
guided to nontarget tissues and limited amounts of radioactivity can be administered 
safely in radioimmunotherapy. 
Reduction of background activity might be achieved by pretargeting methods In 
these methods, the antitumor antibody is administered first and allowed to clear from 
the circulation. In the second step the radionuclide is given as a low-molecular-weight 
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ligand, that either binds to the antibody at the tumor site or is excreted rapidly 
through the kidneys. Several pretargeting approaches have been developed that were 
based on the avid interaction between biotin and avidin (3-6). Pretargeting protocols 
may also make use of antitumor χ antichelate bispecific antibodies and radiometal-
labeled chelates. The feasibility of this approach has been shown in studies in animals 
(7-9) as well as in clinical radioimmunoscintigraphy studies (10-12). In these studies 
the background activity was markedly reduced with good retention of the radiolabeled 
chelate in the tumor, indicating that this approach can improve radioimmunotargeting. 
We have produced and characterized several anti-RCC χ anti-DTPA bsMAbs (13). 
The bsMAb G250 χ DTInl has been used for two-phase targeting of RCC tumors in 
nude mice (9). The two-step protocol has been optimized with respect to the interval 
between both injections, the bsMAb protein dose and the 111ln-DTPA dose. With the 
optimal two-step protocol (15 цд G250 χ DTInl followed 3 days later by a 10-fold 
molar excess of i n ln-DTPA), preferential 1,1ln-DTPA tumor uptake was achieved (6 
%ID/g) and tumor-to-blood ratios increased up to 500 at 24 h p.i. (9). However, the 
l 1 lln-DTPA was poorly retained in the tumor, and for radioimmunotherapy this 
approach had to be further optimized. 
After injection of a radiolabeled chelate, binding of the radiolabeled chelate to the 
circulating bsMAb may occur, causing enhanced background activity. Several studies 
have shown that this can be prevented by injection of a background-reducing agent 
(14,15). Injection of such background-reducing agent resulted in higher tumor-to-
nontumor ratios (14). 
Goodwin et al. (16) and Le Doussal et al. (7,17) showed that the efficacy of 
bsMAb pretargeting approaches might also be improved by using multivalent chelates. 
It is thought that multivalent chelates crosslink t w o bsMAbs (17), leading to 
prolonged binding of the multivalent hapten. Theoretical calculations indicated that the 
rate of loss of radiolabel from a tumor would be reduced 20-fold for a bivalent hapten 
compared with a monovalent hapten (18). 
Multiple injections of radiolabeled chelate might also improve pretargeting 
techniques, provided that chelate-binding sites remain available at the tumor site. In 
our previous pretargeting experiments we noticed major release of the radionuclide 
from the tumor during the first 24 h p.i. (9). However, the bsMAb is still present in 
the tumor and theoretically could be targeted by a second injection of radiolabeled 
chelate. 
Here, we report the further optimization of our two-step approach with respect 
to introduction of a background reduction step, multiple injections of the radiolabeled 
chelate and the use of multivalent radiolabeled chelates. 
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MATERIALS AND METHODS 
Monoclonal antibodies 
The anti-RCC MAb G250 (IgGI) is directed against the RCC-associated antigen G250. 
This antigen is expressed in 75% of RCCs, whereas expression in normal tissues is 
restricted to gastric mucosal cells and cells of the larger bile ducts (20). The 
production and characterization of the bispecific anti-RCC χ anti-DTPA MAb G250 χ 
DTInl has been described (13). 
Radiolabeled chelates 
'"/n-DTPA 
Forty μΙ of 1 l 1 lnCI 3 (Mallinckrodt, Petten, The Netherlands) was added to 150 μΙ 0.5 M 
sodium acetate pH 6.1 and 4.8-16.9 μΙ DTPA ( 5 . 3 x 1 0 5 M in 0.5 M sodium acetate 
pH 6.1) and incubated for 60 min at room temperature. Radiochemical purity of n i l n -
DTPA was assessed by instant thin layer chromatography (ITLC) with methanokwater 
(55:45) as an eluent. Cold In-DTPA was prepared similarly: 10 μΙ lnCI3 (4 .19x10
4 M 
in 40 mM HCl), 50 μΙ 0.5 M sodium acetate pH 6.1 and 400-950 μΙ DTPA (5.3x10 5 
M in 0.5 M sodium acetate pH 6.1) were mixed and incubated at room temperature 
for 60 min. l l 1 ln-DTPA and In-DTPA were mixed shortly before use to obtain the 
desired specific activity. 
"4n-diDTPA-FKYK 
A kit diDTPA-FKYK, containing 11 μg diDTPA-FKYK, 0.05 g 2-hydroxypropyl-ß-
cyclodextrin and 0.0044 g citrate, was dissolved in 1 ml water. To 50 μΙ of this kit 
148 μΙ 1 1 1 lnCI3 was added and incubated for 10 min at room temperature. Labeling 
efficiency was determined using ITLC with 10 mM EDTA pH 7.0 as the solvent (R, 
niln-diDTPA-FKYK = 0.9). If labeling efficiency was > 9 5 % a 1-fold molar excess of 
cold InClj was added in order to saturate the DTPA groups. 
"'In-DOTA 
1,4,7,10-Tetraazacyclododecanetetraacetic acid (DOTA) (Parish Chemical Company, 
UT) was labeled essentially as described by Lewis era/. (21). Briefly, 3 μΙ 1 1 1 lnCI3, 9 μΙ 
0.5 M ammonium acetate pH 5.5 and 5.9 μΙ DOTA ( 2 . 2 x 1 0 3 M in 0.5 M ammonium 
acetate pH 5.5) were mixed and incubated at 43°C for 2 h. Complexation of n i l n was 
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assessed by ITLC with methanohwater (55:45) as an eluent. 
"Y-DTPA 
To 41.5 μΙ 88YCI3 (Amersham International, Buckinghamshire, UK) 207.5 μΙ 0.5 M 
sodium acetate pH 6.1 and 10.9 μΙ DTPA ( 5 . 3 x 1 0 s M in 0.5 M sodium acetate pH 
6.1) were added. After 60 min of incubation at room temperature complexing of 88Y 
was assessed by ITLC using methanohwater (55:45) as an eluent. 
"Y-diDTPA-FKYK 
To 343 μΙ of a diDTPA-FKYK kit, 40 μΙ 88YCI3 and 1.44 μΙ YCI3 ( 2 . 3 4 x 1 0
3 M in 40 
mM HCl) were added and incubated for 10 min at room temperature. Labeling 
efficiency was determined as described above for i nln-diDTPA-FKYK. 
Background-reducing agents 
BSA-DTPA-ln 
Bovine serum albumin (BSA) (Sigma Chemical Co., St. Louis, MO) was conjugated 
with the cyclic anhydride of DTPA (Sigma) in 0.1 M carbonate buffer pH 9.5 at a 
1:125 molar ratio as described by Hnatowich et al. (22). lnCI3 was added at a 4:1 
DTPA:ln molar ratio to the BSA-DTPA, whereafter BSA-DTPA-ln was purified by 
dialysis against PBS. Twenty-two DTPAs were conjugated per BSA molecule as 
determined by the ITLC method described by Hnatowich era/. (22). 
IgM-DTPA-ln 
IgM (ICN Biomedicals Inc., Costa Mesa, CA) was conjugated with the cyclic anhydride 
of DTPA at a 1:4000 molar ratio as described above. Twenty DTPAs were conjugated 
per IgM molecule as determined by ITLC (22). 
Competitive antigen-binding assay 
To determine whether radiolabeled chelates could compete for the binding of bsMAb 
G250 χ DTInl to BSA-DTPA-ln, competitive antigen-binding assays were performed 
as described (13). 
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Animal studies 
The NU-12 RCC xenograft was established from a primary tumor by serial 
subcutaneous (s.c.) transplantation in nude mice (23). NU-12 tumors were initiated in 
6-week-old BALB/c nu/nu mice. NU-12 was serially transplanted by implanting viable 
tumor specimens (1-2 mm3) s.c. in the flank of the mice. All radiopharmaceuticals 
were injected intravenously through the tail vein. 
To calculate the amount of agent to be injected in the second or third step, a 
blood volume of 2 ml per mouse was assumed. In addition, G250 χ DTInl blood 
levels at 3, 4, and 5 days p.i. were assumed to be 12 percent of the injected dose per 
g (%ID/g), 11 %ID/g and 10 %ID/g, respectively. 
In biodistribution experiments each group contained 3-6 mice with tumors of 
0.01 to 0.3 g. The amount of radiolabel in whole tumor and in tissues (blood, muscle, 
liver, kidneys and spleen) was determined by gamma-counting along with an injection 
standard. From these biodistribution data, the %ID/g and the tumor-to-blood ratios 
were calculated. In the multiple injection experiments data were expressed as the 
amount of radioactivity per g tissue (cpm/g). Statistical analysis was performed using 
one-way analysis of variance, with Bonferroni posttest correction for multiple 
comparisons. Data were considered to be significantly different if the p-value was 
smaller than 0.05. 
In imaging experiments 3 mice with NU-12 tumors of 0.4 to 0.6 g were 
anesthesized (nitrous oxide/oxygen/halothane) and placed prone on a gamma camera 
(Orbiter, Siemens, Hoffman Estates, IL) equipped with a medium-energy parallel hole 
collimator. Images (at least 100,000 counts per image) were obtained up to 7 days 
p.i. and stored in a 256x256 matrix. The images were analyzed by drawing regions of 
interest over the whole animal, the tumor and the heart region. The tumor-to-heart 
and the tumor-to-whole body ratios were calculated. 
Three-step targeting of NU-12 tumors 
Mice were injected with 15 μg G250 χ DTIn l . Three days later mice were injected 
with a 0, 0.5, 1, 3 or 6-fold molar excess of BSA-DTPA-ln or IgM-DTPA-ln. Thirty min 
later a 10-fold molar excess of 111ln-DTPA was administered. One h later 
biodistribution of n i ln-DTPA was determined. 
Tumor retention of 111ln-DTPA after three-step targeting of NU-12 tumors 
Mice were injected with 15 цд G250 χ DTIn l . After 3 days mice were injected with a 
equimolar dose of IgM-DTPA-ln, followed 30 min later by a 10-fold molar excess of 
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111ln-DTPA. Biodistribution of η Ί η was determined 1, 3, 6, 24 and 48 h after 
injection. 
Repeated "1 In-DTPA injections 
The design of these experiments is summarized in Table 1. Mice were primed with 15 
μg G250 χ DTIn l . 111ln-DTPA or Ιη-DTPA was administered as a 10-fold molar 
excess. Mice were dissected 24 h after the last 111ln-DTPA injection. 
TABLE 1 
Multiple injections of 111ln-DTPA - injection scheme 
Day 0 Day 3 Day 4 Day 5 
G250 χ DTInl "Ίη-DTPA dissection 
G250 χ DTInl 1l1ln-DTPA dissection 
G250 χ DTInl "Ίη-DTPA - — -
G250 χ DTInl "Ίη-DTPA dissection 
G250X DTInl "Ίη-DTPA -
G250 χ DTInl - "Ίη-DTPA 
G250xDTIn1 In-DTPA "Ίη-DTPA dissection 
G250 χ DTInl "Ίη-DTPA "Ίη-DTPA dissection 
G250 χ DTInl Ιη-DTPA In-DTPA "Ίη-DTPA 
G250X DTInl "Ίη-DTPA "Ίη-DTPA "Ίη-DTPA 
















Divalent versus monovalent '"In-DTPA 
Mice were injected with 15 цд G250 χ DTIn l . After 3 days a 0.03 to 300-fold molar 
excess of n iln-diDTPA-FKYK or 1 n ln-DTPA was injected. Biodistribution was 
determined after 1 h. 
Tumor retention of "Ίη-diDTPA-FKYK 
Mice were primed with 15 цд G250 χ DTIn l . Three days later a 0.3-fold (optimal 
tumor-to-blood ratio) or 45-fold molar excess (saturating dose level) of n i ln-diDTPA-
FKYK was injected. Biodistribution was determined after 1, 4, 24, 48 and 72 h. 
Radioimmunodetection of NU-12 tumors 
Mice were primed with 1 5 μg G250 χ D T I n l . Three days later a 0.3-fold molar excess 
niln-diDTPA-FKYK was injected. Images were recorded 5 min, and 1, 2, 4, 20, 48, 
72, 96, 120 and 168 h p.i. 
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Biodistribution of "Ίη-DOTA, ""Y-DTPA or *8Y-diDTPA-FKYK after G250 χ DTInl 
priming 
Mice were injected with 6 цд or 15 цд G250 or G250 χ D T I n l . Three days later a 
100-fold molar excess of 11 Ίη-DOTA, a 10-fold molar excess of 88Y-DTPA or a 10-fold 
molar excess of 8BY-diDTPA-FKYK was injected. After 1 h biodistribution of the 
radiolabel was determined. 
RESULTS 
Competitive antigen-binding assay 
To study whether In-DTPA, Ιη-DOTA, Y-DTPA, In-diDTPA-FKYK or Y-diDTPA-FKYK 
were bound by G250 χ DTInl as effectively as BSA-DTPA-ln, competitive antigen-
binding assays were performed (Table 2). All chelates competed for the binding of 
G250 χ DTInl to BSA-DTPA-ln. The IC5 0 of G250 χ DTInl for binding In-DTPA was 
dependent on the amount of In incorporated in the DTPA. The IC50 of Y-DTPA was 
190-fold lower compared with In-DTPA. The IC50 of Ιη-DOTA was 2-fold lower 
compared with In-DTPA. The IC50 of In-diDTPA-FKYK was 3-fold higher compared 
with In-DTPA. Similar to Y-DTPA, the IC50 of Y-diDTPA-FKYK was significantly lower 
compared with In-diDTPA-FKYK. 
TABLE 2 
Competitive antigen-binding assay - determination of IC50 
Chelate Ratio metalxhelate IC50 (M) 
In-DTPA 1:3462 415x10 9 
In-DTPA 1:116 258x10 9 
In-DTPA 1:12 59.9x109 
In-DTPA 1:1 5.9x109 
Y-DTPA 1:1 1100x109 
In-DOTA 1:3462 760x10 9 
In-diDTPA-FKYK 1:1 3.8x109 
Y-diDTPA-FKYK 1_J 440x10 9 
Biodistribution of 111ln-DOTA, 88Y-DTPA and 88Y-diDTPA-FKYK after 
G250 χ DTInl priming 
No significant differences were observed in the biodistribution of 1 l 1ln-DOTA or 88Y-
DTPA after G250 or after G250 χ DTInl priming, indicating that i n ln-DOTA and 88Y-
DTPA were not specifically bound by the pretargeted G250 χ DTInl in the tumor 
(data not shown). 
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No specific binding of 88Y-diDTPA-FKYK was achieved in the tumor, since no 
differences were observed between G250 and G250 χ DTInl primed animals (data 
not shown). In both groups higher uptake in muscle (3-fold), liver (5-fold) and kidneys 
(2-fold) was observed compared with n iln-diDTPA-FKYK at the same dose level. 
Three-step targeting of NU-12 tumors 
To reduce the binding of 11lln-DTPA to circulating G250 χ DTIn l , two different 
background-reducing agents were studied. The effect of administration of BSA-DTPA-
In is shown in Table 3. The amount of 11 lln-DTPA in the blood was significantly 
reduced already at a 0.5-fold molar excess i n ln-DTPA. No reduction was seen in the 
uptake of i n ln-DTPA in the tumor up to a 3-fold molar excess of BSA-DTPA-ln. At the 
6-fold molar excess the amount of 11 lln-DTPA in the tumor was significantly reduced. 
Due to the efficient blocking of binding of 111ln-DTPA to circulating G250 χ DTIn l , the 
tumor-to-blood ratios were significantly higher compared with the two-step strategy, 
irrespective of the dose of BSA-DTPA-ln. The 3-fold molar excess of BSA-DTPA-ln 
gave the best background reduction, in terms of high 111ln-DTPA tumor uptake and 
12-fold higher tumor-to-blood ratios. 
TABLE 3 
Comparison of different background-reducing agents 
Uptake (%ID/g) and tumor-to-blood ratio (TBR) for background-reducing agent excess 


















3.48 ± 0.54 
0.46 ±0.079 
2.44 ± 0 . 2 0 
0.90 ± 0.22 
1.10±0.22 
1.21 ± 0 . 1 6 
0.37 ± 0 . 1 0 
4.22 ± 1.25 
0.23 ± 0 . 0 1 4 
2.26 ±0.21 
0.32 ±0.0027 
3.47 ± 0 . 8 6 
0.25 ± 0.089 
0.16 ±0.056 
2.75 ± 1.22 
0.093 ±0.012 
1.28 ±0.21 
0.084 ± 0.032 
9.18 ± 2.80 
0.49 ± 0 . 1 2 
0.19 ±0.045 
3.88 ± 1.57 
0.13 ±0.014 
1.48 ± 0 . 2 2 
0.15 ±0.012 
8.12 ± 3 . 7 5 
IgM-DTPA-ln 
0.17 ± 0.049 
0.093 ±0.022 
3.99 ± 1.29 
0.095 ± 0.022 
1.41 ± 0 . 3 4 
0.087 ±0.031 
24.05 ± 5.36 
0.22 ±0.058 
0.16 ± 0 . 0 9 3 
2.95 ± 1.30 
0.12 ±0.061 
1.40 ±0.25 
0.094 ± 0. 01 7 
12.99 ± 3.38 
0.11 ±0.021 
0.050 ± 0.021 
2.07 ± 0 . 8 2 
0.11 ± 0.026 
1.54 ± 0 . 5 2 
0.077 ±0.020 
22.00 ± 13.28 
0.12 ±0.060 




0.081 ± 0.025 
7.40 ±3.88 
0.025 + 0.007 
0.025 ± 0.005 
1.24 ± 0 . 5 0 
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Administration of IgM-DTPA-ln (irrespective of the dose) also resulted in 
significant reduction of the amount of 11 lln-DTPA in the blood (Table 3). Tumor uptake 
of l 1 ,ln-DTPA remained constant up to a 1-fold molar excess of IgM-DTPA-ln and was 
significantly lower at higher dose levels. The tumor-to-blood ratio increased 24-fold at 
a 1-fold molar excess of IgM-DTPA-ln compared with the two-step approach. The 
tumor-to-blood ratio at a 1-fold molar excess of IgM-DTPA-ln was significantly higher 
compared to the tumor-to-blood ratio at a 3-fold molar excess of BSA-DTPA-ln and 
therefore the 1-fold molar excess of IgM-DTPA-ln was chosen as the optimal 
background-reducing agent. 
Tumor retention of 111ln-DTPA after three-step targeting of NU-12 tumors 
The retention of 1 l1ln-DTPA in the tumor after G250 χ DTInl injection followed by 
IgM-DTPA-ln clearance was studied during 48 h. From 1 h onwards U 1ln-DTPA 
cleared from all tissues, including the tumor (Fig. 1). However, '11ln-DTPA cleared 
much more rapidly from the blood and from nontarget organs than from the tumor. 
Consequently, the tumor-to-blood ratios increased with time up to 100 at 3 h p.i. 
However, tumor retention at later time points was lower as compared to our 
previously published two-step protocol (9). For radioimmunotherapy protocols optimal 
uptake and retention of 1111n-DTPA is essential and therefore we decided to use the 
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FIGURE 1. Tumor retention of n ' ln-DTPA after three-step targeting of NU-12 tumors. Mice were 
injected with 15 цд G250 χ DTInl and 3 days later with a 1-fold molar excess of IgM-DTPA-ln. Thirty 
min later a 10-fold molar excess of 1l1ln-DTPA was injected. Biodistribution was determined at 1, 6, 
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Multiple injections of "Mn-DTPA 
To determine whether repeated tumor targeting with 1 1 lln-DTPA could be achieved, 
injections of l11ln-DTPA were given up to 3 consecutive days. The uptake of 1 l 1 l n -
DTPA in the tumor, expressed as %ID/g, remained similar, irrespective of the number 
of previous injections (Fig. 2A). These data indicate that 1 or 2 injections of In-DTPA 
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FIGURE 2. Mult iple injections of "Чп-DTPA. Mice were primed w i t h 15 цд G 2 5 0 χ D T I n 1 . A t day 3, 4 
and/or 5 a 10-fold molar excess of " Ί η - D T P A was injected according to the scheme l isted in Table 1 . 
Biodistribution was determined 24 h after the last injection. 
In Figure 2B data on the 11lln-DTPA accumulation in the tumor are expressed as 
cpm/g. In this manner the attribution of every n i ln-DTPA injection on tumor uptake 
121 
Radioimmunotargeting of RCC with bispecific monoclonal antibodies 
could be determined. The accumulation of n i ln-DTPA in the tumor of mice in group 8 
could now be compared with those in group 2 plus those in group 4. The cpm/g n i l n -
DTPA in the tumor of mice of group 8 was similar to the sum of both separate 
injections (Fig. 2B). Likewise, the cpm/g 111ln-DTPA in the tumors of mice of group 10 
was similar to the sum of the cpm/g tumor of mice of groups 3, 5 and 6, indicating 
that all 3 injections contributed to the accumulation, without interference of previous 
injections. Both in group 8 and group 10 the cpm/g were significantly higher 
compared with the single injections. These data indicate that multiple injections lead 
to a higher tumor uptake of ,11ln-DTPA. A similar additive effect was observed in the 
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FIGURE 3. Effect of the l nln-diDTPA-FKYK and "'In-DTPA dose. Mice were injected with 15 μg G 2 5 0 
χ DTInl followed 3 days later by a 0.03 to 300-fold molar excess of n ,ln-diDTPA-FKYK (A) or " Ί η -
DTPA (B). One h later biodistribution of the " ' I n label was determined. In addition, the absolute 
amount of l nln-diDTPA-FKYK (C) and , 1 1ln-DTPA (D) accumulated per g NU-12 tumor was calculated. 
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Divalent versus monovalent 111ln-DTPA 
The biodistribution of 111ln-diDTPA-FKYK and 111ln-DTPA was compared at different 
dose levels. At low doses very high tumor uptake of inln-diDTPA-FKYK was obtained 
(78 %ID/g at a 0.03-fold molar excess) (Fig ЗА). At doses higher than a 0.1-fold 
molar excess, the %ID/g in the tumor decreased. At low amounts of i n ln-diDTPA-
FKYK (0.03 to 0.3-fold molar excess) very high tumor-to-blood ratios were obtained 
(7 at 1 h p.i.) (Fig.ЗА). In contrast, n i ln-DTPA uptake in the tumor reached plateau at 
low doses of 111ln-DTPA to a level that did not exceed 9 %ID/g (Fig 3B). At doses 
higher than a 1-fold molar excess of l 1 1ln-DTPA, uptake in the tumor decreased. 
Tumor-to-blood ratios did not exceed 2 (Fig. 3B). 
At each dose level the absolute amount of l1 lln-diDTPA-FKYK and 111ln-DTPA in 
the tumor was calculated. The amount of 111ln-diDTPA-FKYK in the tumor increased 
with increasing dose up to a 45-fold molar excess of 111ln-diDTPA-FKYK. At that dose 
level a plateau was reached, indicating saturation of G250 χ DTInl at the tumor site 
(Fig. 3C). Extrapolation of the saturation plot of 111ln-DTPA indicated that G250 χ 
DTInl at the tumor site was saturated at a 100-fold molar excess l l 1 ln-DTPA (Fig. 
3D). 
Tumor retention of 111ln-diDTPA-FKYK 
At the 111ln-diDTPA-FKYK dose resulting in high relative tumor uptake (0.3-fold molar 
excess) the biodistribution of the radiolabel was studied over a 3-day period. Again, 
high tumor uptake was observed (53 %ID/g 1 h p.i.) (Fig. 4A). l11ln-diDTPA-FKYK 
was fully retained in the tumor during 72 h. In contrast, 111ln-diDTPA-FKYK cleared 
from all other organs from 4 h onwards. Consequently, tumor-to-blood ratios 
increased with time to 2250 at 72 h p.i. The absolute amount of i n ln-DTPA in the 
tumor remained constant up to 72 h p.i. (Fig. 4B). 
At the saturating dose level 111ln-diDTPA-FKYK was also completely retained in 
the tumor up to 48 h p.i. (Fig. 4C). inln-diDTPA-FKYK cleared rapidly from the other 
organs from 4 h onwards (Fig. 4C). Tumor-to-blood ratios increased with time up to 
200 at 48 h p.i. Tumor-to-blood ratios were lower compared with n'ln-diDTPA-FKYK 
at the 0.3-fold molar excess, due to the relatively higher amount of 111ln-diDTPA-
FKYK in the blood at the saturating dose. 
The absolute amount of 11,ln-diDTPA-FKYK in the tumor at the 45-fold molar 
excess was not significantly different compared with the 0.3-fold molar excess. 
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FIGURE 4. Tumor retention of 1 1 ,ln-diDTPA-FKYK at a 0 3-fold molar excess (A) of a 45-fold molar 
excess (C) 1 t o 7 2 h after injection. Mice were primed 3 days earlier w i t h 15 цд G250 χ D T I n 1 . The 
absolute amount of n l ln-diDTPA-FKYK per д tumor was calculated at each t ime point (B). 
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Radioimmunodetection of NU-12 tumors 
The retention of 1nln-diDTPA-FKYK at the 0.3-fold molar excess was studied in more 
detail on the gamma camera (Fig. 5). The tumor became visible as early as 1 h p.i., 
while from 4 h onwards the tumor was clearly visualized with only minor uptake in 
the nontarget tissues. Quantitive analysis of the images indicated that the percentage 
of the injected dose (%ID) in the tumor rapidly increased from 2.7 ± 1.3 %ID at 5 min 
p.i. to 6.0 ± 1 . 4 %ID at 1 h p.i. Maximum tumor uptake was obtained at 4 and 20 h 
p.i. (7.5 %ID). Thereafter, tumor uptake slowly decreased: at 7 days p.i. tumor 
uptake was still as high as 3.5 ± 1 . 6 %ID. In contrast, activity in the nontarget 
tissues rapidly decreased. Twenty h after administration n'ln-diDTPA-FKYK was 
completely cleared from the circulation. Due to the high tumor uptake and rapid blood 
clearance tumor-to-heart ratios increased with time up to 106 at 48 h p.i. Seven days 
after injection the tumor-to-heart ratio was as high as 64. Tumor uptake was high, 
while clearance from the rest of the body was relatively fast and complete. This was 
reflected by the high tumor-to-whole body ratios (51.6% at 20 h p.i. to 38.3% at 
168 h p.i.). At 20 h p.i. more than 5 0 % of the whole body activity was in the tumor. 
$, # * φ ·* φ *ί 
:> min. 1 hr. 4hr. 
Φ m Ψ m * : 
20 hr. % h r . 168 ш 
FIGURE 5. Radioimmunodetection of NU-12 tumors. Mice were primed with 15 μα, G250 χ DTIn1 
followed 3 days later by a 0.3-fold molar excess lnln-diDTPA-FKYK. Images were recorded at 5 min 
and 1, 4, 20, 96 and 168 h after injection. 
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DISCUSSION 
Sustained levels of radiolabeled antibodies in nontarget organs hamper the efficacy of 
radioimmunotherapy, because they limit the amount of radionuclide that can be 
administered. Pretargeting protocols could reduce the residence time of radiolabel in 
nontarget organs. In previous studies, we have established two-step targeting of RCC 
xenografts (9). However, in view of the relatively low uptake and retention of i n l n -
DTPA in the tumor, additional optimization of the approach was necessary. In the 
present study we further optimized the two-step protocol, wi th respect to introduction 
of a background-reducing agent, multiple injections of radiolabeled chelate and 
introduction of a bivalent chelate. 
In the two-step approach relatively high amounts of 111ln-DTPA in the blood were 
found shortly after injection (4 %ID/g), due to binding of 1 l1ln-DTPA to circulating 
G250 χ DTInl (9). This high background activity might be overcome by injection of a 
background-reducing agent shortly before the injection of l 1 l ln-DTPA (8,14,15). We 
investigated the effect of injection of the background-reducing agents BSA-DTPA-ln 
and IgM-DTPA-ln on the biodistribution of i n ln-DTPA. After administration of both 
agents 'n ln-DTPA levels in the blood were reduced significantly, even at doses as low 
as a 0.5-fold molar excess, indicating efficient blocking of the DTPA binding site of 
G250 χ DTIn l . Tumor uptake of 11lln-DTPA was similar compared with the two-step 
protocol up to a 3-fold molar excess of BSA-DTPA-ln or a 1-fold molar excess of IgM-
DTPA-ln, and was significantly lower at higher doses. Somewhat different results 
were obtained by Schumacher er al. (8). In their two-step approach very high amounts 
of 67Ga-chelate were found in the blood (27 %ID/g) at 1 h p.i., whereas in the tumor 
the uptake was not higher than 4 %ID/g. Administration of increasing doses of a 
blocking agent 15 min before administration of 67Ga-chelate resulted in decreased 
blood levels and increased tumor uptake of 67Ga-chelate. 
In our experiments, IgM-DTPA-ln was more effective in reducing binding of 1 " l n -
DTPA to circulating G250 χ DTInl than BSA-DTPA-ln. In view of the high tumor 
uptake and tumor-to-blood ratio achieved, we decided to use a 1-fold molar excess of 
IgM-DTPA-ln in further studies. 
Introduction of the background-reducing agent altered the kinetics of 1 l1ln-DTPA 
in the tumor. 111ln-DTPA was more rapidly cleared from the tumor and other organs, 
although clearance of n i ln-DTPA from the tumor was slower compared with that from 
other organs. n i ln-DTPA blood levels were low already at 1 h p.i. Due to the low 
blood levels, high tumor-to-blood ratios were obtained from 3 h onwards ( > 5 0 ) . 
Similar results were obtained by Schumacher et al. (8). From 1 h to 4 h p.i. of 67Ga-
chelate the tumor uptake decreased 6-fold. Tumor-to-blood ratios increased 6-fold 
from 1 to 4 h p.i. 
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Compared with our two-step protocol (9) U 1 ln-DTPA decreased more rapidly in 
the tumor using the three-step procedure. With the three-step protocol higher tumor-
to-blood ratios were obtained at early time points (1-6 h p.i.), which is beneficial for 
radioimmunoscintigraphy. However, with the three-step protocol the 111ln-DTPA tumor 
uptake was significantly lower at later time points. As our ultimate goal is the 
development of radioimmunotherapy, we decided to proceed with the two-step 
method to study the potential of our pretargeting approach. 
Since i n ln-DTPA cleared from the tumor during the first 24 h after injection, we 
investigated whether G250 χ DTInl at the site of the tumor could be retargeted with 
n i ln-DTPA. We have previously shown that tumor-bound G250 χ DTInl could be 
targeted with U 1 ln-DTPA up to 7 days p.i. (9). We studied the effect of repeated 
injection of 111ln-DTPA on day 3, 4, or 5 p.i. of G250 χ D T I n l . n i ln-DTPA tumor 
uptake was similar 24 h p.i., irrespective of the number of previous injections, 
indicating that G250 χ DTInl was available for binding 111ln-DTPA in the tumor at day 
3, 4 and 5. Most importantly, the amount of n i ln-DTPA in the tumor after 2 or 3 
injections was similar to the added amounts of the single injections, indicating that at 
least 3 injections can be given with good uptake of n i ln-DTPA after each injection. 
Axworthy et al. (19) reported similar findings for at least t w o injections of 90Y-DOTA-
biotin after priming with MAb-streptavidin. For radioimmunotherapeutic protocols 
these multiple injections could be useful to enhance the amount of radiolabel in the 
tumor. 
After optimization of the two-step radioimmunotargeting protocol, the 
radioimmunotherapeutic feasibility of the two-step protocol was investigated. DOTA 
was studied as an alternative chelate, because of the more avid complexation of Ί 1 1Ιη 
and 90Y (24). However, substitution of DOTA for DTPA led to a dramatically altered 
biodistribution. No tumor targeting was seen. The different in vivo behavior could not 
be explained by differences in affinity constant of G250 χ DTInl for binding the 
radiolabeled chelates: the competitive binding assay showed only a 2-fold difference 
in IC50 value. The lack of appropriate DOTA targeting compelled us to investigate
 88Y-
DTPA as therapeutic chelate. No specific binding was observed to G250 χ DTInl , 
probably due to the low affinity of G250 χ DTInl for binding Y-DTPA (the IC50 of 
G250 χ DTInl for Y-DTPA was 190-fold lower compared with In-DTPA). 
The efficacy of radioimmunotargeting approaches might be enhanced using 
bivalent chelates, since higher tumor uptake and prolonged retention have been 
achieved (7,16,17). Using l11ln-diDTPA-FKYK very high tumor uptake (78 %ID/g) and 
tumor-to-blood ratios were achieved. In contrast, with n i ln-DTPA tumor uptake did 
not exeed 9 %ID/g and tumor-to-blood ratios remained below 2. G250 χ DTInl at the 
tumor site was saturated at a 45-fold molar excess n iln-diDTPA-FKYK or a 100-fold 
molar excess 1 1 lln-DTPA. Le Doussal et al. (7) also showed improved tumor uptake of 
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the bivalent chelate n iln-di-ln-DTPA-TL. At low dose levels the uptake of 1 1 1 ln-
diDTPA-FKYK in the tumor was at least 10-fold higher compared with the tumor 
uptake of 111ln-di-ln-DTPA-TL. In addition, tumor-to-blood ratios were 4-fold higher 
with 111ln-diDTPA-FKYK. 
11lln-diDTPA-FKYK was very well retained in the tumor, irrespective of 1 1 1 ln-
diDTPA-FKYK dose. Up to 72 h p.i. there was virtually no release of i n ln-diDTPA-
FKYK from the tumor. Tumor-to-blood ratios as high as 2250 were observed at 72 h 
p.i. at the low dose n iln-diDTPA-FKYK. These ratios were reduced to one tenth at the 
saturating inln-diDTPA-FKYK dose, due to the relative higher amount of 111ln-diDTPA-
FKYK in the blood at this dose level. No differences were observed in the absolute 
amount of n ,ln-diDTPA-FKYK in the tumor at both dose levels. These data indicate 
that for radioimmunotherapeutic purposes the low dose of inln-diDTPA-FKYK 
probably is superior, because of the higher tumor-to-blood ratios and the similar 
absolute amount of inln-diDTPA-FKYK in the tumor. In our model the effect of 
bivalent chelate was even more pronounced than in the studies of Le Doussal et al. 
(7). They studied the tumor retention of n1ln-di-ln-DTPA-TL in a carefully optimized 
animal model. Tumor uptake of 1l1ln-di-ln-DTPA-TL decreased from 4-7 %ID/g at 1 h 
p.i. to 1 %ID/g at 48 h p.i. Tumor-to-plasma ratios increased from 2 at 1 h p.i. to 15 
at 48 h p.i. 
The imaging experiments indicated that l11ln-diDTPA-FKYK was retained 
excellent in the tumor during a 7-days period. The %ID in the tumor was as high as 
3.5 %ID 7 days p.i. This prolonged tumor retention, together with the rapid blood 
clearance indicate that this two-step approach could be a very suitable approach for 
radioimmunotargeting of cancer. 
i n l n in diDTPA-FKYK was exchanged for 88Y to test its therapeutic applicability. 
With 88Y-diDTPA-FKYK no specific retention of chelate in the tumor was observed. 
This was probably caused by the relatively low affinity of G250 χ DTInl for 88Y-
diDTPA-FKYK, since in the competitive ELISA the IC50 of Y-diDTPA-FKYK was 60-fold 
lower compared with In-diDTPA-FKYK. High 88Y background activity was observed in 
muscle, liver, and kidneys, compared with "'In-diDTPA-FKYK. This might be caused 
by the fact that a COOH group of DTPA is used for conjugation to the peptide, 
probably leading to less stable chelation of 88Y in DTPA. For therapeutic studies 
development of a new peptidic chelate might be necessary. We would propose a 
mixed chelate based on a peptide backbone containing t w o In-DTPA groups for 
binding to the bsMAb in the tumor and an 90Y-DOTA group for stably chelating the 
therapeutic radionuclide. A second option might be the radioiodination of In-diDTPA-
FKYK with 1 3 1 l for therapeutic applications as described by Gautherot et al. (25). 
In conclusion, the efficacy of radioimmunotargeting could be increased very 
effectively by using bivalent 11lln-diDTPA-FKYK instead of "'In-DTPA. Very high 
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tumor uptake (up to 78 %ID/g) was observed. More importantly, very high tumor-to-
blood ratios were achieved up to 7 days p.i., due to the very good retention of n i l n -
diDTPA-FKYK at the site of the tumor. In the near future the therapeutic potential of 
these bivalent chelates will be further evaluated. 
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Conclusions and perspectives 
CONCLUSIONS AND PERSPECTIVES 
Almost all conventional radioimmunodetection and radioimmunotherapy protocols 
inevitably lead to relatively high background activity in nontarget organs. This is 
predominantly caused by the relatively slow clearance of the radiolabeled monoclonal 
antibody (MAb) from the blood. Several approaches have been studied to overcome 
this high background activity. One of these approaches involves the use of antitumor 
χ antichelate bispecific monoclonal antibodies (bsMAbs) and radiolabeled chelates 
(pretargeting approach). In the studies described in this thesis a two-phase 
radioimmunotargeting protocol with anti-renal cell carcinoma (RCC) χ anti-
diethylenetriaminepentaacetic acid (DTPA) bispecific monoclonal antibodies has been 
developed and optimized. 
Five different anti-DTPA monoclonal antibodies were developed (Chapter 2). The 
affinity constants of the M Abs for binding 111ln-DTPA were in the same order of 
magnitude (0.19-0.23 nM 1 ) as reported for other antichelate MAbs. In addition, all 
anti-DTPA MAbs also reacted with DTPA loaded with various other metals. For all 
anti-DTPA MAbs, with the exception of DTIn3, In-DTPA was recognized most 
efficiently. The affinity for binding In-DTPA was 10 to 100-fold higher than the 
affinity for binding DTPA loaded with other metals. Similar preference for indium-
labeled chelates has been observed with other antichelate antibodies. Involvement of 
l n 3 + in the antibody-antigen interaction may explain the higher affinity of the MAbs for 
indium labeled chelates. 
The anti-DTPA Mabs also displayed a remarkable chelate specificity. The 
chelates recognized by DTIn l , DTIn2 and DTIn4 (DTPA and isothiocyanato-benzyl-
1,4,7,10-tetraazadodecanetetraacetic acid (ITC-Bz-DOTA)) share a N(N')-diacetic acid 
group, whereas the chelates recognized by DTIn3 (DTPA, ITC-Bz-DTPA and 
ethylenediaminetetraacetic acid (EDTA)) share a N'-acetic acid group, suggesting the 
presence of different antigenic structures within the DTPA molecule. Theoretically, 
the broad reactivity of the MAbs makes these antibodies suitable for imaging as well 
as for therapy. 
The bispecific anti-RCC χ anti-DTPA antibodies were produced biologically. As 
described in Chapter 1, the main advantage of this technique is the assembly of 
bsMAb in the same environment as the parental MAbs. In addition, the bsMAb 
producing quadroma is an infinite source of bsMAb in contrast to the chemically 
produced bsMAbs. Five quadroma fusions were performed (Chapter 2). Three fusions 
resulted in quadromas actually secreting bsMAbs. In these quadromas, 10-15% of the 
IgG formed was bsMAb, indicating total random association of the heavy and light 
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chains from both parental hybridoma cells. Fusion of isotype-mismatched or isotype-
matched hybridomas G250 and DTIn3 did not result in production of functional 
bsMAb. It appeared that successful assembly of bsMAbs is determined by factors 
other than the isotype of the parental antibodies. BsMAbs that can not be produced 
biologically, might be produced chemically. 
For each bsMAb an individual purification protocol was developed (Chapter 2). 
Mixed isotype bsMAbs as well as matched isotype bsMAbs of non IgGI subclass can 
be purified in t w o steps. After protein A affinity chromatography to purify all IgG-like 
quadroma products (with correct heavy chain χ heavy chain pairing), the bsMAb could 
be purified in one step from this pool of IgGs by cation exchange chromatography. 
Purification of matched isotype bsMAb appeared more difficult, especially IgGI χ lgG1 
bsMAbs. After protein A affinity chromatography purification, several contaminants 
were present in the bsMAb containing IgG pool. Two further purification steps were 
necessary to isolate the bsMAb. 
Establishment and characterization of a suitable experimental tumor model was 
very important for in vivo studies of the pretargeting approach (Chapter ЗА). For 
characterization of nude mouse models the anti-RCC antibodies G250 and RC 38 
were used. Two different RCC tumor models were studied (NU-12 and SK-RC-52). 
Very high uptake of MAb G250 (125 %ID/g) was observed 3 days postinjection in the 
NU-12 tumor. The protein dose of the G250 antibody markedly influenced the 
biodistribution of MAb G250. G250 antigen in the tumor was saturated at G250 
antibody doses exceeding 3 цд, because the amount of G250 specifically 
accumulated per g tumor reached plateau at that dose. High tumor-to-blood ratios 
were achieved at low (non-saturating) protein doses, mainly due to the high tumor 
uptake at these dose levels. Saturation at such a low antibody dose level is rather 
uncommon. In general, tumor saturation has been described at doses in excess of 100 
μg. For MAb RC 38 NU-12 tumor saturation was observed at 25 цд. High tumor 
uptake in RCC tumors has been attributed to the relatively high vascular permeability 
in RCC compared with non-RCC. We obtained high tumor uptake with G250 and 
moderately high uptake with RC 38 in the same NU-12 model, indicating that other 
factors also play a role in the uptake of MAbs in RCC tumors. In the SK-RC-52 model 
the biodistribution of G250 was completely different. Three days after injection of low 
protein doses, extremely low blood and low tumor levels were found, indicating that 
the SK-RC-52 tumor had a profound effect on the biodistribution of G250. Tumor 
saturation was not observed as a result of the rapid clearance of G250 in SK-RC-52 
tumor bearing mice. These differences in biodistribution could not be explained by 
differences in vascular permeability, differences in antigen distribution, number of 
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antigens per cell or shedding of the G250 antigen. They may be due to differences in 
internalization of MAb G250 by tumor cells. Thus, it appeared that - in case of G250 -
not the G250 antigen determines whether the antibody is internalized, but the tumor 
environment. The animal data obtained with the NU-12 model strikingly resembled the 
data obtained in a phase I antibody dose escalation study in RCC patients: at low 
protein doses relatively high tumor uptake was observed, whereas at doses exceeding 
10 mg, tumor uptake was 10-fold lower, suggesting that in RCC patients saturation 
of available G250 epitopes occurred at relatively low G250 protein doses (10-25 mg). 
The internalizing SK-RC-52 model was used to study the influence of 
radionuclide on the tumor retention of radiolabeled MAb G250 (Chapter 3B). G250 
was labeled with i e eRe via the MAG3 chelator an with i n l n via the DTPA chelator, 
and the biodistribution was compared with G250 labeled with 1 2 5 l via the iodogen 
method (representative for 1 3 1 l that is most commonly used in radioimmunotherapy 
studies). The metallic radionuclide 1 , 1 ln was retained in the tumor after internalization. 
In contrast, the metallic radionuclide 186Re and the non-metallic radionuclide 1 2 5 l were 
not retained in the tumor. Thus, labeling of G250 with 18eRe in comparison with 1 2 5 l -
G250 has no additional advantage for radioimmunotherapy in terms of retention in the 
tumor, in contrast with i n l n and 90Y labeled G250. 
The studies in Chapters 4 to 6 showed that the pretargeting approach required 
extensive optimization of a series of parameters - such as the interval between 
injection of the antibody and of the radiolabeled chelate, the amount of antibody 
administered and the amount of radiolabeled chelate administered - to achieve high 
tumor uptake of radiolabeled chelate. The first prerequisite for efficient targeting of 
radiolabeled chelate to the tumor was the administration of a suitable bsMAb protein 
dose. As with the parental antibody, saturation of G250 antigen in the tumor occurred 
at a low bsMAb protein dose (15 цд). The second most important variable was the 
amount of radiolabeled chelate injected. At relatively low amounts of radiolabeled 
chelate high uptake in the tumor was observed, whereas at higher amounts the 
relative uptake in the tumor decreased. In addition, the interval between 
administration of bsMAb and of radiolabeled chelate was important. At intervals 
longer than 3 days, uptake of the radiolabeled chelate in the tumor decreased. 
Optimization of all parameters resulted in high uptake of radiolabeled chelate in the 
tumor and in high tumor-to-blood ratios. These data indicate the necessity of careful 
tuning of the amounts of bsMAb and chelate in two-phase protocols, as has been 
shown in other studies using bispecific antitumor χ antichelate antibodies. In addition, 
fine tuning of various parameters might be a prerequisite for all pretargeting 
approaches, to achieve high tumor uptake. 
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In the two-step protocol blood levels of radiolabeled chelate at aerlier time points 
were relatively high, due to binding of the radiolabeled chelate to circulating antibody 
(Chapters 4 and 6). Binding of radiolabeled chelate to circulating antibody can be 
reduced by administration of a background-reducing agent, as has been shown in 
several preclinical as well as in clinical pretargeting studies. In these studies chelate-
conjugated serum proteins were used as background-reducing agents. In other 
studies, second antibodies or avidin were used to enhance clearance of (biotinylated) 
MAbs. In our studies these different strategies were compared. Administration of 
background-reducing agents resulted in increased target-to-blood ratios, due to the 
reduction or blocking of anti-DTPA MAb in the blood. The efficiency of blocking 
antichelate antibody depended on the background-reducing agent used. Background-
reducing agents containing DTPA groups proved to be more successful than goat 
antimouse IgG and avidin, possibly because DTPA-containing background-reducing 
agents block the DTPA binding site of the circulating antibody, while the other 
background-reducing agents have to remove the antichelate antibody from the 
circulation. In addition to the influence of the presence of DTPA groups in the 
background-reducing agent, the nature of the carrier protein was also important as 
well as the amount of background-reducing agent administered (Chapter 6). 
Circulating bsMAb was more efficiently blocked using IgM-DTPA-ln than BSA-DTPA-
In. Administration of the background-reducing agent resulted in a rapid increase in 
tumor-to-blood ratios. 
Apart from high tumor-to-blood ratios shortly after injection of the background-
reducing agent, good retention of the radiolabeled chelate in the tumor, is of crucial 
importance (Chapters 5 and 6). In our three-step protocol i n ln-DTPA was less well 
retained in the tumor compared with the two-step protocol. The three-step protocol 
resulted in higher tumor-to-blood ratios at early time points p.i. (1-6 h), which might 
be beneficial for radioimmunoscintigraphy. In contrast, the two-step protocol revealed 
significantly higher tumor-to-blood ratios at 24 h p.i. - caused by the prolonged 
retention of 111ln-DTPA - which is preferable for radioimmunotherapeutic purposes. 
Repeated injections of radiolabeled chelate have not been used before with 
bsMAbs. The G250 χ DTInl bsMAb in the tumor could be targeted at least three 
times by sequential administration of radiolabeled chelate (Chapter 6). With avidin-
biotin pretargeting approaches similar findings have been reported for repeated 
injections. Due to the relatively rapid release of n i ln-DTPA from the tumor, probably 
caused by the low affinity constant of bsMAb for binding 1 1 lln-DTPA, bsMAb in the 
tumor could be retargeted. Injection of as many as 3 doses of 111ln-DTPA resulted in 
significant higher amounts of radiolabeled chelate in the tumor compared to a single 
135 
Conclusions and perspectives 
injection. The amount of i n ln-DTPA in the tumor after 2 or 3 injections was similar to 
the sum of the amount of 1 l1ln-DTPA targeted to the tumor after each separate 
injection. The main advantage of this protocol is that the radiation dose delivered to 
the tumor will increase. Non-bound radiolabeled chelate or released radiolabeled 
chelate was very rapidly cleared via the kidneys. With directly labeled MAbs longer 
time intervals are needed before a second dose can be administered safely, due to the 
slow clearance of radiolabeled MAb from the circulation. 
The two-step targeting of RCC tumors with 1 1 1 ln markedly improved when 
monovalent DTPA was replaced by bivalent DTPA (Chapter 6). The higher relative 
uptake of radiolabeled chelate in the tumor increased 8-fold with the bivalent chelate 
at low amounts of chelate injected (78 %ID/g versus 9 %ID/g for 1 l1ln-DTPA). The 
uptake of bivalent DTPA in our experiments was at least 10-fold higher compared 
with the tumor uptake reported in other studies. In addition, tumor-to-blood ratios 
were 4-fold higher compared with other studies. Furthermore retention in the tumor 
was prolonged compared with the monovalent chelate. Up to 7 days postinjection 
bivalent DTPA was retained in the tumor. In contrast, most of the monovalent 1 1 1 ln-
DTPA was released from the tumor within 3 h after injection. These differences in 
tumor retention may be caused by the bivalent interaction of n iln-diDTPA-FKYK with 
G250 χ DTInl in the tumor. In addition, if 11,ln-diDTPA-FKYK is monovalently bound 
to one bsMAb molecule and is released, it might be more efficiently catched by 
another bsMAb molecule nearby in the tumor compared with monovalent '11ln-DTPA, 
resulting in prolonged retention. In other studies bivalent chelate was released from 
the tumor within 48 h. Therefore, we observed higher tumor-to-blood ratios at later 
time points compared with studies . 
For radioimmunotherapeutic use of the two-step protocol, powerful radionuclides 
other than 1 1 1 ln are required. We have determined the in vivo biodistribution of 1 1 1 ln-
DOTA, 88Y-DTPA and 88Y-diDTPA-FKYK and compared those to 11 lln-DTPA. We 
observed that the in vitro competitive binding assay could not predict the in vivo 
behavior of the radiolabeled chelates (Chapters 2 and 6). With In-DOTA, Y-DTPA and 
Y-diDTPA-FKYK preferential binding to G250 χ DTInl was found in competitive 
ELISAs, whereas no binding to pretargeted G250 χ DTInl was obtained in vivo. 
Apparently, the potential of a radiolabeled chelate has to be determined in vivo and 
can not be predicted on the basis of in vitro analyses. The difficulties in switching 
from a chelate appropriate for imaging to a chelate appropriate for therapy have also 
been observed in other studies. The presence of an In-DTPA group in the chelate 
seems a prerequisite to achieve good targeting of the radiolabeled chelate to the 
tumor. Therefore, other investigators have radioiodinated the peptide backbone of the 
bivalent chelate for therapeutic application, while targeting to the tumor was achieved 
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via the In-DTPA group. 
In conclusion, the studies presented in this thesis showed the feasibility of the 
two-step approach: high uptake of radiolabeled chelate in the tumor could be achieved 
after optimization of several parameters. The protein dose of bsMAb as well as the 
chelate dose has to be determined carefully. Two-step targeting could be improved 
most effectively by using bivalent chelates. At the optimized conditions high uptake of 
bivalent chelate in the tumor was observed (78 %ID/g). In addition, bivalent chelate 
was retained at least 7 days. To develop a therapeutic protocol based on these results 
one may concider to radioiodinate the peptide backbone of the bivalent chelate with 
1 3 1 1 . However, it would be preferable to use 90Y-labeled chelates for 
radioimmunotherapeutic applications. Therefore we think that a mixed chelate would 
be most preferable, e.g., a peptide backbone conjugated with DTPA and DOTA. The 
DTPA labeled with cold In could be used to target the mixed chelate to the bsMAb at 
the site of the tumor. The DOTA chelate could be radiolabeled with 90Y to achieve a 
high dose of a therapeutic radionuclide at the site of the tumor. 
Overall, we have produced anti-RCC χ anti-DTPA bsMAbs and have successfully 
used these for radioimmunotargeting of RCC xenografts in nude mice. Very high 
tumor uptake and very good retention of the radiolabeled chelate were observed. 
Therefore, we think that this two-step targeting protocol might be suited for rapid 
detection of primary RCC or metastasized RCC in patients. In addition, the 
development of a therapeutic application of this two-step protocol might be possible. 
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Monoclonal antibodies (MAbs) against tumor-associated antigens have been shown to 
localize preferentially in tumors. These antibodies can be used as vehicles to direct 
cytotoxic agents, e.g., cytostatic drugs, toxins or radionuclides, to tumors. 
Radiolabeled antibodies can eradicate not only the targeted tumor cells, but also 
neighboring cells. Monoclonal antibodies, however, are slowly cleared from the 
circulation, leading to persistingly high levels of radioactivity in nontarget organs. Due 
to this slow clearance optimal visualization of the tumor is delayed for several days. In 
addition, sustained levels of radiolabeled antibody in the blood and normal tissues, do 
increase toxicity to nontarget tissues and thus limit the amount of radioactivity that 
can be administered safely in radioimmunotherapy. The efficacy of 
radioimmunodetection and radioimmunotherapy can be improved by enhancing the 
uptake of radiolabeled MAbs in tumors or by reducing the activity in the background. 
Reduction of background activity can be achieved using pretargeting protocols. In 
such protocols the monoclonal antibody and the radionuclide are administered 
separately. The monoclonal antibody, that will accumulate in the tumor, is 
administered first and allowed to clear from the circulation. Thereafter the radionuclide 
is given as a low-molecular-weight chelate. When not bound to tumor targeted 
monoclonal antibody, the chelate is rapidly cleared via the kidneys. This separated 
administration fundamentally changes the kinetics of tumor accretion and whole-body 
clearance of the radiolabel, as compared to directly labeled antibodies. Several 
pretargeting strategies have been studied, among which the antitumor χ antichelate 
bispecific antibody based pretargeting strategies. The studies as described in this 
thesis aimed to develop and optimize two-phase radioimmunotargeting strategies 
using bispecific monoclonal antibodies. 
In Chapter 1 a detailed overview is given of approaches to increase the efficacy 
of radioimmunotargeting of tumors. First, approaches are discussed that aim to 
increase the uptake of radiolabeled antibody in the tumor. Thereafter, approaches to 
enhance the clearance of circulating radiolabeled antibody are discussed. Among these 
approaches are the multi-step protocols, including the antitumor χ antichelate 
bispecific antibody based pretargeting strategies. 
In Chapter 2 the production and characterization of three bsMAbs against renal 
cell carcinoma (RCC) and the chelate 1,4,7-triazaheptane-N,N',N"-pentaacetic acid 
(DTPA) is described. Five different antibodies against DTPA have been produced; i.e., 
DTInl , DTIn2, DTIn3, DTIn4 and DTY4. Competitive binding assays indicated that the 
anti-DTPA antibodies reacted with DTPA chelated with indium, yttr ium, chromium, 
iron or zinc. The affinity constants for 11lln-DTPA ranged from 0.19 to 0.23 nM"1. 
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Using various chelates, a remarkable chelate specificity of the anti-DTPA antibodies 
was demonstrated, suggesting the presence of different essential structures within 
the DTPA molecule that determine the reactivity of the antibodies. Thereafter, the 
production of bsMAbs via somatic cell fusion is described. Hybridomas G250 and 
DTY4, DTIn2 and DTInl were successfully fused to produce and secrete functional 
G250 χ DTY4, G250 χ DTIn2 and G250 χ DTInl bispecific antibodies. Bispecific 
antibodies were purified to homogeneity from quadroma induced ascites using protein 
A affinity chromatography followed by hydroxylapatite chromatography and/or cation 
exchange chromatography. 
In Chapter ЗА t w o RCC animal models were characterized - NU-12 and SK-RC 
52 - aiming to select the best model for the bsMAb based pretargeting studies. The 
parental MAb G250 and another anti-RCC MAb, RC 38, were used in these studies. 
The biodistribution of radioiodinated G250 was completely different in the t w o 
models. The uptake of G250 in NU-12 tumors was very high at low protein doses 
(125 percent injected dose per gram (%ID/g)), but decreased at higher doses, 
indicating tumor saturation. Saturation of G250 antigen in the NU-12 tumor occurred 
at 3 цд protein. In this model 9,200 G250 determinants per cell could be targeted, 
which is 6 . 1 % only of the number of G250 determinants as determined in vitro. The 
RC 38 uptake in NU-12 tumors remained constant up to 10 цд (40 %ID/g) and 
decreased at higher doses. RC 38 antigens were saturated at 25 цд RC 38. With RC 
38, 15% of the available antigens were targeted. In contrast, in SK-RC-52 tumors 
very low G250 uptake was observed at low antibody doses (4 %ID/g), while tumor 
uptake increased at higher doses. The different G250 biodistribution is most likely 
caused by different processing of the antibody by the t w o tumors studied. The 
biodistribution of G250 in NU-1 2 tumors appeared to be the best representation of the 
biodistribution of G250 in RCC patients. Therefore, the NU-12 model was chosen for 
further studies using bsMAb G250 χ D T I n l . 
The SK-RC-52 model that was studied in Chapter ЗА was used to study the 
impact of various radionuclides on the biodistribution and tumor retention of MAb 
G250. MAb G250 was radiolabeled with 1B6Re via the MAG3 chelate, with 1 l 1 l n via 
the DTPA chelate and with 1 2 5 l via the iodogen method. The biodistribution of the 3 
radiolabels differed considerably. 1 2 5 l , 1 l 1 l n and 186Re labeled G250 were processed 
rapidly in the tumor. Both 1 2 5 l and 186Re were rapidly excreted from the tumor. In 
contrast, 1 , 1 ln was retained well in the tumor after metabolization. These data indicate 
that not all radiometals are retained in the tumor. The dynamic behavior of the 
radionuclide after metabolization thus appeared largely dependent on the chelate used 
to incorporate the radionuclide. 
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Several parameters of the pretargeting approach were studied in rats with 
Staphylococcus aureus infection. In Chapter 4 the targeting of S. aureus infections by 
99mTc-DTPA after anti-DTPA MAb DTInl priming is described. The pretargeting 
protocol was optimized with respect to the interval between both injections, the 
clearance of circulating DTInl-99mTc-DTPA complexes and the DTInl protein dose. 
Infections could be visualized with an interval of only 2 h between both injections. 
Relatively high background activity was observed due to DTInl -99mTc-DTPA 
complexes in the circulation. Background reduction with various agents had a 
prominent effect on DTInl as well as on 99mTc-DTPA biodistribution. The best 
background reduction was obtained using BSA-DTPA-ln. The abscess uptake of " T c -
DTPA significantly increased at DTInl doses > 100 цд. In conclusion, infections could 
be targeted very efficiently with low background activity using a carefully tuned 
pretargeting approach. 
In Chapter 5 the two-step targeting of NU-12 RCC tumors using bsMAb G250 χ 
DTInl and 111ln-DTPA is described. The bsMAb G250 χ DTInl was injected first and 
111ln-DTPA thereafter. The effect of several parameters was studied. The tumor 
uptake of 1 l 1ln-DTPA was similar upto a 3-day interval between bsMAb and 1 1 1 ln-
DTPA injections and decreased thereafter. Therefore, a 3-day interval was chosen for 
further studies. The effect of G250 χ DTInl protein dose was studied. High tumor 
uptake (30 %ID/g) was seen up to 4 цд and decreased thereafter. The G250 antigen 
in the tumor was saturated at 15 цд G250 χ DTIn l . At the saturating bsMAb dose 
the amount of 111ln-DTPA was varied. At a 10-fold molar excess the highest %ID/g 
1l1ln-DTPA in the tumor was observed (beneficial for radioimmunoscintigraphy), but at 
a 100-fold excess the amount of n 1 ln-DTPA (ng/g) in the tumor was the highest 
(preferential for radioimmunotherapy). Using the optimized conditions (15 цд G250 χ 
DTInl and a 10-fold molar excess 111ln-DTPA) the tumor retention of ,11ln-DTPA was 
studied over a 2-day period. Good tumor retention of U 1 ln-DTPA was observed, while 
the radiolabel cleared rapidly from the blood. Consequently, tumor-to-blood ratios 
increased with time, reaching values as high as 500 at 24 h postinjection. RCC 
xenografts can thus be targeted efficiently using G250 χ DTInl and 111ln-DTPA. 
However, the approach requires careful tuning of interval between both injections, of 
the bsMAb dose, and of the bsMAb:radiolabeled chelate ratio. 
In Chapter 6 the two-phase targeting of renal cell carcinoma was further 
optimized. In the two-step approach high 111ln-DTPA blood activity was observed 
shortly after injection, due to binding of i n ln-DTPA to circulating G250 χ DTInl . This 
binding could be efficiently blocked by injection of BSA-DTPA-ln or IgM-DTPA-ln 
shortly before injection of l n ln-DTPA. One hour postinjection of i n ln-DTPA, tumor-to-
blood ratios increased 24-fold compared with the two-step approach. However, i n l n -
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DTPA was less well retained in the tumor in the three-step protocol compared with 
the two-step protocol, leading to lower tumor-to-blood ratios. Using the two-step 
protocol a single injection of 111ln-DTPA was compared with 2 or 3 injections at one 
day apart. The efficacy of radioimmunotargeting was improved, in view of the 
significantly higher amount of 1"ln-DTPA (cpm/g) in the tumor after 2 or 3 injections 
compared to that after 1 injection. In addition, we compared the biodistribution of 
bivalent inln-diDTPA-FKYK and monovalent 111ln-DTPA at various dose levels. With 
'nln-diDTPA-FKYK very high tumor uptake was obtained (up to 78 %ID/g 1 h p.i.). At 
higher doses tumor uptake decreased, indicating saturation of G250 χ DTInl at the 
site of the tumor. In contrast, with i n ln-DTPA the highest tumor uptake obtained was 
9 %ID/g only. 111ln-diDTPA-FKYK was retained very well in the tumor for at least 72 h 
(no release). Due to the clearance of n iln-diDTPA-FKYK from the circulation from 4 h 
onwards, tumor-to-blood ratios increased up to 2250 at 72 h postinjection. In a 
radioimmunodetection experiment the amount of 111ln-diDTPA-FKYK remained very 
high in the tumor during 7 days. 
Overall, renal cell carcinoma tumors can be targeted very efficiently with 1 1 1 ln-
diDTPA-FKYK after pretargeting with bsMAb G250 χ DTIn l . To achieve this high 
uptake and long retention of 1l1ln-diDTPA-FKYK in the tumor, several parameters had 
to be optimized, i.e., the interval between both injections, the bsMAb protein dose 
and the ratio between bsMAb and inln-diDTPA-FKYK. At the optimal conditions very 
high tumor uptake (up to 78 %ID/g), long retention in the tumor (at least 7 days) and 
very high tumor-to-blood ratios (up to 2250) were obtained. Therefore, this two-step 
approach might be suited for rapid detection of primary RCC or metastasized RCC in 








Monoclonale antistoffen (MAb) zijn eiwitten die in staat zijn specifiek een bepaalde 
structuur (antigeen) te herkennen en te binden. Een aantal van deze antigenen komt in 
verhoogde mate voor op tumor cellen (tumor-geassocieerde antigenen). Antistoffen 
die deze tumor-geassocieerde antigenen herkennen kunnen gebruikt worden als 
dragers om stoffen die toxisch zijn voor de cellen, naar tumoren te brengen. 
Voorbeelden van deze toxische stoffen zijn toxines, chemotherapeutica en 
radioactieve stoffen. Het voordeel van de koppeling van radioactieve stoffen aan 
monoclonale antistoffen, ten opzichte van toxines en chemotherapeutica, is dat de 
antistof niet aan elke cel in de tumor hoeft te binden om de cel te kunnen doden. De 
radioactieve straling kan ook voor cellen die in de buurt gelegen zijn dodelijk zijn. Een 
nadeel van monoclonale antistoffen die een radioactieve stof dragen is dat deze 
monoclonale antistoffen slechts langzaam uit het lichaam geklaard worden. Daardoor 
blijft er langdurig radioactiviteit aanwezig in het lichaam. Om die reden moet er enkele 
dagen gewacht worden voordat de radioactiviteit in de tumor zichtbaar gemaakt kan 
worden, ten opzichte van de radioactiviteit in de rest van het lichaam. Dit afbeelden 
gebeurt met behulp van een gamma-camera (radioimmunodetectie). Ook voor 
therapeutische doeleinden is het hoge radioactiviteitsniveau in het bloed en andere 
niet-doelwit organen een beperkende factor voor de hoeveelheid radioactief 
gemarkeerde antistof die veilig kan worden toegediend (radioimmunotherapie). 
Radioimmunodetectie of radioimmunotherapie kan in principe op twee manieren 
worden verbeterd. Ten eerste kan geprobeerd worden de hoeveelheid van de 
radioactief gemarkeerde antistof in de tumor te verhogen. Ten tweede, kan de 
effectiviteit verhoogd worden door de hoeveelheid van de radioactief gemarkeerde 
antistof te verlagen in het bloed en andere niet-doelwit organen. Verlaging van de 
radioactiviteit in bloed en andere organen kan onder andere bereikt worden met behulp 
van een meerstaps benadering. In een meerstaps benadering worden de monoclonale 
antistof en de radioactiviteit niet tegelijkertijd toegediend, maar na elkaar. Eerst wordt 
de monoclonal antistof toegediend. Deze kan dan aan het antigeen op de tumorcel 
binden. Dan wordt enige tijd gewacht, tot de monoclonale antistof die niet aan een 
tumorcel gebonden is, grotendeels uit het bloed en de andere niet-doelwit organen 
verdwenen is. Op dat moment wordt de radioactiviteit toegediend in de vorm van een 
klein molecuul. Dit kleine molecuul kan snel binden aan de monoclonale antistof in de 
tumor. Als het kleine molecuul niet gebonden wordt in de tumor, kan dit het lichaam 
snel verlaten via de nieren, zodat er weinig radioactiviteit achterblijft in de rest van het 




Bispecifieke antistoffen herkennen twee verschillende antigenen. Ze hebben dus 
als het ware twee verschillende pootjes. In de studies beschreven in dit proefschrift is 
gebruik gemaakt van bispecifieke antistoffen die een antigeen herkennen aanwezig op 
niercel carcinoma tumoren en een antigeen aanwezig op het kleine molecuul DTPA. In 
deze meerstaps benaderingen wordt eerst de bispecifieke antistof toegediend, zonder 
dat er een radioactieve stof aan is gekoppeld. Deze bispecifieke antistof localiseert in 
de tumor door met het ene pootje te binden aan het antigeen in de tumor. Daarna 
wordt de radioactiviteit toegediend, gebonden aan DTPA. Dit radioactieve DTPA kan 
vervolgens binden aan het andere pootje van de bispecifieke antistof die in de tumor 
aanwezig ¡s. Omdat DTPA een klein molecuul is wordt het zeer snel door de nieren 
uitgescheiden, indien geen binding aan de bispecifieke antistof in de tumor optreedt. 
In dit proefschrift wordt verslag gedaan van onderzoek naar verschillende 
aspecten van een dergelijke meerstaps benadering waarbij gebruik gemaakt is van 
bispecifieke antistoffen gericht tegen niercel carcinoma en DTPA. 
In Hoofdstuk 1 wordt een gedetailleerd overzicht gegeven van de wijzen waarop 
de effectiviteit van radioimmunodetectie en/of radioimmunotherapie verbeterd kan 
worden. Allereerst worden benaderingen besproken die beogen de opname van 
radioactief gemarkeerde antistof in de tumor te vergroten. Daarna wordt aandacht 
besteed aan technieken om de hoeveelheid radioactief gemarkeerde antistof te 
verlagen in het bloed en in de normale organen. Tot deze laatste groep horen ook de 
meerstaps benaderingen, die aan de orde komen in het laatste deel van de inleiding. 
In Hoofdstuk 2 wordt de produktie en karakterisering van drie bispecifieke 
antistoffen gericht tegen niercel carcinoma tumoren en DTPA beschreven. Allereerst 
werden vijf verschillende anti-DTPA antistoffen geproduceerd, te weten DTIn l , DTIn2, 
DTIn3, DTIn4 en DTY4. Hierbij bleek dat de anti-DTPA antistoffen DTPA herkenden 
met daarin de metalen indium, yttrium, chroom, ijzer of zink. Voor de verschillende 
anti-DTPA antistoffen werd de affiniteit bepaald voor het binden van radioactief 
lndium-111 (n ' ln)-DTPA. De affiniteitsconstante van de antistoffen varieerde van 
0.19 tot 0.23 n M 1 . De anti-DTPA antistoffen herkenden niet alleen DTPA, maar ook 
een aantal op DTPA gelijkende moleculen. Vervolgens werden bispecifieke antistoffen 
geproduceerd. De antistoffen gericht tegen niercel carcinoma (MAb G250) en DTPA 
(DTInl tot en met DTY4) werden geproduceerd door zogenaamde hybridoma cellen. 
Door nu de monoclonale antistof G250 producerende hybridomacellen te fuseren met 
de anti-DTPA antistoffen producerende hybridomacellen werden quadromacellen 
gevormd die bispecifieke antistoffen kunnen uitscheiden. Daarna zijn de bispecifieke 
antistoffen G250 χ DTY4, G250 χ DTIn2 en G250 χ DTInl in grote hoeveelheden 
geproduceerd in muizen in de vorm van ascites. De bispecifieke antistoffen werden uit 
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de ascites gezuiverd met behulp van proteine A affiniteitschromatografie en 
hydroxylapatite chromatografie en/of kationenwisselaar chromatografie. 
Hoofdstuk ЗА beschrijft de karakterisatie van twee niercel carcinoma 
diermodellen (NU-12 en SK-RC-52). Doel was het beste model te selecteren voor 
studies met de bispecifieke antistoffen. In beide modellen werd de verdeling in de 
organen (biodistributie) van de radioactief gemarkeerde antistof G250 en een andere 
anti-niercel carcinoma antistof, RC 38, bestudeerd. De biodistributie in muizen met 
een tumor bleek in de modellen zeer variabel. Zo werd in het NU-12 model bij lage 
doses antistof een zeer hoge tumor opname gevonden (125 procent van de 
toegediende dosis per gram tumor (%ID/g)). Bij hogere doses antistof nam de opname 
in de tumor af, hetgeen op verzadiging van het antigeen in de tumor duidde. De G250 
antigenen in de tumor werden verzadigd bij een G250 antistof dosis van 3 цд G250. 
In dit model konden slechts 9200 antigenen per tumorcel gebonden worden door de 
G250 antistof in de muis. Dit is slechts 6.1 % van de hoeveelheid antigenen die er op 
elke tumorcel aanwezig zijn. De opname van de antistof RC 38 in de NU-12 tumor 
bleef constant tot een dosis van 10 μg (40 %ID/g). Bij hogere doses nam de tumor 
opname af. Het RC 38 antigeen werd verzadigd door 15 цд RC 38 toe te dienen. 
Daarentegen werrd in het SK-RC-52 model een zeer lage G250 opname in de tumor 
gevonden bij de lage antistof doses (4 %ID/g). Bij hogere doses nam de hoeveelheid in 
de tumor toe. Het verschil in G250 biodistributie in beide modellen wordt zeer 
waarschijnlijk veroorzaakt door een verschil in de verwerking van de antistof door de 
tumoren. De biodistributie van G250 in het NU-12 model is zeer vergelijkbaar met de 
biodistributie van G250 in patiënten met niercel carcinoma tumoren. Op geleide van 
de zojuist genoemde bevindingen werd het NU-12 model gekozen voor het verder 
onderzoeken van de meerstaps targeting van niercel carcinoma tumoren met de 
bispecifieke antistof G250 χ DTIn l . 
Het SK-RC-52 diermodel dat in Hoofdstuk ЗА werd gebruikt, is in Hoofdstuk 3B 
gebruikt om de invloed van de soort radioactieve stof die gekoppeld is aan de antistof 
G250, op de retentie van de antistof in de tumor, te bestuderen. Daarto werd G250 
gekoppeld aan rhenium-186 (186Re) via het kleine molecuul MAG3. G250 werd 
eveneens gemarkeerd met 1 1 1 ln via het kleine molecuul DTPA. Tenslotte werd G250 
gemarkeerd met jodium-125 (12sl) via de jodogen-methode. De biodistributie van deze 
drie verschillende radionucliden verschilde onderling aanzienlijk. Zowel , 8 eRe, 1 1 1 ln als 
1 2 5 l gemarkeerd G250 werd zeer snel door de tumor opgenomen en verwerkt. Daarna 
werden 186Re en 1 2 5 l zeer snel weer uitgescheiden door de tumorcel. In tegenstelling 
tot 186Re en 1 2 5 l werd l 1 l l n niet snel uitgescheiden, maar bleef gedurende langere tijd 
aanwezig in de tumorcel. Deze resultaten gaven aan dat niet alle metaalachtige 
radioactieve stoffen (186Re en i n l n ) op dezelfde manier verwerkt worden door de 
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tumor. Het gedrag van de radioactieve stof na verwerking van de antistof door de 
tumor hangt dus in grote mate af van het kleine molecuul dat gebruikt is om de 
radioactieve stof te koppelen aan de antistof. 
Om verschillende parameters die meerstaps protocollen kunnen beïnvloeden te 
bestuderen werd gebruik gemaakt van ratten met een Staphylococcus aureus infectie 
(Hoofdstuk 4). Antistoffen hopen zich in infecties op zonder te binden aan een 
antigeen. Dit is een gevolg van de locaal toegenomen bloed doorstroming en de 
verhoging in de permeabiliteit van de bloedvaten. In de eerste stap werd de anti-DTPA 
antistof DTInl ingespoten en in de tweede fase technetium-99m (99mTc)-DTPA. 99mTc-
DTPA bond aan het DTInl in de infectie. Vervolgens werden verschillende aspecten 
van deze benadering geoptimaliseerd. Allereerst is het interval tussen beide stappen 
gevarieerd. Twee uur nadat het DTInl toegediend was kon het 99mTc-DTPA al binden 
aan DTInl in de infectie. Kort na toediening van 99mTc-DTPA werd nog een vrij grote 
hoeveelheid 99mTc-DTPA in het bloed gezien. Dit leek het gevolg van het feit dat " T c -
DTPA gebonden werd door DTInl dat nog in de bloedbaan aanwezig was (vorming 
van 99mTc-DTPA-DTIn1 complexen). Deze binding aan DTInl in het bloed kon 
verminderd worden door een extra stap toe te voegen. Kort voor injectie van het 
99mTc-DTPA werd daarom een stof toegediend waarmee DTInl in het bloed ongeschikt 
gemaakt werd voor binding aan " T c - D T P A . Vier verschillende stoffen werden getest 
voor deze extra stap. De beste resultaten werden behaald met het eiwit BSA-DTPA-ln. 
Tenslotte bleek dat de binding van 99mTc-DTPA in de infectie beter werd naarmate 
meer DTInl werd toegediend (>100 μg). Met het geoptimaliseerde protocol konden 
infecties zeer snel en duidelijk afgebeeld worden via genoemde meerstaps benadering. 
In Hoofdstuk 5 wordt de twee-staps targeting van NU-12 niercel carcinoma 
tumoren in muizen met behulp van de bispecifieke antistof G250 χ DTInl en 1 l l l n -
DTPA beschreven. Het twee-fasen systeem werd op verschillende punten 
geoptimaliseerd. Allereerst werd het interval tussen toediening van de bispecifieke 
antistof en het l11ln-DTPA gevarieerd. Tot een interval van 3 dagen werd het 1 l 1 l n -
DTPA goed gebonden in de tumor, door het daar aanwezige G250 χ DTIn l . Bij een 
langer interval nam de binding van i n ln-DTPA in de tumor af. Voor de daarop 
volgende experimenten werd daarom een interval van 3 dagen aangehouden. 
Vervolgens werd de eiwitdosis van de bispecifieke antistof geoptimaliseerd. Bij lage 
hoeveelheden G250 χ DTInl bond relatief veel G250 χ DTInl aan het antigeen in de 
tumor (30 %ID/g). Bij doses hoger dan 4 цд nam de opname in de tumor echter weer 
af. Het antigeen in de tumor werd geheel verzadigd bij een bispecifieke antistof eiwit 
dosis van 15 цд G250 χ DTIn l . Tenslotte werd de dosis 1 1 lln-DTPA gevarieerd. Bij 
een 10-voudige overmaat, ten opzichte van de hoeveelheid G250 χ DTInl die nog 
aanwezig was in het bloed, werd de hoogste relatieve opname van het n i ln-DTPA 
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(%ID/g) ¡η de tumor gevonden. Dit ¡s optimaal voor radioimmunodetectie. Bij een 100-
voudige overmaat werd de grootste hoeveelheid i n ln-DTPA (ng/g) in de tumor 
gevonden. Dit is optimaal voor radioimmunotherapie. Gebruik makend van het 
optimale protocol (15 цд G250 χ DTIn1 en een 10-voudige overmaat 111ln-DTPA) 
werd de retentie van n i ln-DTPA in de tumor bestudeerd. De retentie van 11lln-DTPA in 
de tumor was goed. De hoeveelheid H 1ln-DTPA in het bloed nam echter snel af in de 
ti jd. Hierdoor nam de verhouding tussen de hoeveelheid radioactiviteit in de tumor en 
in het bloed snel toe tot 500 (24 uur na injectie). Dit is gunstig voor zowel 
radioimmunodetectie als voor radioimmunotherapie). Niercel carcinoma tumoren in 
muizen kunnen dus goed zichtbaar gemaakt worden met een twee-staps benadering. 
Ook hier moeten echter alle parameters geoptimaliseerd worden voor een goed 
resultaat. 
In Hoofdstuk 6 zijn verschillende mogelijkheden bestudeerd die de twee-staps 
benadering, zoals die in Hoofdstuk 5 gebruikt is, geschikt zouden kunnen maken voor 
gebruik in een therapeutische toepassing. In de twee-staps benadering werd kort na 
injectie van het 11,ln-DTPA een relatief hoge hoeveelheid radioactiviteit in het bloed 
gezien. Dit werd veroorzaakt door de binding van het 1 1 lln-DTPA aan de bispecifieke 
antistof G250 χ DTInl die circuleerde in het bloed. De binding van i n ln-DTPA aan het 
G250 χ DTInl in het bloed kon efficient verhinderd worden door de toediening van 
een stof die het DTPA bindende gedeelte van G250 χ DTInl blokkeerde in het bloed. 
Twee verschillende blokkerende stoffen werden onderzocht. Met IgM-DTPA-ln werd 1 
uur na injectie van het n , ln-DTPA, de verhouding tussen het 111ln-DTPA in de tumor 
en die in het bloed 24x hoger was dan wanneer de blokkerende stof niet geïnjecteerd 
werd. Helaas bleek dat de retentie van het i n lnDTPA in de tumor onder deze 
omstandigheden minder goed dan in de twee-staps benadering (zoals beschreven in 
Hoofdstuk 5). Verdere experimenten werden dan ook uitgevoerd met het twee-staps 
protocol. Vervolgens werd onderzocht of het mogelijk was de toediening van 1 1 l ln-
DTPA 2x of 3x te herhalen. De effectiviteit van de twee-staps benadering kon 
inderdaad vergroot worden door meermalen 111ln-DTPA toe te dienen. Na meerdere 
toedieningen werd een significant hogere hoeveelheid 11lln-DTPA in de tumor 
gevonden vergeleken met eenmalige toediening. Verder zou de effectiviteit van de 
twee-staps benadering nog vergroot kunnen worden door kleine moleculen te 
gebruiken waarin twee DTPA groepen aanwezig zijn (bivalente chelaten; 111ln-diDTPA-
FKYK), in plaats van het eenvoudige kleine molecuul DTPA zoals dat tot dan toe 
gebruikt werd. Met bivalente chelaten werd in studies van anderen hogere opname in 
de tumor waargenomen. Daarnaast bleek de verblijftijd van het bivalente chelaat in de 
tumor ook langer. De biodistributie van n ' ln-diDTPA-FKYK werd vergeleken met die 
van 1l1ln-DTPA. Beide preparaten werden in verschillende doses toegediend in de 
tweede stap. Met "'In-diDTPA-FKYK werd een zeer hoge opname in de tumor gezien 
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(78 %ID/g) bij relatief lage doses (0.03-voudige overmaat). Bij grotere hoeveelheden 
nam de opname in de tumor weer af. Met het 1 n ln-DTPA werd een maximale opname 
in de tumor van 9 %ID/g gezien. De retentie van 111ln-diDTPA-FKYK in de tumor was 
zeer goed. Na 72 uur was er nog evenveel in de tumor aanwezig als na 1 uur. Doordat 
het ,nln-diDTPA-FKYK 4 uur na injectie wel klaarde uit het bloed, nam de verhouding 
tussen de hoeveelheid 1l1ln-diDTPA-FKYK in de tumor en in het bloed toe tot 2250 
(72 uur na injectie). In een radioimmunodetectie experiment bleef het l11ln-diDTPA-
FKYK gedurende 7 dagen aanwezig in de tumor. 
Samenvattend, bleek dat 1l1ln-diDTPA-FKYK zeer efficient opgenomen kon 
worden in niercel carcinoma tumoren in muizen na toediening in de eerste fase van 
G250 χ DTIn l . Voor het bereiken van deze hoge opname en lange retentie in de tumor 
was het noodzakelijk verschillende parameters te optimaliseren, te weten het interval 
tussen de eerste en tweede stap, de eiwitdosis van de bispecifieke antistof en de 
verhouding tussen de hoeveelheid bispecifieke antistof en de hoeveelheid n i l n -
diDTPA-FKYK. Onder de optimale condities werd zeer hoge opname in de tumor (78 
%ID/g), lange retentie in de tumor (tenminste 7 dagen) en een zeer hoge verhouding 
tussen de hoeveelheid inln-diDTPA-FKYK in de tumor en het bloed (oplopend to 
2250) bereikt. Gezien deze feiten lijkt deze twee-staps benadering zeer geschikt voor 
het opsporen van primaire niercel carcinoma tumoren of van gemetastaseerde niercel 
carcinoma tumoren in patiënten. Daarnaast zou de ontwikkeling van een 






Dat na bijna vijf jaar van wetenschappelijk onderzoek die mooie proefschrift heeft 
kunnen verschijnen is te danken aan een intensieve samenwerking met een groot 
aantal mensen. 
Mijn promotor, Frans Corstens. Frans, van jou kreeg ik alle gelegenheid het onderzoek 
af te ronden op een manier die mij zeer veel voldoening schenkt. Jouw kritische blik 
op de artikelen in dit proefschrift was van enorm belang. 
Mijn co-promotoren, Otto Boerman en Egbert Oosterwijk. Otto en Egbert, samen 
hebben we alle stadia van een promotie onderzoek doorlopen. De eerste goede 
resultaten, de bijna twee jaar met diverse problemen en de grote hoeveelheid 
succesvolle experimenten in de laatste twee jaar. Altijd kon ik bij jullie terecht voor 
goede raad of hulp. Dat heeft mij gestimuleerd toch verder te gaan met het 
onderzoekswerk. 
Mijn analisten, Mirjam de Weijert en Jeannette Oosterwijk. Mirjam en Jeannette, 
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De medewerkers van het Centraal Dierenlaboratorium, en in het bijzonder Pim Peelen, 
Gerrie Grutters, Hennie Eijkholt, Bianca de Weem en Geert Poelen. Pim, ik reken jou 
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verliepen, hoe ingewikkeld ze soms ook waren. 
Onze hot-lab specialist, Emile Koenders. Emile, door jouw grote kennis en ervaring 
konden we voor dagelijkse problemen snel een oplossing vinden. 
De bijvak-student, Rob Roovers. Rob, jouw enorme inzet in het kader van het 
onderzoek aan MN-14 bispecifieke antistoffen had een beter resultaat verdiend. Toch 
was het enorm belangrijk dat dat pionierswerk verricht werd. 
De collega's uit het aquarium. Martijn, Conny, Wim, Els, Noor en Peter. De gezellige 
sfeer in het aquarium heeft er zeker toe bijgedragen dat ik iedere dag weer zin had 
naar het werk te gaan. 
De collega's van de afdeling Nucleaire Geneeskunde. De gezellige uren in de 
koffiekamer en elders maken de afdeling Nucleaire Geneeskunde tot een afdeling waar 
het zeer prettig is te vertoeven. 
Tenslotte, de collega's van het Urologisch Research Laboratorium. De prettige sfeer 
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